<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35419092</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1844-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of medicine and life</Title><ISOAbbreviation>J Med Life</ISOAbbreviation></Journal><ArticleTitle>Diet, fibers, and probiotics for irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>174</StartPage><EndPage>179</EndPage><MedlinePgn>174-179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25122/jml-2022-0028</ELocationID><Abstract><AbstractText>Many aspects make irritable bowel syndrome (IBS) challenging for both patients and physicians. The unclear pathogenesis with many pathways to be explored, bothering symptoms that affect the quality of life, and many subtypes of the condition are only a few reasons that make IBS difficult to control and obtain satisfactory results. Treatment options start with general advice for lifestyle, continue with non-pharmaceutical treatments, and finally touch classic treatments. In this review, pharmaceutical treatment options are not accounted for. Consensus groups and meta-analyses have concluded guidelines that overall are the same, with variations in the strength of recommendations and some cultural and geographical particularities. Dietary interventions, probiotics, and fibers can be seen as non-pharmaceutical treatments that coexist in various protocols because of the relevant evidence regarding their efficacy in treating IBS symptoms.</AbstractText><CopyrightInformation>&#xa9;2022 JOURNAL of MEDICINE and LIFE.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Adelina Nicoleta</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Faculty of Natural and Human Sciences, Fan S. Noli University, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Reitano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Regional Hospital Kor&#xe7;e, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitra&#x219;cu</LastName><ForeName>Dan Lucian</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>J Med Life</MedlineTA><NlmUniqueID>101477617</NlmUniqueID><ISSNLinking>1844-122X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009005">Monosaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009005" MajorTopicYN="N">Monosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FGID &#x2013; functional gastrointestinal disorders</Keyword><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">FODMAP &#x2013; fermentable oligosaccharides, disaccharides, monosaccharides, and polyols</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; C irritable bowel syndrome subtype with constipation</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; D irritable bowel syndrome subtype with diarrhea</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">LFD &#x2013; low FODMAP diet</Keyword><Keyword MajorTopicYN="N">NICE/mNICE &#x2013; National Institute for Health and Care Excellence/modified diet</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">non-pharmacological therapy</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35419092</ArticleId><ArticleId IdType="pmc">PMC8999090</ArticleId><ArticleId IdType="doi">10.25122/jml-2022-0028</ArticleId><ArticleId IdType="pii">JMedLife-15-174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drossman DA. Functional gastrointestinal disorder and the Rome IV process. Functional gastrointestinal disorders. In: Drossman DA, Chang L, Chey WD, et al., editors. Disorders of brain-gut interaction. 4th. Vol. 1. Raleigh, NC: Rome Foundation; 2016. pp. 1&#x2013;32.</Citation></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, Farmer AD, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Dumitrascu DL, Fukudo S, Gerson C, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66(6):1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99&#x2013;114.e3. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson OS, Whitehead W, T&#xf6;rnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262&#x2013;1273.e3. doi: 10.1053/j.gastro.2019.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.12.021</ArticleId><ArticleId IdType="pubmed">31917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Staller K, Barshop K, Dai E, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103&#x2013;8109. doi: 10.3748/wjg.v21.i26.8103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i26.8103</ArticleId><ArticleId IdType="pmc">PMC4499353</ArticleId><ArticleId IdType="pubmed">26185382</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Schneck S, Blackman C, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54(7):1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Surdea-Blaga T, Cozma-Petrut A, Dumitra&#x15f;cu DL. Dietary interventions and irritable bowel syndrome &#x2013; what really works?. Curr Opin Gastroenterol. 2021;37(2):152&#x2013;157. doi: 10.1097/MOG.0000000000000706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000706</ArticleId><ArticleId IdType="pubmed">33332914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozma-Petru&#x163; A, Loghin F, Miere D, Dumitra&#x15f;cu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol. 2017;23(21):3771&#x2013;3783. doi: 10.3748/wjg.v23.i21.3771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i21.3771</ArticleId><ArticleId IdType="pmc">PMC5467063</ArticleId><ArticleId IdType="pubmed">28638217</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Jakobsson Ung E, Sadik R, Ringstr&#xf6;m G. Experiences of the effects of physical activity in persons with irritable bowel syndrome (IBS): a qualitative content analysis. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1194&#x2013;1200. doi: 10.1080/00365521.2018.1519596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2018.1519596</ArticleId><ArticleId IdType="pubmed">30472905</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Ringstr&#xf6;m G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015 Jan 14;21(2):600&#x2013;8. doi: 10.3748/wjg.v21.i2.600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i2.600</ArticleId><ArticleId IdType="pmc">PMC4294172</ArticleId><ArticleId IdType="pubmed">25593485</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi: 10.3390/nu11081824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11081824</ArticleId><ArticleId IdType="pmc">PMC6723613</ArticleId><ArticleId IdType="pubmed">31394793</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K, Reed DE, Schneider T, Dang F, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017 Jul;66(7):1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824&#x2013;1832. doi: 10.1038/ajg.2016.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.434</ArticleId><ArticleId IdType="pubmed">27725652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PR, Halmos EP, Muir JG. Review article: FODMAPS, prebiotics and gut health-the FODMAP hypothesis revisited. Aliment Pharmacol Ther. 2020;52:233&#x2013;246. doi: 10.1111/apt.15818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15818</ArticleId><ArticleId IdType="pubmed">32562590</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, Liljebo T, Collin L, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Lomer MC, Anderson JL, Barrett JS, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitrascu DL, Baban A, Bancila I, Barboi O, et al. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021;30(2):291&#x2013;306. doi: 10.15403/jgld-3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.15403/jgld-3581</ArticleId><ArticleId IdType="pubmed">33951120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AI, Garrido M, Castro-Po&#xe7;as F. Irritable Bowel Syndrome: News from an Old Disorder. GE Port J Gastroenterol. 2020;27(4):255&#x2013;268. doi: 10.1159/000503757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503757</ArticleId><ArticleId IdType="pmc">PMC7383263</ArticleId><ArticleId IdType="pubmed">32775547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina AG, Dallio M, Romeo M, Di Somm A, et al. Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. Nutrients. 2020;12(4):928. doi: 10.3390/nu12040928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12040928</ArticleId><ArticleId IdType="pmc">PMC7231245</ArticleId><ArticleId IdType="pubmed">32230832</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe M, Jansen C, Martin L, Williams M, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1) doi: 10.1111/nmo.13154. doi: 10.1111/nmo.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="pubmed">28707437</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpato E, Auricchio R, Penagini F, Campanozzi A, et al. Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics. Ital J Pediatr. 2019;45(1):9. doi: 10.1186/s13052-019-0606-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-019-0606-1</ArticleId><ArticleId IdType="pmc">PMC6329096</ArticleId><ArticleId IdType="pubmed">30635010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Deng Y, Chu H, Cong Y, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:262&#x2013;268.e1. doi: 10.1016/j.cgh.2012.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.11.034</ArticleId><ArticleId IdType="pubmed">23246646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta D, Ghoshal UC, Misra A, Misra A, et al. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol. 2007;22:2261&#x2013;2265. doi: 10.1111/j.1440-1746.2007.04986.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2007.04986.x</ArticleId><ArticleId IdType="pubmed">17559357</ArticleId></ArticleIdList></Reference><Reference><Citation>Varju P, Gede N, Szakacs Z, Hegyi P, et al. Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterol Motil. 2019;31:e13527. doi: 10.1111/nmo.13527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13527</ArticleId><ArticleId IdType="pmc">PMC7379306</ArticleId><ArticleId IdType="pubmed">30560578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan N, Morden A, Bischof D, King EA, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1002&#x2013;1010. doi: 10.1097/MEG.0000000000000425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000425</ArticleId><ArticleId IdType="pubmed">26148247</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367&#x2013;1374. doi: 10.1038/ajg.2014.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.195</ArticleId><ArticleId IdType="pubmed">25070054</ArticleId></ArticleIdList></Reference><Reference><Citation>McRorie JW. Evidence-Based Approach to Fiber Supplementsand Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50:82&#x2013;89. doi: 10.1097/NT.0000000000000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NT.0000000000000082</ArticleId><ArticleId IdType="pmc">PMC4415962</ArticleId><ArticleId IdType="pubmed">25972618</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Andrews CN, MacQueen G, Korownyk C, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019 Apr;2(1):6&#x2013;29. doi: 10.1093/jcag/gwy071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi: 10.1136/bmj.b3154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b3154</ArticleId><ArticleId IdType="pmc">PMC3272664</ArticleId><ArticleId IdType="pubmed">19713235</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B. Psyllium as therapeutic and drug delivery agent. Int J Pharm. 2007;334(1-2):1&#x2013;14. doi: 10.1016/j.ijpharm.2007.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2007.01.028</ArticleId><ArticleId IdType="pubmed">17329047</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir J. An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2019;15:387&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676347</ArticleId><ArticleId IdType="pubmed">31391809</ArticleId></ArticleIdList></Reference><Reference><Citation>Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7(1):87&#x2013;92. doi: 10.1111/j.1365-2036.1993.tb00074.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.1993.tb00074.x</ArticleId><ArticleId IdType="pubmed">8439642</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Bowyer RK, Leach H, Gulia P, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016 Oct;29(5):549&#x2013;75. doi: 10.1111/jhn.12385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12385</ArticleId><ArticleId IdType="pubmed">27272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GR, Hutkins R, Sanders ME, Prescott SL, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506&#x2013;14. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823&#x2013;1836. doi: 10.1042/BCJ20160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A, Abu Bake F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020;9(3):685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodi&#xf1;o-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garc&#xed;a R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289&#x2013;310. doi: 10.1007/s12325-018-0673-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-018-0673-5</ArticleId><ArticleId IdType="pmc">PMC5859043</ArticleId><ArticleId IdType="pubmed">29498019</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Thompson J, Gulia P, Lomer MC, (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association) British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):576&#x2013;592. doi: 10.1111/jhn.12386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12386</ArticleId><ArticleId IdType="pubmed">27265510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Nov;48(10):1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S, Okumura T, Inamori M, Okuyama Y, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193&#x2013;217. doi: 10.1007/s00535-020-01746-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci. 2020;36(3):160&#x2013;170. doi: 10.1002/kjm2.12154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12154</ArticleId><ArticleId IdType="pmc">PMC11896346</ArticleId><ArticleId IdType="pubmed">31782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F, Ni H, Asche CV, Kim M, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191&#x2013;1197. doi: 10.1080/03007995.2017.1292230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2017.1292230</ArticleId><ArticleId IdType="pubmed">28166427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayzeele-Decherf A, Pelerin F, Leuillet S, Douillard B, et al. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol. 2017;23(2):336&#x2013;344. doi: 10.3748/wjg.v23.i2.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i2.336</ArticleId><ArticleId IdType="pmc">PMC5236513</ArticleId><ArticleId IdType="pubmed">28127207</ArticleId></ArticleIdList></Reference><Reference><Citation>Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021;21(1):44&#x2013;52. doi: 10.7861/clinmed.2020-0980.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0980</ArticleId><ArticleId IdType="pmc">PMC7850201</ArticleId><ArticleId IdType="pubmed">33479067</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2(Suppl 2)):S129&#x2013;S134. doi: 10.1093/cid/civ085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ085</ArticleId><ArticleId IdType="pmc">PMC4490230</ArticleId><ArticleId IdType="pubmed">25922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17(3):252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22314561</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1899-1505</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of physiology and pharmacology : an official journal of the Polish Physiological Society</Title><ISOAbbreviation>J Physiol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>599</EndPage><MedlinePgn>591-9</MedlinePgn></Pagination><Abstract><AbstractText>Stress, which is defined as an acute threat to homeostasis, shows both short- and long-term effects on the functions of the gastrointestinal tract. Exposure to stress results in alterations of the brain-gut interactions ("brain-gut axis") ultimately leading to the development of a broad array of gastrointestinal disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal diseases, food antigen-related adverse responses, peptic ulcer and gastroesophageal reflux disease (GERD). The major effects of stress on gut physiology include: 1) alterations in gastrointestinal motility; 2) increase in visceral perception; 3) changes in gastrointestinal secretion; 4) increase in intestinal permeability; 5) negative effects on regenerative capacity of gastrointestinal mucosa and mucosal blood flow; and 6) negative effects on intestinal microbiota. Mast cells (MC) are important effectors of brain-gut axis that translate the stress signals into the release of a wide range of neurotransmitters and proinflammatory cytokines, which may profoundly affect the gastrointestinal physiology. IBS represents the most important gastrointestinal disorder in humans, and is characterized by chronic or recurrent pain associated with altered bowel motility. The diagnostic testing for IBS patients include routine blood tests, stool tests, celiac disease serology, abdominal sonography, breath testing to rule out carbohydrate (lactose, fructose, etc.) intolerance and small intestinal bacterial overgrowth. Colonoscopy is recommended if alarming symptoms are present or to obtain colonic biopsies especially in patients with diarrhoea predominant IBS. The management of IBS is based on a multifactorial approach and includes pharmacotherapy targeted against the predominant symptom, behavioural and psychological treatment, dietary alterations, education, reassurance and effective patient-physician relationship. When evaluating for the stress-induced condition in the upper GI tract, the diagnostic testing includes mainly blood tests and gastroscopy to rule out GERD and peptic ulcer disease. The therapy for these conditions is mainly based on the inhibition of gastric acid by proton pump inhibitors and eradication of Helicobacter pylori-infection. Additionally, melatonin an important mediator of brain gut axis has been shown to exhibit important protective effects against stress-induced lesions in the gastrointestinal tract. Finally, probiotics may profoundly affect the brain-gut interactions ("microbiome-gut-brain axis") and attenuate the development of stress-induced disorders in both the upper and lower gastrointestinal tract. Further studies on the brain-gut axis are needed to open new therapeutic avenues in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Thuringia Clinic Saalfeld, Teaching Hospital of the University Jena, Germany. pkonturek@thueringen-kliniken.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brzozowski</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>J Physiol Pharmacol</MedlineTA><NlmUniqueID>9114501</NlmUniqueID><ISSNLinking>0867-5910</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000930">Antidiarrheals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000930" MajorTopicYN="N">Antidiarrheals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017615" MajorTopicYN="N">Enteric Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22314561</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37541528</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1206</StartPage><EndPage>1218</EndPage><MedlinePgn>1206-1218</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2023.07.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(23)04838-2</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.</AbstractText><AbstractText Label="METHODS">MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.</AbstractText><AbstractText Label="RESULTS">We identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.</AbstractText><AbstractText Label="CONCLUSIONS">Some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodoory</LastName><ForeName>Vivek C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khasawneh</LastName><ForeName>Mais</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Eamonn M M</ForeName><Initials>EMM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayyedi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom. Electronic address: alexf12399@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2024 Mar;166(3):545-546. doi: 10.1053/j.gastro.2023.11.019.</RefSource><PMID Version="1">37979710</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Gastroenterology. 2024 Nov;167(6):1248. doi: 10.1053/j.gastro.2024.08.017.</RefSource><PMID Version="1">39207347</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal Bloating</Keyword><Keyword MajorTopicYN="N">Abdominal Pain</Keyword><Keyword MajorTopicYN="N">Irritable Bowel Syndrome</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>31</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37541528</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2023.07.018</ArticleId><ArticleId IdType="pii">S0016-5085(23)04838-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35433498</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>859967</StartPage><MedlinePgn>859967</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">859967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2022.859967</ELocationID><Abstract><AbstractText Label="BACKGROUND">Irritable bowel syndrome (IBS) is a common gastrointestinal condition. Studies regarding the treatment of IBS with probiotics have not yielded consistent results, and the best probiotics has not yet been confirmed. Therefore, we performed a network meta-analysis (NMA) to assess the relative rank order of different probiotics for IBS.</AbstractText><AbstractText Label="METHOD">We searched for RCTs on the efficacy of probiotics for IBS until August 25, 2021. The primary outcome was the symptom relief rate, as well as global symptoms, abdominal pain, bloating, and straining scores. The NMA was conducted using Stata 15.0. We also used meta-regression to explore whether the treatment length and dose influenced the efficacy.</AbstractText><AbstractText Label="RESULTS">Forty-three RCTs, with 5,531 IBS patients, were included in this analysis. Firstly, we compared the efficacy of different probiotic species. <i>B.coagulans</i> exhibited the highest probability to be the optimal probiotic specie in improving IBS symptom relief rate, as well as global symptom, abdominal pain, bloating, and straining scores. In regard to the secondary outcomes, <i>L.plantarum</i> ranked first in ameliorating the QOL of IBS patients, but without any significant differences compared with other probiotic species in standardized mean differences (SMD) estimates. Moreover, patients received <i>L.acidophilus</i> had lowest incidence of adverse events. The meta-regression revealed that no significant differences were found between participants using different doses of probiotics in all outcomes, while the treatment length, as a confounder, can significantly influence the efficacy of probiotics in ameliorating abdominal pain (Coef = -2.30; p = 0.035) and straining (Coef = -3.15; p = 0.020) in IBS patients. Thus, we performed the subgroup analysis on treatment length subsequently in these two outcomes, which showed that efficacy of <i>B.coagulans</i> using 8 weeks ranked first both in improving the abdominal pain and straining scores. Additionally, <i>B. coagulans</i> still had significant efficacy compared to different types of probiotic combinations in present study.</AbstractText><AbstractText Label="CONCLUSIONS">The findings of this NMA suggested that <i>B.coagulans</i> had prominent efficacy in treating IBS patients, and incorporating <i>B.coagulans</i> into a probiotic combination, or genetically engineering it to amplify its biological function may be a future research target to treat IBS patients. With few direct comparisons available between individual therapies today, this NMA may have utility in forming treatment guideline for IBS with probiotics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhang, Zhang, Zhang, Sun and Duan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cunzheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jindong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>China Center for Evidence Based Medical and Clinical Research, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35433498</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M. W., et al. . (2014). Cytokine and Clinical Response to Saccharomyces Boulardii Therapy in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized Trial. Eur. J. Gastroenterol. Hepatol. 26, 630&#x2013;639. doi:&#xa0;10.1097/MEG.0000000000000094</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A., Houghton L. A., Morris J., Reilly B., Guyonnet D., Feuillerat. N., et al. . (2009). Clinical Trial: The Effects of a Fermented Milk Product Containing Bifidobacterium Lactis DN-173 010 on Abdominal Distension and Gastrointestinal Transit in Irritable Bowel Syndrome With Constipation. Aliment. Pharmacol. Ther. 29, 104&#x2013;114. doi:&#xa0;10.1111/j.1365-2036.2008.03853.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03853.x</ArticleId><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. (2020). Heat-Inactivated Bifidobacterium Bifidum MIMBb75 (SYN-HI-001) in the Treatment of Irritable Bowel Syndrome: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Clinical Trial. Lancet Gastroenterol. Hepatol. 5, 658&#x2013;666. doi:&#xa0;10.1016/S2468-1253(20)30056-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauserman M., Michail S. (2005). The Use of Lactobacillus GG in Irritable Bowel Syndrome in Children: A Double-Blind Randomized Control Trial. J. Pediatr. 147, 197&#x2013;201. doi:&#xa0;10.1016/j.jpeds.2005.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2005.05.015</ArticleId><ArticleId IdType="pubmed">16126049</ArticleId></ArticleIdList></Reference><Reference><Citation>Begtrup L. M., de Muckadell O. B., Kjeldsen J., Christensen R. D., Jarb&#xf8;l D. E.. (2013). Long-Term Treatment With Probiotics in Primary Care Patients With Irritable Bowel Syndrome&#x2013;a Randomised, Double-Blind, Placebo Controlled Trial. Scand. J. Gastroenterol. 48, 1127&#x2013;1135. doi:&#xa0;10.3109/00365521.2013.825314</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2013.825314</ArticleId><ArticleId IdType="pubmed">23957590</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C. J., Ford A. C. (2020). Global Burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors. Nat. Rev. Gastroenterol. Hepatol. 17, 473&#x2013;486. doi:&#xa0;10.1038/s41575-020-0286-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. (2021). Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA 325, 865&#x2013;877. doi:&#xa0;10.1001/jama.2020.22532</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22532</ArticleId><ArticleId IdType="pubmed">33651094</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabotti M., Scirocco A., Maselli M. A., Severi C.. (2015). The Gut-Brain Axis: Interactions Between Enteric Microbiota, Central and Enteric Nervous Systems. Ann. Gastroenterol. 28, 203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367209</ArticleId><ArticleId IdType="pubmed">25830558</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C. H., Jo S. Y., Park H. J., Chang S. K., Byeon J. S., Myung S. J.. (2011). A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Saccharomyces Boulardii in Irritable Bowel Syndrome: Effect on Quality of Life. J. Clin. Gastroenterol. 45, 679&#x2013;683. doi:&#xa0;10.1097/MCG.0b013e318204593e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed F., Ratcliffe J., Fernandez L., Tomenson B., Palmer S., Rigby C., et al. . (2001). Health-Related Quality of Life and Health Care Costs in Severe, Refractory Irritable Bowel Syndrome. Ann. Intern. Med. 134, 860&#x2013;868. doi:&#xa0;10.7326/0003-4819-134-9_part_2-200105011-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-134-9_part_2-200105011-00010</ArticleId><ArticleId IdType="pubmed">11346322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J. M., Bernalier-Donadille A.. (2012). Efficacy and Safety Profile of LCR35 Complete Freeze-Dried Culture in Irritable Bowel Syndrome: A Randomized, Double-Blind Study. World J. Gastroenterol. 18, 2067&#x2013;2075. doi:&#xa0;10.3748/wjg.v18.i17.2067</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P.. (2008). A Double Blind Randomized Controlled Trial of a Probiotic Combination in 100 Patients With Irritable Bowel Syndrome. Gastroenterol. Clin. Biol. 32, 147&#x2013;152. doi:&#xa0;10.1016/j.gcb.2007.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrott&#xe9; P., Sawant P., Jayanthi V. (2012). Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome. World J. Gastroenterol. 18, 4012&#x2013;4018. doi:&#xa0;10.3748/wjg.v18.i30.4012</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Serag H. B., Olden K. (2002). Health-Related Quality of Life Among Persons With Irritable Bowel Syndrome: A Systematic Review. Aliment. Pharmacol. Ther. 16, 1171&#x2013;1185. doi:&#xa0;10.1046/j.1365-2036.2002.01290.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2002.01290.x</ArticleId><ArticleId IdType="pubmed">12030961</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshaghabee F., Rokana N., Gulhane R. D., Sharma C., Panwar H.. (2017). Bacillus As Potential Probiotics: Status, Concerns, and Future Perspectives. Front. Microbiol. 8. doi:&#xa0;10.3389/fmicb.2017.01490</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01490</ArticleId><ArticleId IdType="pmc">PMC5554123</ArticleId><ArticleId IdType="pubmed">28848511</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Klosterhalfen S.. (2009). Randomized Controlled Treatment Trial of Irritable Bowel Syndrome With a Probiotic E.-Coli Preparation (DSM17252) Compared to Placebo. Z Gastroenterol. 47, 209&#x2013;214. doi:&#xa0;10.1055/s-2008-1027702</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1027702</ArticleId><ArticleId IdType="pubmed">19197823</ArticleId></ArticleIdList></Reference><Reference><Citation>Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., et al. . (2014). Anxiety and Depression Comorbidities in Irritable Bowel Syndrome (IBS): A Systematic Review and Meta-Analysis. Eur. Arch. Psychiatry Clin. Neurosci. 264, 651&#x2013;660. doi:&#xa0;10.1007/s00406-014-0502-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-014-0502-z</ArticleId><ArticleId IdType="pubmed">24705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A. C., Harris L. A., Lacy B. E., Quigley E. M. M., Moayyedi P.. (2018). Systematic Review With Meta-Analysis: The Efficacy of Prebiotics, Probiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 48, 1044&#x2013;1060. doi:&#xa0;10.1111/apt.15001</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S., Okumura T., Inamori M., Okuyama Y., Kanazawa M., Kamiya T., et al. . (2021). Evidence-Based Clinical Practice Guidelines for Irritable Bowel Syndrome 2020. J. Gastroenterol. 56 (3), 193&#x2013;217. doi: 10.1007/s00535-020-01746-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K. R.. (2020). Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome. Int. J. Colorectal Dis. 35, 139&#x2013;145. doi:&#xa0;10.1007/s00384-019-03462-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K.. (2011). Randomised Clinical Trial: Bifidobacterium Bifidum MIMBb75 Significantly Alleviates Irritable Bowel Syndrome and Improves Quality of Life&#x2013;A Double-Blind, Placebo-Controlled Study. Aliment. Pharmacol. Ther. 33, 1123&#x2013;1132. doi:&#xa0;10.1111/j.1365-2036.2011.04633.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A. K., Maity C. (2021). Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant]. Med. (Baltimore) 100, e23641. doi:&#xa0;10.1097/MD.0000000000023641</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C. H., et al. . (2007). Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 on the Health-Related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: A Multicentre, Randomized, Double-Blind, Controlled Trial. Aliment. Pharmacol. Ther. 26, 475&#x2013;486. doi:&#xa0;10.1111/j.1365-2036.2007.03362.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03362.x</ArticleId><ArticleId IdType="pubmed">17635382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee K. A., Gonlachanvit S., Ghoshal U. C., Chua A. S. B., Miwa H., Wu J., et al. . (2019). Second Asian Consensus on Irritable Bowel Syndrome. J. Neurogastroenterol. Motil. 25, 343&#x2013;362. doi:&#xa0;10.5056/jnm19041</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm19041</ArticleId><ArticleId IdType="pmc">PMC6657923</ArticleId><ArticleId IdType="pubmed">31327218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A.. (2014). Therapeutic Effects, Tolerability and Safety of a Multi-Strain Probiotic in Iranian Adults With Irritable Bowel Syndrome and Bloating. Arch. Iran Med. 17, 466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir M. A., Ishaque S. M., Ali M. S., Mahmuduzzaman M., Hasan M.. (2011). Role of Saccharomyces Boulardii in Diarrhea Predominant Irritable Bowel Syndrome. Mymensingh Med. J. 20, 397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Camilleri M., McKinzie S., Lempke M. B., Burton D. D., Thomforde G. M., et al. . (2005). A Probiotic Mixture Alleviates Symptoms in Irritable Bowel Syndrome Patients: A Controlled 6-Month Intervention. Aliment. Pharmacol. Ther. 22, 387&#x2013;394. doi:&#xa0;10.1111/j.1365-2036.2005.02579.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02579.x</ArticleId><ArticleId IdType="pubmed">16128676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Myllyluoma E., Rajili&#x107;-Stojanovi&#x107; M., Kyr&#xf6;npalo S., Rasmussen M., J&#xe4;rvenp&#xe4;&#xe4; S., et al. . (2008). Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota. Aliment. Pharmacol. Ther. 27, 48&#x2013;57. doi:&#xa0;10.1111/j.1365-2036.2007.03542.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03542.x</ArticleId><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Camilleri M., McKinzie S., Lempke M. B., Burton D. D., Thomforde G. M., et al. . (2003). A Randomized Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment Pharmacol. Ther. 17, 895&#x2013;904. doi:&#xa0;10.1046/j.1365-2036.2003.01543.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Roque M. I. V., Camilleri M., Stephens D., Burton D. D., Baxter K., et al. . (2005). A Randomized Controlled Trial of a Probiotic Combination VSL# 3 and Placebo in Irritable Bowel Syndrome With Bloating. Neurogastroenterol. Motil. 17, 687&#x2013;696. doi:&#xa0;10.1111/j.1365-2982.2005.00695.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00695.x</ArticleId><ArticleId IdType="pubmed">16185307</ArticleId></ArticleIdList></Reference><Reference><Citation>King T. S., Elia M., Hunter J. O. (1998). Abnormal Colonic Fermentation in Irritable Bowel Syndrome. Lancet 352, 1187&#x2013;1189. doi:&#xa0;10.1016/s0140-6736(98)02146-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(98)02146-1</ArticleId><ArticleId IdType="pubmed">9777836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kligler B., Cohrssen A. (2008). Probiotics. Am. Fam Physician. 78, 1073&#x2013;1078. doi:&#xa0;10.1007/s00384-011-1363-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pubmed">19007054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruis W., et al. . (2012). A Double-Blind Placebo-Controlled Trial to Study Therapeutic Effects of Probiotic Escherichia Coli Nissle 1917 in Subgroups of Patients With Irritable Bowel Syndrome. Int. J. Colorectal Dis. 27, 467&#x2013;474. doi:&#xa0;10.1007/s00384-011-1363-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pmc">PMC3307993</ArticleId><ArticleId IdType="pubmed">22130826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B. E., Pimentel M., Brenner D. M., Chey W. D., Keefer L. A., Long M. D., et al. . (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 116, 17&#x2013;44. doi:&#xa0;10.14309/ajg.0000000000001036</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B. E., Patel N. K. (2017). Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 6, 99. doi:&#xa0;10.3390/jcm6110099</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligaarden S. C., Axelsson L., Naterstad K., Lydersen S., Farup P. G.. (2010). A Candidate Probiotic With Unfavourable Effects in Subjects With Irritable Bowel Syndrome: A Randomised Controlled Trial. BMC Gastroenterol. 10, 16. doi:&#xa0;10.1186/1471-230X-10-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-16</ArticleId><ArticleId IdType="pmc">PMC2831047</ArticleId><ArticleId IdType="pubmed">20144246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhang L., Wang X., Wang Z., Zhang J., Jiang R., et al. . (2016). Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Clin. Gastroenterol. Hepatol. 14, 1602&#x2013;1611.e5. doi:&#xa0;10.1016/j.cgh.2016.05.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2016.05.033</ArticleId><ArticleId IdType="pubmed">27266978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillil&#xe4; M., Huttunen T., M&#xe4;nnikk&#xf6; S., Taalikka M., Tennil&#xe4; J., et al. . (2016). Irritable Bowel Syndrome Symptom Severity Improves Equally With Probiotic and Placebo. World J. Gastroenterol. 22, 10631&#x2013;10642. doi:&#xa0;10.3748/wjg.v22.i48.10631</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R. S., Ahire J. J., Neelamraju J., Tripathi A., Nanal S.. (2019). Randomized Clinical Trial: The Effect of Probiotic Bacillus Coagulans Unique IS2 vs. Placebo on the Symptoms Management of Irritable Bowel Syndrome in Adults. Sci. Rep. 9, 12210. doi:&#xa0;10.1038/s41598-019-48554-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity C., Gupta A. K., Saroj D. B., Biyani A., Bagkar P., Kulkarni J., et al. . (2020). Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus Coagulans LBSC on Human Gut Microbiome Modulation. J. Diet Suppl.18, 577&#x2013;596. doi:&#xa0;10.1080/19390211.2020.1814931</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2020.1814931</ArticleId><ArticleId IdType="pubmed">32896190</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., et al. . (2016). Bacillus Coagulans MTCC 5856 Supplementation in the Management of Diarrhea Predominant Irritable Bowel Syndrome: A Double Blind Randomized Placebo Controlled Pilot Clinical Study. Nutr. J. 15, 21. doi:&#xa0;10.1186/s12937-016-0140-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C. J., Srivastava S., Leyer G. J. (2020). Lactobacillus Acidophilus DDS-1 and Bifidobacterium Lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients 12, 363. doi:&#xa0;10.3390/nu12020363</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F., Lacy B. E., Chang L., Chey W. D., Lembo A. J., Simren M., et al. . (2016). Bowel Disorders. Gastroenterology S0016&#x2013;5085(16)00222-5. doi:&#xa0;10.1053/j.gastro.2016.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P., Andrews C. N., MacQueen G., Korownyk C., Marsiglio M., Graff L., et al. . (2019). Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J. Can. Assoc. Gastroenterol. 2, 6&#x2013;29. doi:&#xa0;10.1093/jcag/gwy071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Y., Cong Y. (2019). Bacillus Coagulans and its Applications in Medicine. Benef. Microbes 10, 679&#x2013;688. doi:&#xa0;10.3920/BM2019.0016</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2019.0016</ArticleId><ArticleId IdType="pubmed">31203635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q. X., et al. . (2018). A Meta-Analysis of the Use of Probiotics to Alleviate Depressive Symptoms. J. Affect. Disord. 228, 13&#x2013;19. doi:&#xa0;10.1016/j.jad.2017.11.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2017.11.063</ArticleId><ArticleId IdType="pubmed">29197739</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielin K., Kordecki H., Birkenfeld B. (2001). A Controlled, Double-Blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients With Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 13, 1143&#x2013;1147. doi:&#xa0;10.1097/00042737-200110000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-200110000-00004</ArticleId><ArticleId IdType="pubmed">11711768</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Naftali T., Hallak R., Vaisman N.. (2005). The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients With Irritable Bowel Syndrome&#x2013;A Double Blind, Placebo-Controlled, Randomized Study. Clin. Nutr. 24, 925&#x2013;931. doi:&#xa0;10.1016/j.clnu.2005.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2005.06.001</ArticleId><ArticleId IdType="pubmed">16051399</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C. J., Savarino E. V., Ford A. C.. (2020). Global Prevalence of Irritable Bowel Syndrome According to Rome III or IV Criteria: A Systematic Review and Meta-Analysis. Lancet Gastroenterol. Hepatol. 5, 908&#x2013;917. doi:&#xa0;10.1016/S2468-1253(20)30217-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., et al. . (2005). Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles. Gastroenterology 128, 541&#x2013;551. doi:&#xa0;10.1053/j.gastro.2004.11.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan M. A., O&#x2019;Morain C. A. (2000). Bacterial Supplementation in the Irritable Bowel Syndrome. A Randomised Double-Blind Placebo-Controlled Crossover Study. Dig. Liver Dis. 32, 294&#x2013;301. doi:&#xa0;10.1016/s1590-8658(00)80021-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1590-8658(00)80021-3</ArticleId><ArticleId IdType="pubmed">11515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., et al. . (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. PloS Med. 18, e1003583. doi:&#xa0;10.1371/journal.pmed.1003583</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003583</ArticleId><ArticleId IdType="pmc">PMC8007028</ArticleId><ArticleId IdType="pubmed">33780438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton D. C. G., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., et al. . (2015). A Randomized Clinical Trial of Saccharomyces Cerevisiae Versus Placebo in the Irritable Bowel Syndrome. Dig. Liver Dis. 47, 119&#x2013;124. doi:&#xa0;10.1016/j.dld.2014.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M. I., Hall G. B., Ghajar K., Nardelli A., Bolino C., Lau J. T., et al. . (2017). Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology 153, 448&#x2013;459.e8. doi:&#xa0;10.1053/j.gastro.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Diaz J., Gomez-Llorente C., Fontana L., Gil A. (2014). Modulation of Immunity and Inflammatory Gene Expression in the Gut, in Inflammatory Diseases of the Gut and in the Liver by Probiotics. World J. Gastroenterol. 20, 15632&#x2013;15649. doi:&#xa0;10.3748/wjg.v20.i42.15632</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i42.15632</ArticleId><ArticleId IdType="pmc">PMC4229528</ArticleId><ArticleId IdType="pubmed">25400447</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S. (2018). Lactobacillus Acidophilus CL1285, Lactobacillus Casei LBC80R and Lactobacillus Rhamnosus CLR2 Improve Quality-of-Life and IBS Symptoms: A Double-Blind, Randomised, Placebo-Controlled Study. Benef. Microbes 9, 697&#x2013;706. doi:&#xa0;10.3920/BM2017.0105</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0105</ArticleId><ArticleId IdType="pubmed">29888656</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J., Li R., Raes J., Arumugam M., Burgdorf K. S., Manichanh C., et al. . (2010). A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature 464, 59&#x2013;65. doi:&#xa0;10.1038/nature08821</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08821</ArticleId><ArticleId IdType="pmc">PMC3779803</ArticleId><ArticleId IdType="pubmed">20203603</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskov H., Burcharth J., Pommergaard H. C., Rosenberg J. (2016). Irritable Bowel Syndrome, the Microbiota and the Gut-Brain Axis. Gut Microbes 7, 365&#x2013;383. doi:&#xa0;10.1080/19490976.2016.1218585</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2016.1218585</ArticleId><ArticleId IdType="pmc">PMC5046167</ArticleId><ArticleId IdType="pubmed">27472486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Goldsmith J. R., Carroll I. M., Barros S. P., Palsson O., Jobin C., et al. . (2014). Lactobacillus Acidophilus NCFM Affects Colonic Mucosal Opioid Receptor Expression in Patients With Functional Abdominal Pain - a Randomised Clinical Study. Aliment. Pharmacol. Ther. 40, 200&#x2013;207. doi:&#xa0;10.1111/apt.12800</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12800</ArticleId><ArticleId IdType="pmc">PMC4613798</ArticleId><ArticleId IdType="pubmed">24853043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel Y., Ringel-Kulka T. (2015). The Intestinal Microbiota and Irritable Bowel Syndrome. J. Clin. Gastroenterol. 49 Suppl 1, S56&#x2013;S59. doi:&#xa0;10.1097/MCG.0000000000000418</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000418</ArticleId><ArticleId IdType="pubmed">26447966</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L. M., McCahon D., Holder R., Wilson S., Hobbs F. D. (2013). A Randomised Controlled Trial of a Probiotic &#x2018;Functional Food&#x2019; in the Management of Irritable Bowel Syndrome. BMC Gastroenterol. 13, 45. doi:&#xa0;10.1186/1471-230X-13-45</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-45</ArticleId><ArticleId IdType="pmc">PMC3605320</ArticleId><ArticleId IdType="pubmed">23496803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., et al. . (2007). Lactobacillus Acidophilus Modulates Intestinal Pain and Induces Opioid and Cannabinoid Receptors. Nat. Med. 13, 35&#x2013;37. doi:&#xa0;10.1038/nm1521</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1521</ArticleId><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;ndergaard B., Olsson J., Ohlson K., Svensson U., Bytzer P., Ekesbo R. (2011). Effects of Probiotic Fermented Milk on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial. Scand. J. Gastroenterol. 46, 663&#x2013;672. doi:&#xa0;10.3109/00365521.2011.565066</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.565066</ArticleId><ArticleId IdType="pubmed">21443416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., et al. . (2020). A 2-Strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial. Dig. Liver Dis. 52, 534&#x2013;540. doi:&#xa0;10.1016/j.dld.2019.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2019.12.009</ArticleId><ArticleId IdType="pubmed">31952938</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C. (2015). Mental Health: Thinking From the Gut. Nature 518, S12&#x2013;S15. doi:&#xa0;10.1038/518S13a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/518S13a</ArticleId><ArticleId IdType="pubmed">25715275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D. H., Song J. H., Kim H. J., Lee J. H., Son H. J., Chang D. K., et al. . (2008). Therapeutic Effect of Lactobacillus Acidophilus-SDC 2012, 2013 in Patients With Irritable Bowel Syndrome. Dig. Dis. Sci. 53, 2714&#x2013;2718. doi:&#xa0;10.1007/s10620-007-0196-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B. M., Gralnek I. M., Bolus R., Chang L., Dulai G. S., Mayer E. A., et al. . (2004). Clinical Determinants of Health-Related Quality of Life in Patients With Irritable Bowel Syndrome. Arch. Intern. Med. 164, 1773&#x2013;1780. doi:&#xa0;10.1001/archinte.164.16.1773</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.16.1773</ArticleId><ArticleId IdType="pubmed">15364671</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Pelerin F., Cayzeele D. A., Maudet C., Housez B., Cazaubiel M., et al. . (2016). Randomized Double Blind Placebo-Controlled Trial of Saccharomyces Cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: Improvement in Abdominal Pain and Bloating in Those With Predominant Constipation. U. Eur. Gastroenterol. J. 4, 353&#x2013;362. doi:&#xa0;10.1177/2050640615602571</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S.. (2014). Randomized Clinical Trial: Effect of Lactobacillus Plantarum 299 V on Symptoms of Irritable Bowel Syndrome. Nutrition 30, 1151&#x2013;1157. doi:&#xa0;10.1016/j.nut.2014.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2014.02.010</ArticleId><ArticleId IdType="pubmed">25194614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudha M. R., Jayanthi N., Aasin M., Dhanashri R. D., Anirudh T. (2018). Efficacy of Bacillus Coagulans Unique IS2 in Treatment of Irritable Bowel Syndrome in Children: A Double Blind, Randomised Placebo Controlled Study. Benef. Microbes 9, 563&#x2013;572. doi:&#xa0;10.3920/BM2017.0129</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0129</ArticleId><ArticleId IdType="pubmed">29695183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y. Y., Li M., Li Y. Y., Li L. X., Zhai W. Z., Wang P. (2018). The Effect of Clostridium Butyricum on Symptoms and Fecal Microbiota in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Sci. Rep. 8, 2964. doi:&#xa0;10.1038/s41598-018-21241-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21241-z</ArticleId><ArticleId IdType="pmc">PMC5813237</ArticleId><ArticleId IdType="pubmed">29445178</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A. Y., Li M., Li Y. Y., Li L. X., Zhai W. Z., Wang P. (2016). Efficacy of Lactobacillus Casei Shirota for Patients With Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 28, 8&#x2013;14. doi:&#xa0;10.1097/MEG.0000000000000484</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000484</ArticleId><ArticleId IdType="pubmed">26469356</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D. H., Paine P. A., Black C. J., Houghton L. A., Everitt H. A., Corsetti M., et al. . (2021). British Society of Gastroenterology Guidelines on the Management of Irritable Bowel Syndrome. Gut 70, 1214&#x2013;1240. doi:&#xa0;10.1136/gutjnl-2021-324598</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P. J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., et al. . (2006). Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women With Irritable Bowel Syndrome. Am. J. Gastroenterol. 101, 1581&#x2013;1590. doi:&#xa0;10.1111/j.1572-0241.2006.00734.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins T., Sequoia J. (2017). Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am. Fam Physician. 96, 170&#x2013;178. doi:&#xa0;10.1007/s10620-014-3299-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">28762696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R. K., Yang C., Song G. H., Wong J., Ho K. Y. (2015). Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig. Dis. Sci. 60, 186&#x2013;194. doi:&#xa0;10.1007/s10620-014-3299-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">25092036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano J. M., Yu K., Donaldson G. P., Shastri G. G., Ann P., Ma L., et al. . (2015). Indigenous Bacteria From the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell 161, 264&#x2013;276. doi:&#xa0;10.1016/j.cell.2015.02.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.02.047</ArticleId><ArticleId IdType="pmc">PMC4393509</ArticleId><ArticleId IdType="pubmed">25860609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y. Q., Zuo X. L., Zhen Y. B., Yang J., Liu C. H. (2008). Clinical Trial: Effect of Active Lactic Acid Bacteria on Mucosal Barrier Function in Patients With Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 28, 994&#x2013;1002. doi:&#xa0;10.1111/j.1365-2036.2008.03818.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37184752</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Antibiotics and Probiotics for Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>687</StartPage><EndPage>699</EndPage><MedlinePgn>687-699</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-023-01871-y</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a disorder of a gut-brain interaction characterised by abdominal pain and a change in stool form or frequency. Current symptom-based definitions and the classification of IBS promote heterogeneity amongst patients, meaning that there may be several different pathophysiological abnormalities leading to similar symptoms. Although our understanding of IBS is incomplete, there are several indicators that the microbiome may be involved in a subset of patients. Techniques including a faecal sample analysis, colonic biopsies, duodenal aspirates or surrogate markers, such as breath testing, have been used to examine the gut microbiota in individuals with IBS. Because of a lack of a clear definition of what constitutes a healthy gut microbiota, and the fact that alterations in gut microbiota have only been shown to be associated with IBS, a causal relationship is yet to be established. We discuss several hypotheses as to how dysbiosis may be responsible for IBS symptoms, as well as potential treatment strategies. We review the current evidence for the use of antibiotics and probiotics to alter the microbiome in an attempt to improve IBS symptoms. Rifaximin, a non-absorbable antibiotic, is the most studied antibiotic and has now been licensed for use in IBS with diarrhoea in the USA, but the drug remains unavailable in many countries for this indication. Current evidence also suggests that certain probiotics, including Lactobacillus plantarum DSM 9843 and Bifidobacterium bifidum MIMBb75, may be efficacious in some patients with IBS. Finally, we describe the future challenges facing us in our attempt to modulate the microbiome to treat IBS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodoory</LastName><ForeName>Vivek C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Room 125, 4th Floor, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK. alexf12399@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Room 125, 4th Floor, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK. alexf12399@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L36O5T016N</RegistryNumber><NameOfSubstance UI="D000078262">Rifaximin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078262" MajorTopicYN="N">Rifaximin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37184752</ArticleId><ArticleId IdType="doi">10.1007/s40265-023-01871-y</ArticleId><ArticleId IdType="pii">10.1007/s40265-023-01871-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702295</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049223</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28404070</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049221</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32115-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Craig O, Gracie DJ, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32973070</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-322519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229&#x2013;39 (quiz 40).</Citation><ArticleIdList><ArticleId IdType="pubmed">18371141</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01740.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Staller K, Olen O, Soderling J, Roelstraete B, Tornblom H, Khalili H, et al. Mortality risk in irritable bowel syndrome: results from a nationwide prospective cohort study. Am J Gastroenterol. 2020;115(5):746&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32108661</ArticleId><ArticleId IdType="pmc">7196022</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Locke GR 3rd, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160713</ArticleId><ArticleId IdType="pmc">2887253</ArticleId><ArticleId IdType="doi">10.1038/ajg.2010.40</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Bianchi Porro G, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38(10):1031&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14621276</ArticleId><ArticleId IdType="doi">10.1080/00365520310004524</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57:323&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">36544055</ArticleId><ArticleId IdType="doi">10.1111/apt.17356</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56(5):844&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">35794733</ArticleId><ArticleId IdType="pmc">9543519</ArticleId><ArticleId IdType="doi">10.1111/apt.17132</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28196491</ArticleId><ArticleId IdType="pmc">5310011</ArticleId><ArticleId IdType="doi">10.1186/s12955-017-0611-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113(10):1540&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30254230</ArticleId><ArticleId IdType="doi">10.1038/s41395-018-0262-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Simren M, Jakobsson S. Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with irritable bowel syndrome. BMC Gastroenterol. 2022;22(1):73.</Citation><ArticleIdList><ArticleId IdType="pubmed">35183112</ArticleId><ArticleId IdType="pmc">8858507</ArticleId><ArticleId IdType="doi">10.1186/s12876-022-02158-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res. 1990;34(5):483&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2231481</ArticleId><ArticleId IdType="doi">10.1016/0022-3999(90)90022-V</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S, McMahon C, Lee HN, Katon J, Shin A, Rangan V, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17(12):2471-8.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31419572</ArticleId><ArticleId IdType="pmc">7675784</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2019.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, CLINICAL, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol. 2020;18(2):392-8.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">31154027</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2019.05.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, et al. Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. Aliment Pharmacol Ther. 2015;41(5):449&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25586008</ArticleId><ArticleId IdType="doi">10.1111/apt.13074</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of psychological comorbidity on the prognosis of irritable bowel syndrome. Am J Gastroenterol. 2021;116(7):1485&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">33840729</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001247</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022;56(1):110&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491477</ArticleId><ArticleId IdType="pmc">9325446</ArticleId><ArticleId IdType="doi">10.1111/apt.16939</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco ME, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pubmed">31002149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28058026</ArticleId><ArticleId IdType="pmc">5175258</ArticleId><ArticleId IdType="doi">10.3748/wjg.v22.i47.10450</ArticleId></ArticleIdList></Reference><Reference><Citation>Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254-72.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30315778</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2018.08.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. Clin Gastroenterol Hepatol. 2022;20(1):136-44.e31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33010413</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2020.09.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Chang L, Salwen-Deremer JK, Gibson PR, Keefer L, Muir JG, et al. Contrasting clinician and insurer perspectives to managing irritable bowel syndrome: multilevel modeling analysis. Am J Gastroenterol. 2021;116(4):748&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">33982945</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000989</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to pay for medications among patients with Rome IV irritable bowel syndrome. Neurogastroenterol Motil. 2023;35(2): e14483.</Citation><ArticleIdList><ArticleId IdType="pubmed">36178331</ArticleId><ArticleId IdType="doi">10.1111/nmo.14483</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert A. Irritable bowel syndrome: patient-provider interaction and patient education. J Clin Med. 2018;7(1):3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29301273</ArticleId><ArticleId IdType="pmc">5791011</ArticleId><ArticleId IdType="doi">10.3390/jcm7010003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearn M, Whorwell PJ, Vasant DH. Stigma and irritable bowel syndrome: a taboo subject? Lancet Gastroenterol Hepatol. 2020;5(6):607&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">31924568</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30348-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">33903147</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30996042</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2018-318160</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155(6):1753&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">30144426</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2018.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71:1117&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">34376515</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325214</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32276950</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-321191</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859183</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30324-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberio B, Savarino EV, Black CJ, Ford AC. Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.08.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.08.025</ArticleId><ArticleId IdType="pubmed">34425274</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">20427395</ArticleId><ArticleId IdType="doi">10.1136/gut.2009.202234</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042-54.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28069350</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.12.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63(11):1737&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24310267</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2013-305994</ArticleId></ArticleIdList></Reference><Reference><Citation>David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336217</ArticleId><ArticleId IdType="doi">10.1038/nature12820</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ. 2012;111(1):17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22533211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208106</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1004409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27528177</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">19602448</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2009.06.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20467896</ArticleId><ArticleId IdType="doi">10.1007/s10620-010-1276-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, et al. Small intestinal bacterial overgrowth in irritable bowel wyndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31913194</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11151884</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2000.03368.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31136009</ArticleId><ArticleId IdType="doi">10.1111/apt.15330</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982-94.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709830</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.06.020</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole PW, Flemer B. From culture to high-throughput sequencing and beyond: a layperson&#x2019;s guide to the &#x201c;omics&#x201d; and diagnostic potential of the microbiome. Gastroenterol Clin North Am. 2017;46(1):9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28164855</ArticleId><ArticleId IdType="doi">10.1016/j.gtc.2016.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugerth LW, Andreasson A, Talley NJ, Forsberg AM, Kjellstrom L, Schmidt PT, et al. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 2020;69(6):1076&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31601615</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-318717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111-23.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27725146</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg G, Rybakova D, Fischer D, Cernava T, Verges MC, Charles T, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020;8(1):103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32605663</ArticleId><ArticleId IdType="pmc">7329523</ArticleId><ArticleId IdType="doi">10.1186/s40168-020-00875-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20203603</ArticleId><ArticleId IdType="pmc">3779803</ArticleId><ArticleId IdType="doi">10.1038/nature08821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26824647</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179.</Citation><ArticleIdList><ArticleId IdType="pubmed">29899036</ArticleId><ArticleId IdType="pmc">6000740</ArticleId><ArticleId IdType="doi">10.1136/bmj.k2179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">20664075</ArticleId><ArticleId IdType="doi">10.1152/physrev.00045.2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, et al. Gut microbiota in patients with irritable bowel syndrome: a systematic review. Gastroenterology. 2019;157(1):97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30940523</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(6):1844-54.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20816835</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2010.08.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn&#x2019;s disease revealed by a metagenomic approach. Gut. 2006;55(2):205&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16188921</ArticleId><ArticleId IdType="pmc">1856500</ArticleId><ArticleId IdType="doi">10.1136/gut.2005.073817</ArticleId></ArticleIdList></Reference><Reference><Citation>Avuthu N, Guda C. Meta-analysis of altered gut microbiota reveals microbial and metabolic biomarkers for colorectal cancer. Microbiol Spectr. 2022;10(4): e0001322.</Citation><ArticleIdList><ArticleId IdType="pubmed">35766483</ArticleId><ArticleId IdType="doi">10.1128/spectrum.00013-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, et al. Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology. 2022;163(4):908&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">35724733</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.06.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MZ, Tran M, Xu T, Tierney BT, Patel C, Kostic AD. Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. Microbiome. 2022;10(1):218.</Citation><ArticleIdList><ArticleId IdType="pubmed">36482486</ArticleId><ArticleId IdType="pmc">9733034</ArticleId><ArticleId IdType="doi">10.1186/s40168-022-01373-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A, Marrone G, Di Daniele F, Ottaviani E, Wilson Jones G, Bernini R, et al. Impact of gut microbiota composition on onset and progression of chronic non-communicable diseases. Nutrients. 2019;11(5):1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">31091761</ArticleId><ArticleId IdType="pmc">6567014</ArticleId><ArticleId IdType="doi">10.3390/nu11051073</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19043404</ArticleId><ArticleId IdType="doi">10.1038/nature07540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, et al. Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes. 2015;2(3):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756039</ArticleId><ArticleId IdType="pmc">4705851</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson&#x2019;s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7(1):27.</Citation><ArticleIdList><ArticleId IdType="pubmed">33692356</ArticleId><ArticleId IdType="pmc">7946946</ArticleId><ArticleId IdType="doi">10.1038/s41531-021-00156-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26311042</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(15)00293-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">27711063</ArticleId><ArticleId IdType="doi">10.1038/nm.4185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22699611</ArticleId><ArticleId IdType="pmc">3376388</ArticleId><ArticleId IdType="doi">10.1038/nature11053</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med. 2018;24(10):1526&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30150717</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0160-1</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018;24(10):1532&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30150716</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0164-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan F, van Sinderen D, O&#x2019;Toole PW, Stanton C. Feeding the microbiota: transducer of nutrient signals for the host. Gut. 2017;66(9):1709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28663354</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2017-313872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri M, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut. 2020;69(7):1218&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">32066625</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-319654</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol. 2010;21(2):149&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20434324</ArticleId><ArticleId IdType="doi">10.1016/j.copbio.2010.03.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20566857</ArticleId><ArticleId IdType="pmc">2900693</ArticleId><ArticleId IdType="doi">10.1073/pnas.1002601107</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire MK, McGuire MA. Human milk: mother nature&#x2019;s prototypical probiotic food? Adv Nutr. 2015;6(1):112&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25593150</ArticleId><ArticleId IdType="pmc">4288270</ArticleId><ArticleId IdType="doi">10.3945/an.114.007435</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17(5):553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25974298</ArticleId><ArticleId IdType="pmc">5555213</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2015.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555(7695):210&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29489753</ArticleId><ArticleId IdType="doi">10.1038/nature25973</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke SF, Murphy EF, O&#x2019;Sullivan O, Lucey AJ, Humphreys M, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014;63(12):1913&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25021423</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2013-306541</ArticleId></ArticleIdList></Reference><Reference><Citation>Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37(2):223&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26695747</ArticleId><ArticleId IdType="pmc">4590619</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinozzi M, Giffi M, Sini N, Galle F, Valeriani F, De Vito C, et al. Cigarette smoking and human gut microbiota in healthy adults: a systematic review. Biomedicines. 2022;10(2):510.</Citation><ArticleIdList><ArticleId IdType="pubmed">35203720</ArticleId><ArticleId IdType="pmc">8962244</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10020510</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Schlaeppi K, van der Heijden MGA. Keystone taxa as drivers of microbiome structure and functioning. Nat Rev Microbiol. 2018;16(9):567&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">29789680</ArticleId><ArticleId IdType="doi">10.1038/s41579-018-0024-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">24781306</ArticleId><ArticleId IdType="doi">10.1038/ncomms4611</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1&#x2013;2):84&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24412651</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.12.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE. 2012;7(4): e35240.</Citation><ArticleIdList><ArticleId IdType="pubmed">22506074</ArticleId><ArticleId IdType="pmc">3323649</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0035240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29590046</ArticleId><ArticleId IdType="doi">10.1126/science.aao5774</ArticleId></ArticleIdList></Reference><Reference><Citation>Long SL, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017;56:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602676</ArticleId><ArticleId IdType="doi">10.1016/j.mam.2017.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020;130(1):438&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31815740</ArticleId><ArticleId IdType="doi">10.1172/JCI130976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23614584</ArticleId><ArticleId IdType="pmc">3701945</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1109400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan F, Hill C. Language, numeracy and logic in microbiome science. Nat Rev Gastroenterol Hepatol. 2019;16(7):387&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31168062</ArticleId><ArticleId IdType="doi">10.1038/s41575-019-0163-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S, Bahl MI, Baunwall SMD, Hvas CL, Licht TR. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021;87(11):e00395-e421.</Citation><ArticleIdList><ArticleId IdType="pubmed">33741632</ArticleId><ArticleId IdType="pmc">8208139</ArticleId><ArticleId IdType="doi">10.1128/AEM.00395-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Alammar N, Singh R, Nanavati J, Song Y, Chaudhary R, et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 2020;120(4):565&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">31473156</ArticleId><ArticleId IdType="doi">10.1016/j.jand.2019.05.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831718</ArticleId><ArticleId IdType="pmc">1395357</ArticleId><ArticleId IdType="doi">10.1126/science.1110591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol. 2002;68(7):3401&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12089021</ArticleId><ArticleId IdType="pmc">126800</ArticleId><ArticleId IdType="doi">10.1128/AEM.68.7.3401-3407.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G799-807.</Citation><ArticleIdList><ArticleId IdType="pubmed">21737778</ArticleId><ArticleId IdType="pmc">3220325</ArticleId><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel I, Sundin J, Fuentes S, Repsilber D, de Vos WM, Brummer RJ. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther. 2015;42(10):1211&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26376728</ArticleId><ArticleId IdType="doi">10.1111/apt.13399</ArticleId></ArticleIdList></Reference><Reference><Citation>Posserud I, Stotzer PO, Bj&#xf6;rnsson ES, Abrahamsson H, Simr&#xe9;n M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148502</ArticleId><ArticleId IdType="doi">10.1136/gut.2006.108712</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E, Tang J, Pyleris E, Pistiki A, Barbatzas C, Brown J, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50(9):1076&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">25865706</ArticleId><ArticleId IdType="doi">10.3109/00365521.2015.1027261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57(5):1321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262197</ArticleId><ArticleId IdType="doi">10.1007/s10620-012-2033-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva-Millan MJ, Leite G, Wang J, Morales W, Parodi G, Pimentel ML, et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022;117(12):2055&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">36114762</ArticleId><ArticleId IdType="pmc">9722381</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55(8):2135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19830557</ArticleId><ArticleId IdType="doi">10.1007/s10620-009-1012-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(6):1278&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24788320</ArticleId><ArticleId IdType="doi">10.1007/s10620-014-3157-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegazi FZ, Abo-Elnaga IG. Degradation of organic acids by dairy lactic acid bacteria. Zentralbl Bakteriol Naturwiss. 1980;135(3):212&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">6775434</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512&#x2013;9 (e114&#x2013;5).</Citation><ArticleIdList><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty JK, Bhargava A, Buret AG. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol. 2014;20(14):3976&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24744587</ArticleId><ArticleId IdType="pmc">3983453</ArticleId><ArticleId IdType="doi">10.3748/wjg.v20.i14.3976</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020;159(4):1526&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32679220</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.06.090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervier K, Moss S, Kumar N, Adoum A, Barne M, Browne H, et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 2022;71(9):1821&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34810234</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325177</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Gilja OH, Brathen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">31852769</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29980607</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota: a systematic review. J Infect. 2019;79(6):471&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">31629863</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2019.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogsgaard LR, Engsbro AL, Bytzer P. Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort. Scand J Gastroenterol. 2018;53(9):1027&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30189148</ArticleId><ArticleId IdType="doi">10.1080/00365521.2018.1500638</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula H, Grover M, Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, et al. Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders. Neurogastroenterol Motil. 2015;27(11):1580&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303310</ArticleId><ArticleId IdType="pmc">4624515</ArticleId><ArticleId IdType="doi">10.1111/nmo.12655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28(3):281&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26731696</ArticleId><ArticleId IdType="doi">10.1097/MEG.0000000000000557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Zakko S, Ferreira N, Ringel Y, Bortey E, Courtney K, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134(Suppl. 1):A545.</Citation></Reference><Reference><Citation>Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16454838</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00458.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17043337</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-145-8-200610170-00004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30294792</ArticleId><ArticleId IdType="doi">10.1111/apt.15001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125(4):381&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22444104</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2011.08.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A, Heimanson Z, McCallum R, Pimentel M. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2019;114(12):1886&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31688023</ArticleId><ArticleId IdType="pmc">6903366</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(Suppl 1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26618924</ArticleId><ArticleId IdType="doi">10.1111/apt.13437</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Agricultural Organisation of the United Nations (FAO) and World Health Organization (WHO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. https://www.fao.org/3/y6398e/y6398e.pdf . Accessed 23 Feb 2023.</Citation></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24912386</ArticleId><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EM. Probiotics in irritable bowel syndrome: the science and the evidence. J Clin Gastroenterol. 2015;49(Suppl. 1):S60&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26447967</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000000348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, et al. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain: a randomised clinical study. Aliment Pharmacol Ther. 2014;40(2):200&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24853043</ArticleId><ArticleId IdType="pmc">4613798</ArticleId><ArticleId IdType="doi">10.1111/apt.12800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159985</ArticleId><ArticleId IdType="doi">10.1038/nm1521</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15765388</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448-59.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28483500</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32277872</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T, Xu Z, Xia P, Feng Y, Liu B, Liu H, et al. The short-term efficacy of Bifidobacterium quadruple viable tablet in patients with diarrhea-predominant irritable bowel syndrome: potentially mediated by metabolism rather than diversity regulation. Am J Gastroenterol. 2022.</Citation></Reference><Reference><Citation>Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(1):81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">36369645</ArticleId><ArticleId IdType="doi">10.1111/apt.17310</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EJ, Tack J, Crowell MD, Gwee KA, Ke M, Schmulson MJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1469-80.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27147123</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.02.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM. Clinical trials of probiotics in patients with irritable bowel syndrome: some points to consider. J Neurogastroenterol Motil. 2022;28(2):204&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">35189598</ArticleId><ArticleId IdType="pmc">8978119</ArticleId><ArticleId IdType="doi">10.5056/jnm22012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">6145023</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(84)91816-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch&#x2019;s postulates for pyloric Campylobacter. Med J Aust. 1985;142(8):436&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3982345</ArticleId><ArticleId IdType="doi">10.5694/j.1326-5377.1985.tb113443.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126039</ArticleId><ArticleId IdType="doi">10.1126/science.aad3503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126040</ArticleId><ArticleId IdType="pmc">5240844</ArticleId><ArticleId IdType="doi">10.1126/science.aad3369</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">21508958</ArticleId><ArticleId IdType="pmc">3728647</ArticleId><ArticleId IdType="doi">10.1038/nature09944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34203002</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2112</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu13062112</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is still a common functional gastrointestinal disease that presents chronic abdominal symptoms but with a pathophysiology that is not yet fully elucidated. Moreover, the use of the synergistic combination of prebiotics and probiotics, known as synbiotics, for IBS therapy is still in the early stages. Advancements in technology led to determining the important role played by probiotics in IBS, whereas the present paper focuses on the detailed review of the various pathophysiologic mechanisms of action of probiotics, prebiotics, and synbiotics via multidisciplinary domains involving the gastroenterology (microbiota modulation, alteration of gut barrier function, visceral hypersensitivity, and gastrointestinal dysmotility) immunology (intestinal immunological modulation), and neurology (microbiota-gut-brain axis communication and co-morbidities) in mitigating the symptoms of IBS. In addition, this review synthesizes literature about the mechanisms involved in the beneficial effects of prebiotics and synbiotics for patients with IBS, discussing clinical studies testing the efficiency and outcomes of synbiotics used as therapy for IBS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Elemer</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7050-5686</Identifier><AffiliationInfo><Affiliation>Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#x103;linoiu</LastName><ForeName>Lavinia Florina</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0002-0198-0472</Identifier><AffiliationInfo><Affiliation>Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitrea</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5232-7978</Identifier><AffiliationInfo><Affiliation>Institute of Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vodnar</LastName><ForeName>Dan Cristian</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PN-III-P1-1.2-PCCDI-2017-0056</GrantID><Agency>Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005769" MajorTopicYN="N">Gastrointestinal Motility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alternative therapy</Keyword><Keyword MajorTopicYN="N">functional disease</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">gut&#x2013;brain axis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34203002</ArticleId><ArticleId IdType="pmc">PMC8233736</ArticleId><ArticleId IdType="doi">10.3390/nu13062112</ArticleId><ArticleId IdType="pii">nu13062112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jayaraman T., Wong R., Drossman D.A., Lee Y.Y. Communication breakdown between physicians and IBS sufferers: What is the conundrum and how to overcome it? J. R. Coll. Physicians Edinb. 2017;47:138&#x2013;141. doi: 10.4997/JRCPE.2017.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.4997/JRCPE.2017.206</ArticleId><ArticleId IdType="pubmed">28675183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Dumitrascu D., Fukudo S., Gerson C., Ghoshal U.C., Gwee K.A., Hungin A.P.S., Kang J.-Y., Minhu C., Schmulson M., et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66:1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S., Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol. Motil. 2016;29:e12982. doi: 10.1111/nmo.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12982</ArticleId><ArticleId IdType="pmc">PMC5367953</ArticleId><ArticleId IdType="pubmed">27781332</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono J.L., Carson R.T., Flores N.M. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual. Life Outcomes. 2017;15:1&#x2013;8. doi: 10.1186/s12955-017-0611-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-017-0611-2</ArticleId><ArticleId IdType="pmc">PMC5310011</ArticleId><ArticleId IdType="pubmed">28196491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek I.M., Hays R.D., Kilbourne A., Naliboff B., Mayer E.A. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654&#x2013;660. doi: 10.1053/gast.2000.16484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2000.16484</ArticleId><ArticleId IdType="pubmed">10982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal N., Spiegel B.M. The Effect of Irritable Bowel Syndrome on Health-Related Quality of Life and Health Care Expenditures. Gastroenterol. Clin. N. Am. 2011;40:11&#x2013;19. doi: 10.1016/j.gtc.2010.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2010.12.013</ArticleId><ArticleId IdType="pubmed">21333898</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco M.E., Manzoli L., de Giorgio R., Gasbarrini A., Cicchetti A., Bravi F., Altini M., Caio G.P., Ursini F. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: A meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 2019;23:2986&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pubmed">31002149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E. Review article: An analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:817&#x2013;830. doi: 10.1111/apt.14948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14948</ArticleId><ArticleId IdType="pmc">PMC6667996</ArticleId><ArticleId IdType="pubmed">30194692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393&#x2013;1407.e5. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M. The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS) J. Clin. Med. 2018;7:6. doi: 10.3390/jcm7010006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm7010006</ArticleId><ArticleId IdType="pmc">PMC5791014</ArticleId><ArticleId IdType="pubmed">29301380</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Collins S.M., Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014;5:419&#x2013;429. doi: 10.4161/gmic.29417.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.29417</ArticleId><ArticleId IdType="pmc">PMC4153782</ArticleId><ArticleId IdType="pubmed">24921926</ArticleId></ArticleIdList></Reference><Reference><Citation>Labus J.S., Hollister E.B., Jacobs J., Kirbach K., Oezguen N., Gupta A., Acosta J., Luna R.A., Aagaard K., Versalovic J., et al. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5:1&#x2013;17. doi: 10.1186/s40168-017-0260-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-017-0260-z</ArticleId><ArticleId IdType="pmc">PMC5410709</ArticleId><ArticleId IdType="pubmed">28457228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaridis N. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann. Gastroenterol. 2018;31:171&#x2013;187. doi: 10.20524/aog.2018.0229.</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2018.0229</ArticleId><ArticleId IdType="pmc">PMC5825947</ArticleId><ArticleId IdType="pubmed">29507464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.-S. The role of inflammation in irritable bowel syndrome (IBS) J. Inflamm. Res. 2018;11:345&#x2013;349. doi: 10.2147/JIR.S174982.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S174982</ArticleId><ArticleId IdType="pmc">PMC6159811</ArticleId><ArticleId IdType="pubmed">30288077</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajili&#x107;-Stojanovi&#x107; M., Schemann M., et al. Irritable bowel syndrome. Nat. Rev. Dis. Prim. 2016;2:1&#x2013;24. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin. Proc. 2018;93:1858&#x2013;1872. doi: 10.1016/j.mayocp.2018.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.032</ArticleId><ArticleId IdType="pmc">PMC6314474</ArticleId><ArticleId IdType="pubmed">30522596</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Junne F., Klosterhalfen S., Zipfel S., Martens U. Therapy options in irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2010;22:1402&#x2013;1411. doi: 10.1097/MEG.0b013e3283405a17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0b013e3283405a17</ArticleId><ArticleId IdType="pubmed">21389791</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.H., Kwon J.G., Kim S.K., Myung S.-J., Park K.S., Sohn C.-I., Rhee P.-L., Lee K.J., Lee O.Y., Jung H.-K., et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: A randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol. Motil. 2015;27:705&#x2013;716. doi: 10.1111/nmo.12544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12544</ArticleId><ArticleId IdType="pubmed">25809913</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev. Gastroenterol. Hepatol. 2018;12:439&#x2013;445. doi: 10.1080/17474124.2018.1447380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2018.1447380</ArticleId><ArticleId IdType="pubmed">29493330</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M. Probiotics, Prebiotics, and Synbiotics. Elsevier; Amsterdam, The Netherlands: 2016. Probiotics, Prebiotics, Synbiotics, and Other Strategies to Modulate the Gut Microbiota in Irritable Bowel Syndrome (IBS) pp. 549&#x2013;556.</Citation></Reference><Reference><Citation>Yu T., Zheng Y.-P., Tan J.-C., Xiong W.-J., Wang Y., Lin L. Effects of Prebiotics and Synbiotics on Functional Constipation. Am. J. Med. Sci. 2017;353:282&#x2013;292. doi: 10.1016/j.amjms.2016.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2016.09.014</ArticleId><ArticleId IdType="pubmed">28262216</ArticleId></ArticleIdList></Reference><Reference><Citation>Butel M.-J. Probiotics, gut microbiota and health. M&#xe9;d. Mal. Infect. 2014;44:1&#x2013;8. doi: 10.1016/j.medmal.2013.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medmal.2013.10.002</ArticleId><ArticleId IdType="pubmed">24290962</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:e13513. doi: 10.1111/nmo.13513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13513</ArticleId><ArticleId IdType="pubmed">30460770</ArticleId></ArticleIdList></Reference><Reference><Citation>FAO/WHO . Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Amerian C&#xf3;rdoba Park Hotel; C&#xf3;rdoba, Argentina: 2001.</Citation></Reference><Reference><Citation>Collado M.C., Gueimonde M., Sanz Y., Salminen S. Adhesion Properties and Competitive Pathogen Exclusion Ability of Bifidobacteria with Acquired Acid Resistance. J. Food Prot. 2006;69:1675&#x2013;1679. doi: 10.4315/0362-028X-69.7.1675.</Citation><ArticleIdList><ArticleId IdType="doi">10.4315/0362-028X-69.7.1675</ArticleId><ArticleId IdType="pubmed">16865903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira A.T., Teixeira M.M., Martins F.D.S. The Role of Probiotics and Prebiotics in Inducing Gut Immunity. Front. Immunol. 2013;4:445. doi: 10.3389/fimmu.2013.00445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00445</ArticleId><ArticleId IdType="pmc">PMC3859913</ArticleId><ArticleId IdType="pubmed">24376446</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron S., Gorbach S.L. Probiotics: Their role in the treatment and prevention of disease. Expert Rev. Anti-Infect. Ther. 2006;4:261&#x2013;275. doi: 10.1586/14787210.4.2.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.4.2.261</ArticleId><ArticleId IdType="pubmed">16597207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-J., Yu W.-K., Heo T.-R. Identification and screening for antimicrobial activity against Clostridium difficile of Bifidobacterium and Lactobacillus species isolated from healthy infant faeces. Int. J. Antimicrob. Agents. 2003;21:340&#x2013;346. doi: 10.1016/S0924-8579(02)00389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-8579(02)00389-8</ArticleId><ArticleId IdType="pubmed">12672580</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado M.C., Grze&#x15b;kowiak &#x141;., Salminen S. Probiotic Strains and Their Combination Inhibit In Vitro Adhesion of Pathogens to Pig Intestinal Mucosa. Curr. Microbiol. 2007;55:260&#x2013;265. doi: 10.1007/s00284-007-0144-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-007-0144-8</ArticleId><ArticleId IdType="pubmed">17657533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueimonde M., Noriega L., Margolles A., Reyes-Gavil&#xe1;n C.G.D.L., Salminen S. Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human intestinal mucus. Int. J. Food Microbiol. 2005;101:341&#x2013;346. doi: 10.1016/j.ijfoodmicro.2004.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijfoodmicro.2004.11.013</ArticleId><ArticleId IdType="pubmed">15925715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara S., Hashiba H., Hirota T., Forstner J.F. Inhibition of the binding of enterotoxigenic Escherichia coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT2928: Suggestive evidence of blocking of the binding receptor gangliotetraosylceramide on the cell surface. Int. J. Food Microbiol. 2001;67:97&#x2013;106. doi: 10.1016/s0168-1605(01)00432-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0168-1605(01)00432-9</ArticleId><ArticleId IdType="pubmed">11482574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueimonde M., Jalonen L., He F., Hiramatsu M., Salminen S. Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. Food Res. Int. 2006;39:467&#x2013;471. doi: 10.1016/j.foodres.2005.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodres.2005.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito M.B., Diaz J.P., Mu&#xf1;oz-Quezada S., Llorente C.G., Gil A. Probiotic Mechanisms of Action. Ann. Nutr. Metab. 2012;61:160&#x2013;174. doi: 10.1159/000342079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000342079</ArticleId><ArticleId IdType="pubmed">23037511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Rodr&#xed;guez I., S&#xe1;nchez B., Ruiz L., Turroni F., Ventura M., Ruas-Madiedo P., Gueimonde M., Margolles A. Role of Extracellular Transaldolase from Bifidobacterium bifidum in Mucin Adhesion and Aggregation. Appl. Environ. Microbiol. 2012;78:3992&#x2013;3998. doi: 10.1128/AEM.08024-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.08024-11</ArticleId><ArticleId IdType="pmc">PMC3346390</ArticleId><ArticleId IdType="pubmed">22447584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Alakomi H.-L., Skytta E., Saarela M., Mattila-Sandholm T., Latva-Kala K., Helander I.M. Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer Membrane. Appl. Environ. Microbiol. 2000;66:2001&#x2013;2005. doi: 10.1128/AEM.66.5.2001-2005.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.66.5.2001-2005.2000</ArticleId><ArticleId IdType="pmc">PMC101446</ArticleId><ArticleId IdType="pubmed">10788373</ArticleId></ArticleIdList></Reference><Reference><Citation>De Keersmaecker S.C., Verhoeven T.L., Desair J., Marchal K., Vanderleyden J., Nagy I. Strong antimicrobial activity ofLactobacillus rhamnosusGG againstSalmonella typhimuriumis due to accumulation of lactic acid. FEMS Microbiol. Lett. 2006;259:89&#x2013;96. doi: 10.1111/j.1574-6968.2006.00250.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6968.2006.00250.x</ArticleId><ArticleId IdType="pubmed">16684107</ArticleId></ArticleIdList></Reference><Reference><Citation>Makras L., Triantafyllou V., Fayol-Messaoudi D., Adriany T., Zoumpopoulou G., Tsakalidou E., Servin A., De Vuyst L. Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res. Microbiol. 2006;157:241&#x2013;247. doi: 10.1016/j.resmic.2005.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmic.2005.09.002</ArticleId><ArticleId IdType="pubmed">16266797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren J., Magnusson J., Broberg A., Schn&#xfc;rer J., Kenne L. Antifungal 3-Hydroxy Fatty Acids from Lactobacillus plantarum MiLAB. Appl. Environ. Microbiol. 2003;69:7554&#x2013;7557. doi: 10.1128/AEM.69.12.7554-7557.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.69.12.7554-7557.2003</ArticleId><ArticleId IdType="pmc">PMC309954</ArticleId><ArticleId IdType="pubmed">14660414</ArticleId></ArticleIdList></Reference><Reference><Citation>Umu &#xd6;.C.O., Rudi K., Diep D.B. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb. Ecol. Health Dis. 2017;28:1348886. doi: 10.1080/16512235.2017.1348886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16512235.2017.1348886</ArticleId><ArticleId IdType="pmc">PMC5614387</ArticleId><ArticleId IdType="pubmed">28959178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan M., Kjos M., Nes I., Diep D., Lotfipour F. Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance. J. Appl. Microbiol. 2012;113:723&#x2013;736. doi: 10.1111/j.1365-2672.2012.05338.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2012.05338.x</ArticleId><ArticleId IdType="pubmed">22583565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim Z., Winters D.K., Johnson M.G. Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacterium bifidum NCFB. J. Appl. Microbiol. 1999;86:45&#x2013;54. doi: 10.1046/j.1365-2672.1999.00629.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2672.1999.00629.x</ArticleId><ArticleId IdType="pubmed">10030011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen D.S., Cho G.-S., Hanak A., Huch M., Franz C.M., Arneborg N. The effect of bacteriocin-producing Lactobacillus plantarum strains on the intracellular pH of sessile and planktonic Listeria monocytogenes single cells. Int. J. Food Microbiol. 2010;141:S53&#x2013;S59. doi: 10.1016/j.ijfoodmicro.2010.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijfoodmicro.2010.03.040</ArticleId><ArticleId IdType="pubmed">20447709</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokoena M.P. Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and Applications against Uropathogens: A Mini-Review. Molecules. 2017;22:1255. doi: 10.3390/molecules22081255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22081255</ArticleId><ArticleId IdType="pmc">PMC6152299</ArticleId><ArticleId IdType="pubmed">28933759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Dhaka P., Vijay D., Vergis J., Mohan V., Kumar A., Kurkure N.V., Barbuddhe S.B., Malik S., Rawool D.B. Antimicrobial effects of Lactobacillus plantarum and Lactobacillus acidophilus against multidrug-resistant enteroaggregative Escherichia coli. Int. J. Antimicrob. Agents. 2016;48:265&#x2013;270. doi: 10.1016/j.ijantimicag.2016.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2016.05.014</ArticleId><ArticleId IdType="pubmed">27451088</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelschlaeger T.A. Mechanisms of probiotic actions&#x2014;A review. Int. J. Med. Microbiol. 2010;300:57&#x2013;62. doi: 10.1016/j.ijmm.2009.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmm.2009.08.005</ArticleId><ArticleId IdType="pubmed">19783474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohland C.L., Macnaughton W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Liver Physiol. 2010;298:G807&#x2013;G819. doi: 10.1152/ajpgi.00243.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00243.2009</ArticleId><ArticleId IdType="pubmed">20299599</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580&#x2013;591. doi: 10.1053/gast.2001.27224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2001.27224</ArticleId><ArticleId IdType="pubmed">11522742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewaschuk J.B., Diaz H., Meddings L., Diederichs B., Dmytrash A., Backer J., Langen M.L.-V., Madsen K.L. Secreted bioactive factors fromBifidobacterium infantisenhance epithelial cell barrier function. Am. J. Physiol. Liver Physiol. 2008;295:G1025&#x2013;G1034. doi: 10.1152/ajpgi.90227.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90227.2008</ArticleId><ArticleId IdType="pubmed">18787064</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Henry K.C., Donato K.A., Shen-Tu G., Gordanpour M., Sherman P.M. Lactobacillus rhamnosus Strain GG Prevents Enterohemorrhagic Escherichia coli O157:H7-Induced Changes in Epithelial Barrier Function. Infect. Immun. 2008;76:1340&#x2013;1348. doi: 10.1128/IAI.00778-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00778-07</ArticleId><ArticleId IdType="pmc">PMC2292865</ArticleId><ArticleId IdType="pubmed">18227169</ArticleId></ArticleIdList></Reference><Reference><Citation>Masselot C.R., Herrmann A., Carlstedt I., Michalski J.-C., Capon C. Glycosylation of the two O-glycosylated domains of human MUC2 mucin in patients transposed with artificial urinary bladders constructed from proximal colonic tissue. Glycoconj. J. 2008;25:213&#x2013;224. doi: 10.1007/s10719-007-9079-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10719-007-9079-3</ArticleId><ArticleId IdType="pubmed">18004654</ArticleId></ArticleIdList></Reference><Reference><Citation>Moal V.L.-L., Amsellem R., Servin A.L., Coconnier M.-H. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut. 2002;50:803&#x2013;811. doi: 10.1136/gut.50.6.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.50.6.803</ArticleId><ArticleId IdType="pmc">PMC1773224</ArticleId><ArticleId IdType="pubmed">12010882</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillipson M., Johansson M.E.V., Henriksn&#xe4;s J., Petersson J., Gendler S.J., Sandler S., Persson A.E.G., Hansson G.C., Holm L. The gastric mucus layers: Constituents and regulation of accumulation. Am. J. Physiol. Liver Physiol. 2008;295:G806&#x2013;G812. doi: 10.1152/ajpgi.90252.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90252.2008</ArticleId><ArticleId IdType="pubmed">18719000</ArticleId></ArticleIdList></Reference><Reference><Citation>Windle H.J., Fox &#xc1;., N&#xed;Eidhin D., Kelleher D. The Thioredoxin System of Helicobacter pylori. J. Biol. Chem. 2000;275:5081&#x2013;5089. doi: 10.1074/jbc.275.7.5081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.7.5081</ArticleId><ArticleId IdType="pubmed">10671551</ArticleId></ArticleIdList></Reference><Reference><Citation>Aristoteli L.P., Willcox M.D.P. Mucin Degradation Mechanisms by Distinct Pseudomonas aeruginosa Isolates In Vitro. Infect. Immun. 2003;71:5565&#x2013;5575. doi: 10.1128/IAI.71.10.5565-5575.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.71.10.5565-5575.2003</ArticleId><ArticleId IdType="pmc">PMC201046</ArticleId><ArticleId IdType="pubmed">14500475</ArticleId></ArticleIdList></Reference><Reference><Citation>Macfarlane S., Woodmansey E.J., Macfarlane G.T. Colonization of Mucin by Human Intestinal Bacteria and Establishment of Biofilm Communities in a Two-Stage Continuous Culture System. Appl. Environ. Microbiol. 2005;71:7483&#x2013;7492. doi: 10.1128/AEM.71.11.7483-7492.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.71.11.7483-7492.2005</ArticleId><ArticleId IdType="pmc">PMC1287682</ArticleId><ArticleId IdType="pubmed">16269790</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack D.R., Ahrne S., Hyde L., Wei S., A Hollingsworth M. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827&#x2013;833. doi: 10.1136/gut.52.6.827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.52.6.827</ArticleId><ArticleId IdType="pmc">PMC1773687</ArticleId><ArticleId IdType="pubmed">12740338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattar A.F., Teitelbaum D.H., Drongowski R.A., Yongyi F., Harmon C.M., Coran A.G. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int. 2002;18:586&#x2013;590. doi: 10.1007/s00383-002-0855-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00383-002-0855-7</ArticleId><ArticleId IdType="pubmed">12471471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Kim S.-H., Whang K.-Y., Kim Y.-J., Oh S. Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J. Microbiol. Biotechnol. 2008;18:1278&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667857</ArticleId></ArticleIdList></Reference><Reference><Citation>Otte J.-M., Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Liver Physiol. 2004;286:G613&#x2013;G626. doi: 10.1152/ajpgi.00341.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00341.2003</ArticleId><ArticleId IdType="pubmed">15010363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsall B.L. Innate and adaptive mechanisms to control of pathological intestinal inflammation. J. Pathol. 2008;214:242&#x2013;259. doi: 10.1002/path.2286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2286</ArticleId><ArticleId IdType="pubmed">18161750</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ndel M., Schroeder B., Zimmermann K., Huber H., Nuding S., Beisner J., Fellermann K., Stange E.F., Wehkamp J. Probiotic E. coli treatment mediates antimicrobial human &#x3b2;-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2008;2:166&#x2013;172. doi: 10.1038/mi.2008.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2008.77</ArticleId><ArticleId IdType="pmc">PMC10026704</ArticleId><ArticleId IdType="pubmed">19129752</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlee M., E Harder J., K&#xf6;ten B., Stange E.F., Wehkamp J., Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte &#x3b2;-defensin. Clin. Exp. Immunol. 2008;151:528&#x2013;535. doi: 10.1111/j.1365-2249.2007.03587.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2007.03587.x</ArticleId><ArticleId IdType="pmc">PMC2276967</ArticleId><ArticleId IdType="pubmed">18190603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehkamp J., Harder J., Wehkamp K., Meissner B.W.-V., Schlee M., Enders C., Sonnenborn U., Nuding S., Bengmark S., Fellermann K., et al. NF-&#x3ba;B- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: A Novel Effect of a Probiotic Bacterium. Infect. Immun. 2004;72:5750&#x2013;5758. doi: 10.1128/IAI.72.10.5750-5758.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.10.5750-5758.2004</ArticleId><ArticleId IdType="pmc">PMC517557</ArticleId><ArticleId IdType="pubmed">15385474</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez A., Finlay B.B. Defensins in the immunology of bacterial infections. Curr. Opin. Immunol. 2007;19:385&#x2013;391. doi: 10.1016/j.coi.2007.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2007.06.008</ArticleId><ArticleId IdType="pubmed">17702560</ArticleId></ArticleIdList></Reference><Reference><Citation>Farquhar M.G., Palade G.E. Junctional Complexes in Various Epithelia. J. Cell Biol. 1963;17:375&#x2013;412. doi: 10.1083/jcb.17.2.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.17.2.375</ArticleId><ArticleId IdType="pmc">PMC2106201</ArticleId><ArticleId IdType="pubmed">13944428</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas C.M., Versalovic J. Probiotics-host communication. Gut Microbes. 2010;1:148&#x2013;163. doi: 10.4161/gmic.1.3.11712.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.1.3.11712</ArticleId><ArticleId IdType="pmc">PMC2909492</ArticleId><ArticleId IdType="pubmed">20672012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S.C., Goulet J., Tompkins T.A. Probiotics Reduce Enterohemorrhagic Escherichia coli O157:H7- and Enteropathogenic E. coli O127:H6-Induced Changes in Polarized T84 Epithelial Cell Monolayers by Reducing Bacterial Adhesion and Cytoskeletal Rearrangements. Infect. Immun. 2005;73:5183&#x2013;5188. doi: 10.1128/IAI.73.8.5183-5188.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.73.8.5183-5188.2005</ArticleId><ArticleId IdType="pmc">PMC1201237</ArticleId><ArticleId IdType="pubmed">16041036</ArticleId></ArticleIdList></Reference><Reference><Citation>Putaala H., Salusj&#xe4;rvi T., Nordstr&#xf6;m M., Saarinen M., Ouwehand A.C., Hansen E.B., Rautonen N. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res. Microbiol. 2008;159:692&#x2013;698. doi: 10.1016/j.resmic.2008.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmic.2008.08.002</ArticleId><ArticleId IdType="pubmed">18783733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dykstra N.S., Hyde L., Adawi D., Kulik D., Ahrn&#xe9; S., Molin G., Jeppsson B., MacKenzie A., Mack D.R. Pulse Probiotic Administration Induces Repeated Small Intestinal Muc3 Expression in Rats. Pediatr. Res. 2011;69:206&#x2013;211. doi: 10.1203/PDR.0b013e3182096ff0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e3182096ff0</ArticleId><ArticleId IdType="pubmed">21135754</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingberg T.D., Pedersen M.H., Cencic A., Budde B.B. Application of Measurements of Transepithelial Electrical Resistance of Intestinal Epithelial Cell Monolayers To Evaluate Probiotic Activity. Appl. Environ. Microbiol. 2005;71:7528&#x2013;7530. doi: 10.1128/AEM.71.11.7528-7530.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.71.11.7528-7530.2005</ArticleId><ArticleId IdType="pmc">PMC1287686</ArticleId><ArticleId IdType="pubmed">16269795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan S., Dalmasso G., Imbert V., Peyron J.-F., Rampal P., Czerucka D. Saccharomyces boulardii Interferes with Enterohemorrhagic Escherichia coli-Induced Signaling Pathways in T84 Cells. Infect. Immun. 2003;71:766&#x2013;773. doi: 10.1128/IAI.71.2.766-773.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.71.2.766-773.2003</ArticleId><ArticleId IdType="pmc">PMC145355</ArticleId><ArticleId IdType="pubmed">12540556</ArticleId></ArticleIdList></Reference><Reference><Citation>Resta&#x2013;Lenert S., Barrett K.E. Probiotics and Commensals Reverse TNF-&#x3b1;&#x2013; and IFN-&#x3b3;&#x2013;Induced Dysfunction in Human Intestinal Epithelial Cells. Gastroenterology. 2006;130:731&#x2013;746. doi: 10.1053/j.gastro.2005.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.12.015</ArticleId><ArticleId IdType="pubmed">16530515</ArticleId></ArticleIdList></Reference><Reference><Citation>Resta-Lenert S. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) Gut. 2003;52:988&#x2013;997. doi: 10.1136/gut.52.7.988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.52.7.988</ArticleId><ArticleId IdType="pmc">PMC1773702</ArticleId><ArticleId IdType="pubmed">12801956</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorente C.G., Mu&#xf1;oz S., Gil A. Proceedings of the Nutrition Society. Volume 69. Cambridge University Press (CUP); Cambridge, UK: 2010. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics; pp. 381&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">20416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothhammer V., Quintana F.J. The aryl hydrocarbon receptor: An environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 2019;19:184&#x2013;197. doi: 10.1038/s41577-019-0125-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0125-8</ArticleId><ArticleId IdType="pubmed">30718831</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto S., Toshimitsu T., Matsuoka S., Maruyama A., Oh-Oka K., Takamura T., Nakamura Y., Ishimaru K., Fujii-Kuriyama Y., Ikegami S., et al. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. Immunol. Cell Biol. 2014;92:460&#x2013;465. doi: 10.1038/icb.2014.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2014.2</ArticleId><ArticleId IdType="pubmed">24518984</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonowal R., Swimm A., Sahoo A., Luo L., Matsunaga Y., Wu Z., Bhingarde J., Ejzak E.A., Ranawade A., Qadota H., et al. Indoles from commensal bacteria extend healthspan. Proc. Natl. Acad. Sci. USA. 2017;114:E7506&#x2013;E7515. doi: 10.1073/pnas.1706464114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1706464114</ArticleId><ArticleId IdType="pmc">PMC5594673</ArticleId><ArticleId IdType="pubmed">28827345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R., Desai C., Darby T.M., Luo L., Wolfarth A.A., Scharer C.D., Ardita C.S., Reedy A.R., Keebaugh E.S., Neish A.S. Lactobacilli Modulate Epithelial Cytoprotection through the Nrf2 Pathway. Cell Rep. 2015;12:1217&#x2013;1225. doi: 10.1016/j.celrep.2015.07.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.042</ArticleId><ArticleId IdType="pmc">PMC4640184</ArticleId><ArticleId IdType="pubmed">26279578</ArticleId></ArticleIdList></Reference><Reference><Citation>Alc&#xe1;ntara C., Coll-Marqu&#xe9;s J.M., Jad&#xe1;n-Piedra C., V&#xe9;lez D., Devesa V., Z&#xfa;&#xf1;iga M., Monedero V. Polyphosphate in Lactobacillus and Its Link to Stress Tolerance and Probiotic Properties. Front. Microbiol. 2018;9:1944. doi: 10.3389/fmicb.2018.01944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01944</ArticleId><ArticleId IdType="pmc">PMC6137179</ArticleId><ArticleId IdType="pubmed">30245671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: Microbial endocrinology in the design and use of probiotics. BioEssays. 2011;33:574&#x2013;581. doi: 10.1002/bies.201100024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201100024</ArticleId><ArticleId IdType="pubmed">21732396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H., Yang H., Ulloa L., et al. Nicotinic acetylcholine receptor &#x3b1;7 subunit is an essential regulator of inflammation. Nature. 2003;421:384&#x2013;388. doi: 10.1038/nature01339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01339</ArticleId><ArticleId IdType="pubmed">12508119</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony C., Scully P., O&#x2019;Mahony D., Murphy S., O&#x2019;Brien F., Lyons A., Sherlock G., Mac Sharry J., Kiely B., Shanahan F., et al. Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-&#x3ba;B Activation. PLoS Pathog. 2008;4:e1000112. doi: 10.1371/journal.ppat.1000112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000112</ArticleId><ArticleId IdType="pmc">PMC2474968</ArticleId><ArticleId IdType="pubmed">18670628</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas L., Suzuki K., Zhao J. Probiotics: A proactive approach to health. A symposium report. Br. J. Nutr. 2015;114:S1&#x2013;S15. doi: 10.1017/S0007114515004043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114515004043</ArticleId><ArticleId IdType="pubmed">26548336</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis. Cell. 2004;118:229&#x2013;241. doi: 10.1016/j.cell.2004.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2004.07.002</ArticleId><ArticleId IdType="pubmed">15260992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan F., Polk D.B. Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells. J. Biol. Chem. 2002;277:50959&#x2013;50965. doi: 10.1074/jbc.M207050200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M207050200</ArticleId><ArticleId IdType="pmc">PMC4006994</ArticleId><ArticleId IdType="pubmed">12393915</ArticleId></ArticleIdList></Reference><Reference><Citation>Neish A.S. Prokaryotic Regulation of Epithelial Responses by Inhibition of Ikappa B-alpha Ubiquitination. Science. 2000;289:1560&#x2013;1563. doi: 10.1126/science.289.5484.1560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.289.5484.1560</ArticleId><ArticleId IdType="pubmed">10968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., Campieri M., A Kamm M., Knight S.C., Stagg A.J. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602&#x2013;1609. doi: 10.1136/gut.2003.037325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.037325</ArticleId><ArticleId IdType="pmc">PMC1774301</ArticleId><ArticleId IdType="pubmed">15479680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: Recent advances. Inflamm. Bowel Dis. 2009;15:300&#x2013;310. doi: 10.1002/ibd.20602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.20602</ArticleId><ArticleId IdType="pubmed">18626975</ArticleId></ArticleIdList></Reference><Reference><Citation>Drakes M., Blanchard T., Czinn S. Bacterial Probiotic Modulation of Dendritic Cells. Infect. Immun. 2004;72:3299&#x2013;3309. doi: 10.1128/IAI.72.6.3299-3309.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.6.3299-3309.2004</ArticleId><ArticleId IdType="pmc">PMC415669</ArticleId><ArticleId IdType="pubmed">15155633</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson H., Larsson P., Wold A., Rudin A. Pattern of Cytokine Responses to Gram-Positive and Gram-Negative Commensal Bacteria Is Profoundly Changed when Monocytes Differentiate into Dendritic Cells. Infect. Immun. 2004;72:2671&#x2013;2678. doi: 10.1128/IAI.72.5.2671-2678.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.5.2671-2678.2004</ArticleId><ArticleId IdType="pmc">PMC387913</ArticleId><ArticleId IdType="pubmed">15102775</ArticleId></ArticleIdList></Reference><Reference><Citation>Braat H., Brande J.V.D., Van Tol E., Hommes D., Peppelenbosch M., Van Deventer S. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr. 2004;80:1618&#x2013;1625. doi: 10.1093/ajcn/80.6.1618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/80.6.1618</ArticleId><ArticleId IdType="pubmed">15585777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathmakanthan S., Li C.K.F., Cowie J., Hawkey C.J. Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J. Gastroenterol. Hepatol. 2004;19:166&#x2013;173. doi: 10.1111/j.1440-1746.2004.03181.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2004.03181.x</ArticleId><ArticleId IdType="pubmed">14731126</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha-Ram&#xed;rez L.M., P&#xe9;rez-Solano R.A., Casta&#xf1;&#xf3;n-Alonso S.L., Guerrero S.S.M., Pacheco A.R., Garibay M.G., Eslava C. Probiotic Lactobacillus Strains Stimulate the Inflammatory Response and Activate Human Macrophages. J. Immunol. Res. 2017;2017:1&#x2013;14. doi: 10.1155/2017/4607491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/4607491</ArticleId><ArticleId IdType="pmc">PMC5516745</ArticleId><ArticleId IdType="pubmed">28758133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shida K., Kiyoshima-Shibata J., Kaji R., Nagaoka M., Nanno M. Peptidoglycan from lactobacilli inhibits interleukin-12 production by macrophages induced byLactobacillus caseithrough Toll-like receptor 2-dependent and independent mechanisms. Immunology. 2009;128:e858&#x2013;e869. doi: 10.1111/j.1365-2567.2009.03095.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2009.03095.x</ArticleId><ArticleId IdType="pmc">PMC2753894</ArticleId><ArticleId IdType="pubmed">19740347</ArticleId></ArticleIdList></Reference><Reference><Citation>He F., Morita H., Ouwehand A.C., Hosoda M., Hiramatsu M., Kurisaki J.-I., Isolauri E., Benno Y., Salminen S. Stimulation of the Secretion of Pro-Inflammatory Cytokines byBifidobacteriumStrains. Microbiol. Immunol. 2002;46:781&#x2013;785. doi: 10.1111/j.1348-0421.2002.tb02765.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02765.x</ArticleId><ArticleId IdType="pubmed">12516776</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hemert S., Meijerink M., Molenaar D., A Bron P., De Vos P., Kleerebezem M., Wells J.M., Marco M.L. Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells. BMC Microbiol. 2010;10:293. doi: 10.1186/1471-2180-10-293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-10-293</ArticleId><ArticleId IdType="pmc">PMC3000848</ArticleId><ArticleId IdType="pubmed">21080958</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijerink M., van Hemert S., Taverne N., Wels M., De Vos P., Bron P.A., Savelkoul H.F., van Bilsen J., Kleerebezem M., Wells J.M. Identification of Genetic Loci in Lactobacillus plantarum That Modulate the Immune Response of Dendritic Cells Using Comparative Genome Hybridization. PLoS ONE. 2010;5:e10632. doi: 10.1371/journal.pone.0010632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010632</ArticleId><ArticleId IdType="pmc">PMC2869364</ArticleId><ArticleId IdType="pubmed">20498715</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdeano C.M., Cazorla S.I., Dumit J.M.L., V&#xe9;lez E., Perdig&#xf3;n G. Beneficial Effects of Probiotic Consumption on the Immune System. Ann. Nutr. Metab. 2019;74:115&#x2013;124. doi: 10.1159/000496426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000496426</ArticleId><ArticleId IdType="pubmed">30673668</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdeano C.M., Perdig&#xf3;n G. The Probiotic Bacterium Lactobacillus casei Induces Activation of the Gut Mucosal Immune System through Innate Immunity. Clin. Vaccine Immunol. 2006;13:219&#x2013;226. doi: 10.1128/CVI.13.2.219-226.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.13.2.219-226.2006</ArticleId><ArticleId IdType="pmc">PMC1391937</ArticleId><ArticleId IdType="pubmed">16467329</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Amster H., Rochat F., Saudan K., Mignot O., Aeschlimann J. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 1994;10:55&#x2013;63. doi: 10.1111/j.1574-695X.1994.tb00011.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.1994.tb00011.x</ArticleId><ArticleId IdType="pubmed">7874079</ArticleId></ArticleIdList></Reference><Reference><Citation>Isolauri E., Joensuu J., Suomalainen H., Luomala M., Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310&#x2013;312. doi: 10.1016/0264-410X(95)93319-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)93319-5</ArticleId><ArticleId IdType="pubmed">7631519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaila M., Isolauri E., Saxelin M., Arvilommi H., Vesikari T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Arch. Dis. Child. 1995;72:51&#x2013;53. doi: 10.1136/adc.72.1.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.72.1.51</ArticleId><ArticleId IdType="pmc">PMC1510973</ArticleId><ArticleId IdType="pubmed">7717739</ArticleId></ArticleIdList></Reference><Reference><Citation>Majamaa H., Isolauri E., Saxelin M., Vesikari T. Lactic Acid Bacteria in the Treatment of Acute Rotavirus Gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 1995;20:333&#x2013;338. doi: 10.1097/00005176-199504000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-199504000-00012</ArticleId><ArticleId IdType="pubmed">7608829</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.-H., Um J.-I., Lee B.-J., Goh J.-S., Park S.-Y., Kim W.-S., Kim P.-H. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell. Immunol. 2002;219:22&#x2013;27. doi: 10.1016/S0008-8749(02)00579-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-8749(02)00579-8</ArticleId><ArticleId IdType="pubmed">12473264</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinderola G., Matar C., Perdigon G. Role of Intestinal Epithelial Cells in Immune Effects Mediated by Gram-Positive Probiotic Bacteria: Involvement of Toll-Like Receptors. Clin. Vaccine Immunol. 2005;12:1075&#x2013;1084. doi: 10.1128/CDLI.12.9.1075-1084.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.12.9.1075-1084.2005</ArticleId><ArticleId IdType="pmc">PMC1235795</ArticleId><ArticleId IdType="pubmed">16148174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoarau C., Lagaraine C., Martin L., Velge-Roussel F., Lebranchu Y. Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J. Allergy Clin. Immunol. 2006;117:696&#x2013;702. doi: 10.1016/j.jaci.2005.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2005.10.043</ArticleId><ArticleId IdType="pubmed">16522473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeuthen L.H., Fink L., Fr&#xf8;kiaer H. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. Immunology. 2008;124:489&#x2013;502. doi: 10.1111/j.1365-2567.2007.02800.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02800.x</ArticleId><ArticleId IdType="pmc">PMC2492941</ArticleId><ArticleId IdType="pubmed">18217947</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo N.A., Perdigon G., Leblanc A.D.M.D. Oral administration of a probiotic Lactobacillus modulates cytokine production and TLR expression improving the immune response against Salmonella enterica serovar Typhimurium infection in mice. BMC Microbiol. 2011;11:177. doi: 10.1186/1471-2180-11-177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-11-177</ArticleId><ArticleId IdType="pmc">PMC3173335</ArticleId><ArticleId IdType="pubmed">21813005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740&#x2013;745. doi: 10.1038/35047123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35047123</ArticleId><ArticleId IdType="pubmed">11130078</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouladoux N., A Hall J., Grainger J.R., Dos Santos L.M., Kann M.G., Nagarajan V., Verthelyi D., Belkaid Y. Regulatory role of suppressive motifs from commensal DNA. Mucosal Immunol. 2012;5:623&#x2013;634. doi: 10.1038/mi.2012.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2012.36</ArticleId><ArticleId IdType="pmc">PMC3427718</ArticleId><ArticleId IdType="pubmed">22617839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520&#x2013;528. doi: 10.1053/j.gastro.2003.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2003.11.019</ArticleId><ArticleId IdType="pubmed">14762789</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss D.S., Raupach B., Takeda K., Akira S., Zychlinsky A. Toll-Like Receptors Are Temporally Involved in Host Defense. J. Immunol. 2004;172:4463&#x2013;4469. doi: 10.4049/jimmunol.172.7.4463.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.7.4463</ArticleId><ArticleId IdType="pubmed">15034062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourbeyre P., Denery S., Bodinier M. Probiotics, prebiotics, and synbiotics: Impact on the gut immune system and allergic reactions. J. Leukoc. Biol. 2011;89:685&#x2013;695. doi: 10.1189/jlb.1109753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1109753</ArticleId><ArticleId IdType="pubmed">21233408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shida K., Takahashi R., Iwadate E., Takamizawa K., Yasui H., Sato T., Habu S., Hachimura S., Kaminogawa S. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin. Exp. Allergy. 2002;32:563&#x2013;570. doi: 10.1046/j.0954-7894.2002.01354.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0954-7894.2002.01354.x</ArticleId><ArticleId IdType="pubmed">11972603</ArticleId></ArticleIdList></Reference><Reference><Citation>Shihab U.S., Mahfuza R., Mollika P., Masud R., Ranjan Kumar B., Mir Imam I.W., Rafiqul I.K. Ameliorative Effect of Probiotic Strains, Lactobacillus acidophilus and Lactobacillus bulgaricus against Acetic Acid-Induced Inflammation in the Mouse Colon. Am. J. Life Sci. 2020;8:183&#x2013;188. doi: 10.11648/j.ajls.20200806.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.11648/j.ajls.20200806.11</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Bhatia R., Khare P., Sharma S., Rajarammohan S., Bishnoi M., Bhadada S.K., Sharma S.S., Kaur J., Kondepudi K.K. Anti-inflammatory Bifidobacterium strains prevent dextran sodium sulfate induced colitis and associated gut microbial dysbiosis in mice. Sci. Rep. 2020;10:1&#x2013;14. doi: 10.1038/s41598-020-75702-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75702-5</ArticleId><ArticleId IdType="pmc">PMC7596498</ArticleId><ArticleId IdType="pubmed">33122795</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K.W., Malefyt R.D.W., Coffman R.L., O&#x2019;Garra A. Interleukin-10 and Theinterleukin-10 receptor. Annu. Rev. Immunol. 2001;19:683&#x2013;765. doi: 10.1146/annurev.immunol.19.1.683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.19.1.683</ArticleId><ArticleId IdType="pubmed">11244051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pessi T., S&#xfc;tas Y., Hurme M., Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy. 2000;30:1804&#x2013;1808. doi: 10.1046/j.1365-2222.2000.00948.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2222.2000.00948.x</ArticleId><ArticleId IdType="pubmed">11122221</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller D., Bode C., Hammes W.P., Pfeifer A.M., Schiffrin E.J., Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79&#x2013;87. doi: 10.1136/gut.47.1.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.47.1.79</ArticleId><ArticleId IdType="pmc">PMC1727962</ArticleId><ArticleId IdType="pubmed">10861268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 2004;5:169&#x2013;174. doi: 10.1111/j.1443-9573.2004.00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1443-9573.2004.00176.x</ArticleId><ArticleId IdType="pubmed">15612887</ArticleId></ArticleIdList></Reference><Reference><Citation>Colecchia A., Vestito A., La Rocca A., Pasqui F., Nikiforaki A., Festi D. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol. 2006;52:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">17108864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dughera L., Elia C., Navino M., Cisar&#xf2; F. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Bio-Med. Atenei Parm. 2007;78:111&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">17933278</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., Federico A., Chilovi F., Milandri G.L., De Bona M., et al. Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome. J. Clin. Gastroenterol. 2008;42:S218&#x2013;S223. doi: 10.1097/MCG.0b013e31817fadd6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817fadd6</ArticleId><ArticleId IdType="pubmed">18685503</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.-H., Rhee P.-L., Ko S.H., Joo N., Kim S.I., Kim C.-H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;mid A., Strni&#x161;a L., Bajc K., Vuji&#x107;-Podlipec D., Matija&#x161;i&#x107; B.B., Rogelj I. Randomized clinical trial: The effect of fermented milk with the probiotic cultures Lactobacillus acidophilus La-5&#xae; and Bifidobacterium BB-12&#xae; and Beneo dietary fibres on health-related quality of life and the symptoms of irritable bowel syndrome in adults. J. Funct. Foods. 2016;24:549&#x2013;557. doi: 10.1016/j.jff.2016.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jff.2016.04.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.-H., Cho D.-Y., Lee S.-H., Han K.-S., Yang S.-W., Kim J.-H., Lee S.-H., Kim S.-M., Kim K.-N. A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue. Korean J. Fam. Med. 2019;40:2&#x2013;8. doi: 10.4082/kjfm.17.0064.</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.17.0064</ArticleId><ArticleId IdType="pmc">PMC6351792</ArticleId><ArticleId IdType="pubmed">30360032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner A.C., Croffut R.M., Stranahan M.C. Prescript-assist&#x2122; probiotic-prebiotic treatment for irritable bowel syndrome: A methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin. Ther. 2005;27:755&#x2013;761. doi: 10.1016/j.clinthera.2005.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2005.06.005</ArticleId><ArticleId IdType="pubmed">16117982</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser A.M., Spindelboeck W., Halwachs B., Strohmaier H., Kump P., Gorkiewicz G., H&#xf6;genauer C. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur. J. Nutr. 2018;58:2767&#x2013;2778. doi: 10.1007/s00394-018-1826-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-018-1826-7</ArticleId><ArticleId IdType="pmc">PMC6768888</ArticleId><ArticleId IdType="pubmed">30251020</ArticleId></ArticleIdList></Reference><Reference><Citation>Luczynski P., Tramullas M., Viola M., Shanahan F., Clarke G., O&#x2019;Mahony S., Dinan T.G., Cryan J.F. Microbiota regulates visceral pain in the mouse. eLife. 2017;6 doi: 10.7554/eLife.25887.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.25887</ArticleId><ArticleId IdType="pmc">PMC5478269</ArticleId><ArticleId IdType="pubmed">28629511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters M.M., Vicario M., Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65:155&#x2013;168. doi: 10.1136/gutjnl-2015-309151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309151</ArticleId><ArticleId IdType="pubmed">26194403</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., de Giorgio R., Corinaldesi R., Stanghellini V. The Immune System in Irritable Bowel Syndrome. J. Neurogastroenterol. Motil. 2011;17:349&#x2013;359. doi: 10.5056/jnm.2011.17.4.349.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.4.349</ArticleId><ArticleId IdType="pmc">PMC3228974</ArticleId><ArticleId IdType="pubmed">22148103</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J. Neurogastroenterol. Motil. 2016;22:558&#x2013;574. doi: 10.5056/jnm16001.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16001</ArticleId><ArticleId IdType="pmc">PMC5056566</ArticleId><ArticleId IdType="pubmed">27431236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy P.J., Cryan J.F., Dinan T., Clarke G. Irritable bowel syndrome: A microbiome-gut-brain axis disorder? World J. Gastroenterol. 2014;20:14105&#x2013;14125. doi: 10.3748/wjg.v20.i39.14105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i39.14105</ArticleId><ArticleId IdType="pmc">PMC4202342</ArticleId><ArticleId IdType="pubmed">25339800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Zhang B., Verne N.G. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146:41&#x2013;46. doi: 10.1016/j.pain.2009.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2009.06.017</ArticleId><ArticleId IdType="pmc">PMC2763174</ArticleId><ArticleId IdType="pubmed">19595511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyland N.P., Quigley E.M.M., Brint E. Microbiota-host interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions. World J. Gastroenterol. 2014;20:8859&#x2013;8866. doi: 10.3748/wjg.v20.i27.8859.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i27.8859</ArticleId><ArticleId IdType="pmc">PMC4112904</ArticleId><ArticleId IdType="pubmed">25083059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y.-Q., Zuo X.-L., Zhen Y.-B., Yang J., Liu C.-H. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2008;28:994&#x2013;1002. doi: 10.1111/j.1365-2036.2008.03818.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Verd&#xfa; E.F., Berc&#xed;k P., Bergonzelli G.E., Huang X.-X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corth&#xe9;sy-Theulaz I., Collins S.M. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology. 2004;127:826&#x2013;837. doi: 10.1053/j.gastro.2004.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.06.007</ArticleId><ArticleId IdType="pubmed">15362038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Mao Y., Diorio C., Wang L., Huizinga J.D., Bienenstock J., Kunze W. Lactobacillus reuteriingestion and IKCachannel blockade have similar effects on rat colon motility and myenteric neurones. Neurogastroenterol. Motil. 2009;22:98-e33. doi: 10.1111/j.1365-2982.2009.01384.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01384.x</ArticleId><ArticleId IdType="pubmed">19788711</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Anitha M., Vijay&#x2013;Kumar M., Sitaraman S.V., Gewirtz A.T., Srinivasan S. Gut Microbial Products Regulate Murine Gastrointestinal Motility via Toll-Like Receptor 4 Signaling. Gastroenterology. 2012;143:1006&#x2013;1016.e4. doi: 10.1053/j.gastro.2012.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.06.034</ArticleId><ArticleId IdType="pmc">PMC3458182</ArticleId><ArticleId IdType="pubmed">22732731</ArticleId></ArticleIdList></Reference><Reference><Citation>Brint E.K., Mac Sharry J., Fanning A., Shanahan F., Quigley E.M.M. Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome. Am. J. Gastroenterol. 2011;106:329&#x2013;336. doi: 10.1038/ajg.2010.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2010.438</ArticleId><ArticleId IdType="pubmed">21102570</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper A., Naghibi M.M., Garcha D. The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. Foods. 2018;7:13. doi: 10.3390/foods7020013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods7020013</ArticleId><ArticleId IdType="pmc">PMC5848117</ArticleId><ArticleId IdType="pubmed">29373532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.J., Bak Y.-T. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J. Neurogastroenterol. Motil. 2011;17:252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Mao Y.-K., Wang B., Huizinga J.D., Bienenstock J., Kunze W. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am. J. Physiol. Liver Physiol. 2009;296:G868&#x2013;G875. doi: 10.1152/ajpgi.90511.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90511.2008</ArticleId><ArticleId IdType="pubmed">19179624</ArticleId></ArticleIdList></Reference><Reference><Citation>McKernan D.P., Fitzgerald P., Dinan T.G., Cryan J.F. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol. Motil. 2010;22:1029-e268. doi: 10.1111/j.1365-2982.2010.01520.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2010.01520.x</ArticleId><ArticleId IdType="pubmed">20518856</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Stasi E., Marignani M., Severi C., Alloni R., Dicuonzo G., Morelli L., Coppola R., Cicala M. Effect of Acute Mucosal Exposure to Lactobacillus rhamnosus GG on Human Colonic Smooth Muscle Cells. J. Clin. Gastroenterol. 2008;42:S185&#x2013;S190. doi: 10.1097/MCG.0b013e31817e1cac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817e1cac</ArticleId><ArticleId IdType="pubmed">18685510</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;r F., Von Koschitzky H., Roblick U., Bruch H.P., Schulze L., Sonnenborn U., B&#xf6;ttner M., Wedel T., Bottner M. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: Evidence from anin vitroorgan bath study. Neurogastroenterol. Motil. 2009;21:559-e17. doi: 10.1111/j.1365-2982.2008.01258.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01258.x</ArticleId><ArticleId IdType="pubmed">19220758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Han Y., Wang Z., Qin Z., Yang C., Cao J., Chen Y. Role of serotonin on the intestinal mucosal immune response to stress-induced diarrhea in weaning mice. BMC Gastroenterol. 2017;17:82. doi: 10.1186/s12876-017-0634-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-017-0634-5</ArticleId><ArticleId IdType="pmc">PMC5479009</ArticleId><ArticleId IdType="pubmed">28633646</ArticleId></ArticleIdList></Reference><Reference><Citation>Casado-Bedmar M., Keita &#xc5;.V. Potential neuro-immune therapeutic targets in irritable bowel syndrome. Ther. Adv. Gastroenterol. 2020;13 doi: 10.1177/1756284820910630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756284820910630</ArticleId><ArticleId IdType="pmc">PMC7153177</ArticleId><ArticleId IdType="pubmed">32313554</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer P., Farzi A. Neuropeptides and the Microbiota-Gut-Brain Axis. Adv. Exp. Med. Biol. 2014;817:195&#x2013;219. doi: 10.1007/978-1-4939-0897-4_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-0897-4_9</ArticleId><ArticleId IdType="pmc">PMC4359909</ArticleId><ArticleId IdType="pubmed">24997035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee S.H., Pothoulakis C., Mayer E.A. Principles and clinical implications of the brain&#x2013;gut&#x2013;enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009;6:306&#x2013;314. doi: 10.1038/nrgastro.2009.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2009.35</ArticleId><ArticleId IdType="pmc">PMC3817714</ArticleId><ArticleId IdType="pubmed">19404271</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., da Cunha A.P., Rezende R.M., Cialic R., Wei Z., Bry L., Comstock L.E., Gandhi R., Weiner H.L. The Host Shapes the Gut Microbiota via Fecal MicroRNA. Cell Host Microbe. 2016;19:32&#x2013;43. doi: 10.1016/j.chom.2015.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2015.12.005</ArticleId><ArticleId IdType="pmc">PMC4847146</ArticleId><ArticleId IdType="pubmed">26764595</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Santos J., Vanner S.J., Vergnolle N., Zoetendal E.G., Quigley E.M. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016;150:1305&#x2013;1318.e8. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E.A., Savidge T., Shulman R.J. Brain&#x2013;Gut Microbiome Interactions and Functional Bowel Disorders. Gastroenterology. 2014;146:1500&#x2013;1512. doi: 10.1053/j.gastro.2014.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.02.037</ArticleId><ArticleId IdType="pmc">PMC4114504</ArticleId><ArticleId IdType="pubmed">24583088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal U.C., Shukla R., Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196&#x2013;208. doi: 10.5009/gnl16126.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl16126</ArticleId><ArticleId IdType="pmc">PMC5347643</ArticleId><ArticleId IdType="pubmed">28274108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P., Denou E., Collins J., Jackson W., Lu J., Jury J., Deng Y., Blennerhassett P., Macri J., McCoy K.D., et al. The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice. Gastroenterology. 2011;141:599&#x2013;609.e3. doi: 10.1053/j.gastro.2011.04.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.04.052</ArticleId><ArticleId IdType="pubmed">21683077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA. 2011;108:16050&#x2013;16055. doi: 10.1073/pnas.1102999108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102999108</ArticleId><ArticleId IdType="pmc">PMC3179073</ArticleId><ArticleId IdType="pubmed">21876150</ArticleId></ArticleIdList></Reference><Reference><Citation>Luczynski P., Whelan S.O., O&#x2019;Sullivan C., Clarke G., Shanahan F., Dinan T., Cryan J.F. Adult microbiota-deficient mice have distinct dendritic morphological changes: Differential effects in the amygdala and hippocampus. Eur. J. Neurosci. 2016;44:2654&#x2013;2666. doi: 10.1111/ejn.13291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13291</ArticleId><ArticleId IdType="pmc">PMC5113767</ArticleId><ArticleId IdType="pubmed">27256072</ArticleId></ArticleIdList></Reference><Reference><Citation>Roohi E., Jaafari N., Hashemian F. On inflammatory hypothesis of depression: What is the role of IL-6 in the middle of the chaos? J. Neuroinflamm. 2021;18:1&#x2013;15. doi: 10.1186/s12974-021-02100-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02100-7</ArticleId><ArticleId IdType="pmc">PMC7884972</ArticleId><ArticleId IdType="pubmed">33593388</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Blennerhassett P., Lu J., Deng Y., Park A.J., Green W., Denou E., Silva M.A., Santacruz A., Sanz Y., et al. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat. Commun. 2015;6:7735. doi: 10.1038/ncomms8735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8735</ArticleId><ArticleId IdType="pubmed">26218677</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Ling Z., Zhang Y., Mao H., Ma Z., Yin Y., Wang W., Tang W., Tan Z., Shi J., et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav. Immun. 2015;48:186&#x2013;194. doi: 10.1016/j.bbi.2015.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.03.016</ArticleId><ArticleId IdType="pubmed">25882912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu X.-N., Kubo C., Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 2004;558:263&#x2013;275. doi: 10.1113/jphysiol.2004.063388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2004.063388</ArticleId><ArticleId IdType="pmc">PMC1664925</ArticleId><ArticleId IdType="pubmed">15133062</ArticleId></ArticleIdList></Reference><Reference><Citation>Heijtz R.D., Wang S., Anuar F., Qian Y., Bj&#xf6;rkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA. 2011;108:3047&#x2013;3052. doi: 10.1073/pnas.1010529108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010529108</ArticleId><ArticleId IdType="pmc">PMC3041077</ArticleId><ArticleId IdType="pubmed">21282636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey M.T., Dowd S., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. Brain Behav. Immun. 2011;25:397&#x2013;407. doi: 10.1016/j.bbi.2010.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.10.023</ArticleId><ArticleId IdType="pmc">PMC3039072</ArticleId><ArticleId IdType="pubmed">21040780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ja&#x161;arevi&#x107; E., Howerton C.L., Howard C.D., Bale T.L. Alterations in the Vaginal Microbiome by Maternal Stress Are Associated With Metabolic Reprogramming of the Offspring Gut and Brain. Endocrinology. 2015;156:3265&#x2013;3276. doi: 10.1210/en.2015-1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2015-1177</ArticleId><ArticleId IdType="pmc">PMC4541625</ArticleId><ArticleId IdType="pubmed">26079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Golubeva A.V., Crampton S., Desbonnet L., Edge D., O&#x2019;Sullivan O., Lomasney K.W., Zhdanov A., Crispie F., Moloney R.D., Borre Y.E., et al. Prenatal stress-induced alterations in major physiological systems correlate with gut microbiota composition in adulthood. Psychoneuroendocrinology. 2015;60:58&#x2013;74. doi: 10.1016/j.psyneuen.2015.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2015.06.002</ArticleId><ArticleId IdType="pubmed">26135201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharwani A., Mian M.F., Foster J.A., Surette M.G., Bienenstock J., Forsythe P. Structural &amp; functional consequences of chronic psychosocial stress on the microbiome &amp; host. Psychoneuroendocrinology. 2016;63:217&#x2013;227. doi: 10.1016/j.psyneuen.2015.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2015.10.001</ArticleId><ArticleId IdType="pubmed">26479188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Roberfroid M.B. Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J. Nutr. 1995;125:1401&#x2013;1412. doi: 10.1093/jn/125.6.1401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/125.6.1401</ArticleId><ArticleId IdType="pubmed">7782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Probert H.M., Van Loo J., Rastall R.A., Roberfroid M.B. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutr. Res. Rev. 2004;17:259&#x2013;275. doi: 10.1079/NRR200479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1079/NRR200479</ArticleId><ArticleId IdType="pubmed">19079930</ArticleId></ArticleIdList></Reference><Reference><Citation>Huda-Faujan N., Abdulamir A., Fatimah A., Anas O.M., Shuhaimi M., Yazid A., Loong Y. The Impact of the Level of the Intestinal Short Chain Fatty Acids in Inflammatory Bowel Disease Patients Versus Healthy Subjects. Open Biochem. J. 2010;4:53&#x2013;58. doi: 10.2174/1874091X01004010053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874091X01004010053</ArticleId><ArticleId IdType="pmc">PMC2887640</ArticleId><ArticleId IdType="pubmed">20563285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer H.M., Jonkers D.M.A.E., Vanhoutvin S.A.L.W., Troost F.J., Rijkers G., De Bru&#xef;ne A., Bast A., Venema K., Brummer R.-J.M. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin. Nutr. 2010;29:738&#x2013;744. doi: 10.1016/j.clnu.2010.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2010.04.002</ArticleId><ArticleId IdType="pubmed">20471725</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantu-Jungles T.M., Hamaker B.R. New View on Dietary Fiber Selection for Predictable Shifts in Gut Microbiota. mBio. 2020;11:02179-19. doi: 10.1128/mBio.02179-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02179-19</ArticleId><ArticleId IdType="pmc">PMC7029134</ArticleId><ArticleId IdType="pubmed">32071263</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung W.S.F., Meijerink M., Zeuner B., Holck J., Louis P., Meyer A.S., Wells J.M., Flint H.J., Duncan S.H. Prebiotic potential of pectin and pectic oligosaccharides to promote anti-inflammatory commensal bacteria in the human colon. FEMS Microbiol. Ecol. 2017;93 doi: 10.1093/femsec/fix127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsec/fix127</ArticleId><ArticleId IdType="pubmed">29029078</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M. Prebiotics and Probiotics in Digestive Health. Clin. Gastroenterol. Hepatol. 2019;17:333&#x2013;344. doi: 10.1016/j.cgh.2018.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2018.09.028</ArticleId><ArticleId IdType="pubmed">30267869</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson K.S., Gibson G.R., Hutkins R., Reimer R.A., Reid G., Verbeke K., Scott K.P., Holscher H.D., Azad M.B., Delzenne N.M., et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 2020;17:687&#x2013;701. doi: 10.1038/s41575-020-0344-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0344-2</ArticleId><ArticleId IdType="pmc">PMC7581511</ArticleId><ArticleId IdType="pubmed">32826966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney S.M., Gibbons S.M. Designing synbiotics for improved human health. Microb. Biotechnol. 2017;11:141&#x2013;144. doi: 10.1111/1751-7915.12885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.12885</ArticleId><ArticleId IdType="pmc">PMC5743828</ArticleId><ArticleId IdType="pubmed">29205932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Rossi M., Dimidi E., Whelan K. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2019;109:1098&#x2013;1111. doi: 10.1093/ajcn/nqy376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqy376</ArticleId><ArticleId IdType="pubmed">30949662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter J.O., Tuffnell Q., Lee A.J. Controlled Trial of Oligofructose in the Management of Irritable Bowel Syndrome. J. Nutr. 1999;129:1451S&#x2013;1453S. doi: 10.1093/jn/129.7.1451S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/129.7.1451S</ArticleId><ArticleId IdType="pubmed">10395619</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen M., Gudmand-H&#xf8;yer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am. J. Clin. Nutr. 2000;72:1570&#x2013;1575. doi: 10.1093/ajcn/72.6.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/72.6.1570</ArticleId><ArticleId IdType="pubmed">11101487</ArticleId></ArticleIdList></Reference><Reference><Citation>Silk D.B.A., Davis A., Vulevic J., Tzortzis G., Gibson G.R. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009;29:508&#x2013;518. doi: 10.1111/j.1365-2036.2008.03911.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03911.x</ArticleId><ArticleId IdType="pubmed">19053980</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G. A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology. 2014;146:67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M., Barbara G., Flint H.J., Spiegel B.M.R., Spiller R.C., Vanner S., Verdu E.F., Whorwell P., Zoetendal E.G. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2012;62:159&#x2013;176. doi: 10.1136/gutjnl-2012-302167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302167</ArticleId><ArticleId IdType="pmc">PMC3551212</ArticleId><ArticleId IdType="pubmed">22730468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi S.L., Correa D., Pak S.C. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome&#x2014;What is the current evidence? Complement. Ther. Med. 2019;43:73&#x2013;80. doi: 10.1016/j.ctim.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctim.2019.01.010</ArticleId><ArticleId IdType="pubmed">30935559</ArticleId></ArticleIdList></Reference><Reference><Citation>Mego M., Accarino A., Tzortzis G., Vulevic J., Gibson G., Guarner F., Azpiroz F. Colonic gas homeostasis: Mechanisms of adaptation following HOST-G904 galactooligosaccharide use in humans. Neurogastroenterol. Motil. 2017;92:e13080. doi: 10.1111/nmo.13080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13080</ArticleId><ArticleId IdType="pubmed">28418214</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaman J.-W., Mego M., Manichanh C., Ca&#xf1;ellas N., Ca&#xf1;ueto D., Segurola H., Jansana M., Malagelada C., Accarino A., Vulevic J., et al. Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders. Gastroenterology. 2018;155:1004&#x2013;1007. doi: 10.1053/j.gastro.2018.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.06.045</ArticleId><ArticleId IdType="pubmed">29964041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolida S., Gibson G.R. Synbiotics in Health and Disease. Annu. Rev. Food Sci. Technol. 2011;2:373&#x2013;393. doi: 10.1146/annurev-food-022510-133739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-food-022510-133739</ArticleId><ArticleId IdType="pubmed">22129388</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowiak-Kope&#x107; P., &#x15a;li&#x17c;ewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9:1021. doi: 10.3390/nu9091021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9091021</ArticleId><ArticleId IdType="pmc">PMC5622781</ArticleId><ArticleId IdType="pubmed">28914794</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey K.R., Naik S.R., Vakil B.V. Probiotics, prebiotics and synbiotics&#x2014;A review. J. Food Sci. Technol. 2015;52:7577&#x2013;7587. doi: 10.1007/s13197-015-1921-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13197-015-1921-1</ArticleId><ArticleId IdType="pmc">PMC4648921</ArticleId><ArticleId IdType="pubmed">26604335</ArticleId></ArticleIdList></Reference><Reference><Citation>Topping D.L., Fukushima M., Bird A.R. Proceedings of the Nutrition Society. Volume 62. CABI Publishing; Wallingford, UK: 2003. Resistant starch as a prebiotic and synbiotic: State of the art; pp. 171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12749342</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning A.P., Thompson W.G., Heaton K.W., Morris A.F. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2:653&#x2013;654. doi: 10.1136/bmj.2.6138.653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.6138.653</ArticleId><ArticleId IdType="pmc">PMC1607467</ArticleId><ArticleId IdType="pubmed">698649</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y.A., Locke R.G., Talley N.J., Zinsmeister A.R., Fett S.L., Melton J.L. A Comparison of The Rome and Manning Criteria for Case Identification in Epidemiological Investigations of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2000;95:2816&#x2013;2824. doi: 10.1111/j.1572-0241.2000.03192.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2000.03192.x</ArticleId><ArticleId IdType="pubmed">11051354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Patel N.K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017;6:99. doi: 10.3390/jcm6110099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Guo L.-M., Yang S.-Y., Wu Q., Meng F.-J. Effectiveness of probiotics in irritable bowel syndrome: Methodological quality of meta-analyses and systematic reviews. Front. Nurs. 2019;6:115&#x2013;121. doi: 10.2478/FON-2019-0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/FON-2019-0018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United Eur. Gastroenterol. J. 2018;6:604&#x2013;613. doi: 10.1177/2050640617736478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640617736478</ArticleId><ArticleId IdType="pmc">PMC5987284</ArticleId><ArticleId IdType="pubmed">29881616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd E.S., DeLoache W.C., Pruss K.M., Whitaker W.R., Sonnenburg J.L. An exclusive metabolic niche enables strain engraftment in the gut microbiota. Nature. 2018;557:434&#x2013;438. doi: 10.1038/s41586-018-0092-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0092-4</ArticleId><ArticleId IdType="pmc">PMC6126907</ArticleId><ArticleId IdType="pubmed">29743671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A., Moayyedi P., Chey W.D., Harris L.A., Lacy B.E., Saito Y.A., Quigley E.M.M. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018;113:1&#x2013;18. doi: 10.1038/s41395-018-0084-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0084-x</ArticleId><ArticleId IdType="pubmed">29950604</ArticleId></ArticleIdList></Reference><Reference><Citation>Su G.L., Ko C.W., Bercik P., Falck-Ytter Y., Sultan S., Weizman A.V., Morgan R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159:697&#x2013;705. doi: 10.1053/j.gastro.2020.05.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.059</ArticleId><ArticleId IdType="pubmed">32531291</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32054443</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1129-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>The journal of headache and pain</Title><ISOAbbreviation>J Headache Pain</ISOAbbreviation></Journal><ArticleTitle>Gut-brain Axis and migraine headache: a comprehensive review.</ArticleTitle><Pagination><StartPage>15</StartPage><MedlinePgn>15</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s10194-020-1078-9</ELocationID><Abstract><AbstractText>The terminology "gut-brain axis "points out a bidirectional relationship between the GI system and the central nervous system (CNS). To date, several researches have shown that migraine is associated with some gastrointestinal (GI) disorders such as Helicobacter pylori (HP) infection, irritable bowel syndrome (IBS), and celiac disease (CD). The present review article aims to discuss the direct and indirect evidence suggesting relationships between migraine and the gut-brain axis. However, the mechanisms explaining how the gut and the brain may interact in patients with migraine are not entirely clear. Studies suggest that this interaction seems to be influenced by multiple factors such as inflammatory mediators (IL-1&#x3b2;, IL-6, IL-8, and TNF-&#x3b1;), gut microbiota profile, neuropeptides and serotonin pathway, stress hormones and nutritional substances. Neuropeptides including CGRP, SP, VIP, NPY are thought to have antimicrobial impact on a variety of the gut bacterial strains and thus speculated to be involved in the bidirectional relationship between the gut and the brain. According to the current knowledge, migraine headache in patients harboring HP might be improved following the bacteria eradication. Migraineurs with long headache history and high headache frequency have a higher chance of being diagnosed with IBS. IBS and migraine share some similarities and can alter gut microflora composition and thereby may affect the gut-brain axis and inflammatory status. Migraine has been also associated with CD and the condition should be searched particularly in patients with migraine with occipital and parieto-occipital calcification at brain neuroimaging. In those patients, gluten-free diet can also be effective in reducing migraine frequency. It has also been proposed that migraine may be improved by dietary approaches with beneficial effects on gut microbiota and gut-brain axis including appropriate consumption of fiber per day, adhering to a low glycemic index diet, supplementation with vitamin D, omega-3 and probiotics as well as weight loss dietary plans for overweight and obese patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arzani</LastName><ForeName>Mahsa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahromi</LastName><ForeName>Soodeh Razeghi</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbani</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahabizad</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Headache Department, Neurology Ward, Sina University Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelletti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience section - Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy. simona.sacco@univaq.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Togha</LastName><ForeName>Mansoureh</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9368-6835</Identifier><AffiliationInfo><Affiliation>Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. togha1961@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Headache Department, Neurology Ward, Sina University Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. togha1961@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>School of Advanced Studies of the European Headache Federation (EHF-SAS)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Headache Pain</MedlineTA><NlmUniqueID>100940562</NlmUniqueID><ISSNLinking>1129-2369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008881" MajorTopicYN="N">Migraine Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32054443</ArticleId><ArticleId IdType="pmc">PMC7020496</ArticleId><ArticleId IdType="doi">10.1186/s10194-020-1078-9</ArticleId><ArticleId IdType="pii">10.1186/s10194-020-1078-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990&#x2013;2016: a systematic analysis for the global burden of disease study 2016. The Lancet Neurology. 2018;17(11):954&#x2013;976. doi: 10.1016/S1474-4422(18)30322-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30322-3</ArticleId><ArticleId IdType="pmc">PMC6191530</ArticleId><ArticleId IdType="pubmed">30353868</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17(1):104. doi: 10.1186/s10194-016-0699-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-016-0699-5</ArticleId><ArticleId IdType="pmc">PMC5108738</ArticleId><ArticleId IdType="pubmed">27844455</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. doi: 10.1186/s10194-018-0846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-018-0846-2</ArticleId><ArticleId IdType="pmc">PMC5821623</ArticleId><ArticleId IdType="pubmed">29468450</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache. 2018;58(Suppl 1):4&#x2013;16. doi: 10.1111/head.13300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13300</ArticleId><ArticleId IdType="pubmed">29697154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926&#x2013;938. doi: 10.1172/JCI76304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI76304</ArticleId><ArticleId IdType="pmc">PMC4362231</ArticleId><ArticleId IdType="pubmed">25689247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindiyeh N, Aurora SK. What the gut can teach us about migraine. Curr Pain Headache Rep. 2015;19(7):33. doi: 10.1007/s11916-015-0501-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-015-0501-4</ArticleId><ArticleId IdType="pubmed">26049770</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1288&#x2013;G1295. doi: 10.1152/ajpgi.00341.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00341.2012</ArticleId><ArticleId IdType="pubmed">23064760</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. Gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012;113(2):411&#x2013;417. doi: 10.1111/j.1365-2672.2012.05344.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2012.05344.x</ArticleId><ArticleId IdType="pubmed">22612585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaillon JM. Pro- versus anti-inflammatory cytokines: myth or reality. Cellular and molecular biology (Noisy-le-Grand, France). 2001;47(4):695&#x2013;702</Citation><ArticleIdList><ArticleId IdType="pubmed">11502077</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SF, Schaeffer AJ, Thumbikat P. Immune mediators of chronic pelvic pain syndrome. Nature reviews Urology. 2014;11(5):259&#x2013;269. doi: 10.1038/nrurol.2014.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2014.63</ArticleId><ArticleId IdType="pmc">PMC4986688</ArticleId><ArticleId IdType="pubmed">24686526</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49(1):65&#x2013;76. doi: 10.1016/j.brainresrev.2004.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2004.11.006</ArticleId><ArticleId IdType="pubmed">15960987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran R. Neurogenic inflammation and its role in migraine. Semin Immunopathol. 2018;40(3):301&#x2013;314. doi: 10.1007/s00281-018-0676-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-018-0676-y</ArticleId><ArticleId IdType="pubmed">29568973</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32&#x2013;48. doi: 10.1016/j.bbr.2014.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.07.027</ArticleId><ArticleId IdType="pubmed">25078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral FA, Sachs D, Costa VV, Fagundes CT, Cisalpino D, Cunha TM, et al. Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci U S A. 2008;105(6):2193&#x2013;2197. doi: 10.1073/pnas.0711891105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711891105</ArticleId><ArticleId IdType="pmc">PMC2538897</ArticleId><ArticleId IdType="pubmed">18268332</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis. Microbial endocrinology: The microbiota-gut-brain axis in health and disease: Springer; 2014. p. 195&#x2013;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359909</ArticleId><ArticleId IdType="pubmed">24997035</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqsood R, Stone TW. The gut-brain Axis, BDNF. NMDA and CNS Disorders Neurochem Res. 2016;41(11):2819&#x2013;2835. doi: 10.1007/s11064-016-2039-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-2039-1</ArticleId><ArticleId IdType="pubmed">27553784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HX, Wang YP. Gut microbiota-brain Axis. Chin Med J. 2016;129(19):2373&#x2013;2380. doi: 10.4103/0366-6999.190667.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.190667</ArticleId><ArticleId IdType="pmc">PMC5040025</ArticleId><ArticleId IdType="pubmed">27647198</ArticleId></ArticleIdList></Reference><Reference><Citation>Camara-Lemarroy CR, Rodriguez-Gutierrez R, Monreal-Robles R, Marfil-Rivera A. Gastrointestinal disorders associated with migraine: a comprehensive review. World J Gastroenterol. 2016;22(36):8149&#x2013;8160. doi: 10.3748/wjg.v22.i36.8149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i36.8149</ArticleId><ArticleId IdType="pmc">PMC5037083</ArticleId><ArticleId IdType="pubmed">27688656</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG, et al. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol. 2014;5:241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240046</ArticleId><ArticleId IdType="pubmed">25484876</ArticleId></ArticleIdList></Reference><Reference><Citation>Galland L. The gut microbiome and the brain. J Med Food. 2014;17(12):1261&#x2013;1272. doi: 10.1089/jmf.2014.7000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jmf.2014.7000</ArticleId><ArticleId IdType="pmc">PMC4259177</ArticleId><ArticleId IdType="pubmed">25402818</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzi A, Frohlich EE, Holzer P. Gut microbiota and the neuroendocrine system. Neurotherapeutics. 2018;15(1):5&#x2013;22. doi: 10.1007/s13311-017-0600-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0600-5</ArticleId><ArticleId IdType="pmc">PMC5794709</ArticleId><ArticleId IdType="pubmed">29380303</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella C, Giuli C, Agostini S, Bacquie V, Zinni M, Theodorou V, et al. Maternal exposure to low levels of corticosterone during lactation protects against experimental inflammatory colitis-induced damage in adult rat offspring. PLoS One. 2014;9(11):e113389. doi: 10.1371/journal.pone.0113389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113389</ArticleId><ArticleId IdType="pmc">PMC4236199</ArticleId><ArticleId IdType="pubmed">25405993</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini-Khoei H, Haghani-Samani E, Beigi M, Soltani A, Mobini GR, Balali-Dehkordi S, et al. On the role of corticosterone in behavioral disorders, microbiota composition alteration and neuroimmune response in adult male mice subjected to maternal separation stress. Int Immunopharmacol. 2019;66:242&#x2013;250. doi: 10.1016/j.intimp.2018.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.11.037</ArticleId><ArticleId IdType="pubmed">30500621</ArticleId></ArticleIdList></Reference><Reference><Citation>Verd&#xfa; EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55(2):182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz HJ, Mortrud MT, Rivier JE, Brown MR. Calcitonin gene related peptide inhibits basal, pentagastrin, histamine, and bethanecol stimulated gastric acid secretion. Gut. 1985;26(6):550&#x2013;555. doi: 10.1136/gut.26.6.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.26.6.550</ArticleId><ArticleId IdType="pmc">PMC1432758</ArticleId><ArticleId IdType="pubmed">2861147</ArticleId></ArticleIdList></Reference><Reference><Citation>Tache Y, Pappas T, Lauffenburger M, Goto Y, Walsh JH, Debas H. Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs. Gastroenterology. 1984;87(2):344&#x2013;349. doi: 10.1016/0016-5085(84)90711-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(84)90711-X</ArticleId><ArticleId IdType="pubmed">6145652</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Jiang YC, Owyang C. Central CGRP inhibits pancreatic enzyme secretion by modulation of vagal parasympathetic outflow. Am J Phys. 1998;275(5):G957&#x2013;G963.</Citation><ArticleIdList><ArticleId IdType="pubmed">9815024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhu KV, Sherwin E, Schellekens H, Stanton C, Dinan TG, Cryan JF. Feeding the microbiota-gut-brain axis: diet, microbiome, and neuropsychiatry. Transl Res. 2017;179:223&#x2013;244. doi: 10.1016/j.trsl.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2016.10.002</ArticleId><ArticleId IdType="pubmed">27832936</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61(1):37&#x2013;41. doi: 10.1203/01.pdr.0000250014.92242.f3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000250014.92242.f3</ArticleId><ArticleId IdType="pubmed">17211138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096&#x2013;2102. doi: 10.1007/s10620-012-2167-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-012-2167-7</ArticleId><ArticleId IdType="pubmed">22535281</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Floch MH. Prebiotics, probiotics, and dietary Fiber in gastrointestinal disease. Gastroenterol Clin N Am. 2007;36(1):47&#x2013;63. doi: 10.1016/j.gtc.2007.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2007.03.001</ArticleId><ArticleId IdType="pubmed">17472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble EE, Hsu TM, Kanoski SE. Gut to brain Dysbiosis: mechanisms linking Western diet consumption, the microbiome, and cognitive impairment. Front Behav Neurosci. 2017;11:9. doi: 10.3389/fnbeh.2017.00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2017.00009</ArticleId><ArticleId IdType="pmc">PMC5277010</ArticleId><ArticleId IdType="pubmed">28194099</ArticleId></ArticleIdList></Reference><Reference><Citation>Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014;146(6):1564&#x2013;1572. doi: 10.1053/j.gastro.2014.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.01.058</ArticleId><ArticleId IdType="pmc">PMC4216184</ArticleId><ArticleId IdType="pubmed">24503132</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li T, Beasley DE, Hed&#x11b;nec P, Xiao Z, Zhang S, et al. Diet diversity is associated with beta but not alpha diversity of pika gut microbiota. Front Microbiol. 2016;7:1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961685</ArticleId><ArticleId IdType="pubmed">27512391</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnell JA, Reimer RA. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. Gut Microbes. 2012;3(1):29&#x2013;34. doi: 10.4161/gmic.19246.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.19246</ArticleId><ArticleId IdType="pmc">PMC3827018</ArticleId><ArticleId IdType="pubmed">22555633</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010;5:119&#x2013;144. doi: 10.1146/annurev.pathol.4.110807.092135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathol.4.110807.092135</ArticleId><ArticleId IdType="pubmed">20078218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function. Ann N Y Acad Sci. 2009;1165(1):183&#x2013;189. doi: 10.1111/j.1749-6632.2009.04059.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04059.x</ArticleId><ArticleId IdType="pubmed">19538305</ArticleId></ArticleIdList></Reference><Reference><Citation>Y&#xfc;cel M, Kotan D, &#xc7;ift&#xe7;i GG, &#xc7;ift&#xe7;i I, Cikriklar H. Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci. 2016;20(5):930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">27010153</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation. 2010;7(1):27. doi: 10.1186/1742-2094-7-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-27</ArticleId><ArticleId IdType="pmc">PMC2861665</ArticleId><ArticleId IdType="pubmed">20398373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci. 2007;11(4):245&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">17876959</ArticleId></ArticleIdList></Reference><Reference><Citation>Perini F, D'Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, et al. Plasma cytokine levels in migraineurs and controls. Headache. 2005;45(7):926&#x2013;931. doi: 10.1111/j.1526-4610.2005.05135.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2005.05135.x</ArticleId><ArticleId IdType="pubmed">15985111</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez C, Vieites-Prado A, Perez-Mato M, Sobrino T, Rodriguez-Osorio X, Lopez A, et al. Role of adipocytokines in the pathophysiology of migraine: a cross-sectional study. Cephalalgia. 2018;38(5):904&#x2013;911. doi: 10.1177/0333102417720213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102417720213</ArticleId><ArticleId IdType="pubmed">28677995</ArticleId></ArticleIdList></Reference><Reference><Citation>Martami F, Razeghi Jahromi S, Togha M, Ghorbani Z, Seifishahpar M, Saidpour A. The serum level of inflammatory markers in chronic and episodic migraine: a case-control study. Neurol Sci. 2018;39(10):1741&#x2013;1749. doi: 10.1007/s10072-018-3493-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3493-0</ArticleId><ArticleId IdType="pubmed">30009333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathophysiology of Headaches From Molecule to Man. Paolo Martelletti RJ, editor: Springer, Cham; 2015</Citation></Reference><Reference><Citation>Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate Thalamo-cortical pathways relevant to migraine headache. Headache. 2017;57(Suppl 2):97&#x2013;111. doi: 10.1111/head.13083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13083</ArticleId><ArticleId IdType="pmc">PMC5424619</ArticleId><ArticleId IdType="pubmed">28485844</ArticleId></ArticleIdList></Reference><Reference><Citation>Filpa V, Moro E, Protasoni M, Crema F, Frigo G, Giaroni C. Role of glutamatergic neurotransmission in the enteric nervous system and brain-gut axis in health and disease. Neuropharmacology. 2016;111:14&#x2013;33. doi: 10.1016/j.neuropharm.2016.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.08.024</ArticleId><ArticleId IdType="pubmed">27561972</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer P, Reichmann F. Farzi AJN. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut&#x2013;brain axis. 2012;46(6):261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516703</ArticleId><ArticleId IdType="pubmed">22979996</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JA, Born W. Novel peptides from the calcitonin gene: expression, receptors and biological function. Peptides. 1985;6(Suppl 3):265&#x2013;271. doi: 10.1016/0196-9781(85)90384-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0196-9781(85)90384-5</ArticleId><ArticleId IdType="pubmed">3008119</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould HE. Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol. 2007;7(6):570&#x2013;574. doi: 10.1016/j.coph.2007.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2007.09.006</ArticleId><ArticleId IdType="pmc">PMC2692370</ArticleId><ArticleId IdType="pubmed">17954038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballaz S. The unappreciated roles of the cholecystokinin receptor CCK (1) in brain functioning. Rev Neurosci. 2017;28(6):573&#x2013;585. doi: 10.1515/revneuro-2016-0088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2016-0088</ArticleId><ArticleId IdType="pubmed">28343167</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao G, Han X, Hao T, Huang Q, Yu T. Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model. Neurosci Lett. 2015;587:29&#x2013;34. doi: 10.1016/j.neulet.2014.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.12.021</ArticleId><ArticleId IdType="pubmed">25524408</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor TP, van der Kooy D. Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J Neurosci. 1988;8(7):2468&#x2013;2476. doi: 10.1523/JNEUROSCI.08-07-02468.1988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.08-07-02468.1988</ArticleId><ArticleId IdType="pmc">PMC6569540</ArticleId><ArticleId IdType="pubmed">2470872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara LA, Pacioni D, Di Fronzo V, Russo BF, Speranza E, Carlino V, et al. Low-lipid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis. 2015;25(4):370&#x2013;375. doi: 10.1016/j.numecd.2014.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2014.12.006</ArticleId><ArticleId IdType="pubmed">25698152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ornello R, Ripa P, Pistoia F, Degan D, Tiseo C, Carolei A, et al. Migraine and body mass index categories: a systematic review and meta-analysis of observational studies. J Headache Pain. 2015;16(1):27. doi: 10.1186/s10194-015-0510-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-015-0510-z</ArticleId><ArticleId IdType="pmc">PMC4385329</ArticleId><ArticleId IdType="pubmed">25903159</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ, et al. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology. 2011;140(3):903&#x2013;912. doi: 10.1053/j.gastro.2010.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.10.012</ArticleId><ArticleId IdType="pmc">PMC4717904</ArticleId><ArticleId IdType="pubmed">20955703</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666&#x2013;673. doi: 10.1038/mp.2012.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.77</ArticleId><ArticleId IdType="pubmed">22688187</ArticleId></ArticleIdList></Reference><Reference><Citation>Saulnier DM, Ringel Y, Heyman MB, Foster JA, Bercik P, Shulman RJ, et al. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes. 2013;4(1):17&#x2013;27. doi: 10.4161/gmic.22973.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.22973</ArticleId><ArticleId IdType="pmc">PMC3555881</ArticleId><ArticleId IdType="pubmed">23202796</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JA, Neufeld K-AM. Gut&#x2013;brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305&#x2013;312. doi: 10.1016/j.tins.2013.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.01.005</ArticleId><ArticleId IdType="pubmed">23384445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani Z, Nazari S, Etesam F, Nourimajd S, Ahmadpanah M, Razeghi JS. The effect of Synbiotic as an adjuvant therapy to fluoxetine in moderate depression: a randomized multicenter trial. Arch Neurosci. 2018;5(2):e60507. doi: 10.5812/archneurosci.60507.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/archneurosci.60507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106(10):3698&#x2013;3703. doi: 10.1073/pnas.0812874106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812874106</ArticleId><ArticleId IdType="pmc">PMC2656143</ArticleId><ArticleId IdType="pubmed">19234110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal R, Debs LH, Patel AP, Nguyen D, Patel K, O'Connor G, et al. Neurotransmitters: the critical modulators regulating gut-brain Axis. J Cell Physiol. 2017;232(9):2359&#x2013;2372. doi: 10.1002/jcp.25518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.25518</ArticleId><ArticleId IdType="pmc">PMC5772764</ArticleId><ArticleId IdType="pubmed">27512962</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt AH, Stovner LJ, Hagen K, Zwart JA. Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study Cephalalgia. 2008;28(2):144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">18197884</ArticleId></ArticleIdList></Reference><Reference><Citation>Inaloo S, Dehghani SM, Hashemi SM, Heydari M, Heydari ST. Comorbidity of headache and functional constipation in children: a cross-sectional survey. Turk J Gastroenterol. 2014;25(5):508&#x2013;511. doi: 10.5152/tjg.2014.6183.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2014.6183</ArticleId><ArticleId IdType="pubmed">25417610</ArticleId></ArticleIdList></Reference><Reference><Citation>Meucci G, Radaelli F, Prada A, Bortoli A, Crotta S, Cerrato C, et al. Increased prevalence of migraine in patients with uninvestigated dyspepsia referred for open-access upper gastrointestinal endoscopy. Endoscopy. 2005;37(7):622&#x2013;625. doi: 10.1055/s-2005-870251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-870251</ArticleId><ArticleId IdType="pubmed">16010605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#x15f;kersoy C, Peker &#x15e;, Kaya A, &#xdc;nalp A, G&#xf6;kay N. Evaluation of the relationship between migraine disorder andoral comorbidities: multicenter randomized clinical trial. Turkish journal of medical sciences. 2016;46(3):712&#x2013;718. doi: 10.3906/sag-1412-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-1412-71</ArticleId><ArticleId IdType="pubmed">27513246</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Zhou XY, Zhang GX. Association between helicobacter pylori infection and migraine: a meta-analysis. World J Gastroenterol. 2014;20(40):14965&#x2013;14972. doi: 10.3748/wjg.v20.i40.14965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i40.14965</ArticleId><ArticleId IdType="pmc">PMC4209561</ArticleId><ArticleId IdType="pubmed">25356058</ArticleId></ArticleIdList></Reference><Reference><Citation>Savi L, Ribaldone DG, Fagoonee S, Pellicano R. Is helicobacter pylori the infectious trigger for headache?: a review. Infectious disorders drug targets. 2013;13(5):313&#x2013;317. doi: 10.2174/1871526513666131201125021.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871526513666131201125021</ArticleId><ArticleId IdType="pubmed">24304354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol. 2006;6(1):26. doi: 10.1186/1471-230X-6-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-6-26</ArticleId><ArticleId IdType="pmc">PMC1592499</ArticleId><ArticleId IdType="pubmed">17007634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang FY, Lu CL. Irritable bowel syndrome and migraine: bystanders or partners? Journal of neurogastroenterology and motility. 2013;19(3):301&#x2013;311. doi: 10.5056/jnm.2013.19.3.301.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2013.19.3.301</ArticleId><ArticleId IdType="pmc">PMC3714407</ArticleId><ArticleId IdType="pubmed">23875096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielli M, Cremonini F, Fiore G, Addolorato G, Padalino C, Candelli M, et al. Association between migraine and celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol. 2003;98(3):625&#x2013;629. doi: 10.1111/j.1572-0241.2003.07300.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2003.07300.x</ArticleId><ArticleId IdType="pubmed">12650798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Or O, Zelnik N, Shaoul R, Pacht A, Lerner A. The neurologic profile of children and adolescents with inflammatory bowel disease. J Child Neurol. 2015;30(5):551&#x2013;557. doi: 10.1177/0883073814521296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073814521296</ArticleId><ArticleId IdType="pubmed">24700662</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira GR, Teles BC, Brasil EF, Souza MH, Furtado LE, de Castro-Costa CM, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008;14(3):389&#x2013;395. doi: 10.1002/ibd.20304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.20304</ArticleId><ArticleId IdType="pubmed">17924556</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisset X, Bommelaer G, Boube M, Ouchchane L, Goutte M, Dapoigny M, et al. Migraine prevalence in inflammatory bowel disease patients: a tertiary-care Centre cross-sectional study. Eur J Pain. 2017;21(9):1550&#x2013;1560. doi: 10.1002/ejp.1056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejp.1056</ArticleId><ArticleId IdType="pubmed">28508514</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraji F, Zarinfar N, Zanjani AT, Morteza A. The effect of helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain physician. 2012;15(6):495&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">23159967</ArticleId></ArticleIdList></Reference><Reference><Citation>Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;64(10 suppl 2):S9&#x2013;S15. doi: 10.1212/WNL.64.10_suppl_2.S9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.64.10_suppl_2.S9</ArticleId><ArticleId IdType="pubmed">15911785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Zou Y, Zhang X. [Determination of serum calicotonin gene-related peptide in patients with duodenal ulcer infected with Helicobacter pylori]. Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University. 1999;24(3):273&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">12016804</ArticleId></ArticleIdList></Reference><Reference><Citation>Munno I, Marinaro M, Bassi A, Cassiano MA, Causarano V, Centonze V. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache. 2001;41(8):764&#x2013;767. doi: 10.1046/j.1526-4610.2001.01140.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1526-4610.2001.01140.x</ArticleId><ArticleId IdType="pubmed">11576199</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeberle HA, Kubin M, Bamford KB, Garofalo R, Graham DY, El-Zaatari F, et al. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun. 1997;65(10):4229&#x2013;4235. doi: 10.1128/IAI.65.10.4229-4235.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.65.10.4229-4235.1997</ArticleId><ArticleId IdType="pmc">PMC175607</ArticleId><ArticleId IdType="pubmed">9317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Windle HJ, Ang YS, Athie-Morales V, McManus R, Kelleher D. Human peripheral and gastric lymphocyte responses to helicobacter pylori NapA and AphC differ in infected and uninfected individuals. Gut. 2005;54(1):25&#x2013;32. doi: 10.1136/gut.2003.025494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.025494</ArticleId><ArticleId IdType="pmc">PMC1774350</ArticleId><ArticleId IdType="pubmed">15591500</ArticleId></ArticleIdList></Reference><Reference><Citation>Hida N, Shimoyama T, Jr, Neville P, Dixon MF, Axon AT, Shimoyama T, Sr, et al. Increased expression of IL-10 and IL-12 (p40) mRNA in helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J Clin Pathol. 1999;52(9):658&#x2013;664. doi: 10.1136/jcp.52.9.658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.52.9.658</ArticleId><ArticleId IdType="pmc">PMC501540</ArticleId><ArticleId IdType="pubmed">10655986</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JW, Cho YS, Lee SY, Kim ES, Cho H, Shin HE, et al. Concomitant functional gastrointestinal symptoms influence psychological status in Korean migraine patients. Gut and liver. 2013;7(6):668&#x2013;674. doi: 10.5009/gnl.2013.7.6.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2013.7.6.668</ArticleId><ArticleId IdType="pmc">PMC3848535</ArticleId><ArticleId IdType="pubmed">24312707</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson WC, Sullivan SN, Corke M, Rush D. Globus and headache: common symptoms of the irritable bowel syndrome. Can Med Assoc J. 1978;118(4):387&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1817959</ArticleId><ArticleId IdType="pubmed">630498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankarani KB, Akbari M, Tabrizi R. Association of Gastrointestinal Functional Disorders and Migraine Headache: a Population Base study. Middle East journal of digestive diseases. 2017;9(3):139&#x2013;145. doi: 10.15171/mejdd.2017.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/mejdd.2017.64</ArticleId><ArticleId IdType="pmc">PMC5585926</ArticleId><ArticleId IdType="pubmed">28894515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau CI, Lin CC, Chen WH, Wang HC, Kao CH. Association between migraine and irritable bowel syndrome: a population-based retrospective cohort study. Eur J Neurol. 2014;21(9):1198&#x2013;1204. doi: 10.1111/ene.12468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12468</ArticleId><ArticleId IdType="pubmed">24838228</ArticleId></ArticleIdList></Reference><Reference><Citation>Martami F, Ghorbani Z, Abolhasani M, Togha M, Meysamie A, Sharifi A, et al. Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: a cross-sectional study in Iran. Neurol Sci. 2018;39(1):63&#x2013;70. doi: 10.1007/s10072-017-3141-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3141-0</ArticleId><ArticleId IdType="pubmed">29022143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Price DD, Callam CS, Woodruff MA, Verne GN. Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome. J Pain. 2011;12(2):297&#x2013;303. doi: 10.1016/j.jpain.2010.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2010.09.002</ArticleId><ArticleId IdType="pmc">PMC3058359</ArticleId><ArticleId IdType="pubmed">21146468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther. 2004;20(10):1195&#x2013;1203. doi: 10.1111/j.1365-2036.2004.02250.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2004.02250.x</ArticleId><ArticleId IdType="pubmed">15569123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Yu S, Li H, Zhou J, Liu J, Tang W, et al. Clinical features and risk factors for irritable bowel syndrome in migraine patients. Pak J Med Sci. 2017;33(3):720&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510134</ArticleId><ArticleId IdType="pubmed">28811802</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roos N, Giezenaar C, Rovers J, Witteman B, Smits M, Van Hemert S. The effects of the multispecies probiotic mixture ecologic&#xae; barrier on migraine: results of an open-label pilot study. Benef Microbes. 2015;6(5):641&#x2013;646. doi: 10.3920/BM2015.0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2015.0003</ArticleId><ArticleId IdType="pubmed">25869282</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG et al (2014) Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol 5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240046</ArticleId><ArticleId IdType="pubmed">25484876</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013;33(6):408&#x2013;415. doi: 10.1177/0333102412473371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102412473371</ArticleId><ArticleId IdType="pmc">PMC5098810</ArticleId><ArticleId IdType="pubmed">23463252</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgescu D, Reisz D, Gurban CV, Georgescu LA, Ionita I, Ancusa OE, et al. Migraine in young females with irritable bowel syndrome: still a challenge. Neuropsychiatr Dis Treat. 2018;14:21&#x2013;28. doi: 10.2147/NDT.S144955.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S144955</ArticleId><ArticleId IdType="pmc">PMC5741982</ArticleId><ArticleId IdType="pubmed">29302188</ArticleId></ArticleIdList></Reference><Reference><Citation>de Roos NM, van Hemert S, Rovers JMP, Smits MG, Witteman BJM. The effects of a multispecies probiotic on migraine and markers of intestinal permeability-results of a randomized placebo-controlled study. Eur J Clin Nutr. 2017;71(12):1455&#x2013;1462. doi: 10.1038/ejcn.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2017.57</ArticleId><ArticleId IdType="pubmed">28537581</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydinlar EI, Dikmen PY, Tiftikci A, Saruc M, Aksu M, Gunsoy HG, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013;53(3):514&#x2013;525. doi: 10.1111/j.1526-4610.2012.02296.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2012.02296.x</ArticleId><ArticleId IdType="pubmed">23216231</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 2004;141(8):1285&#x2013;1293. doi: 10.1038/sj.bjp.0705762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705762</ArticleId><ArticleId IdType="pmc">PMC1574906</ArticleId><ArticleId IdType="pubmed">15100164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulak A, Paradowski L. Migraine and irritable bowel syndrome. Neurol Neurochir Pol. 2005;39(4 Suppl 1):S55&#x2013;S60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16419571</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther. 2010;31(1):35&#x2013;46. doi: 10.1111/j.1365-2036.2009.04153.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04153.x</ArticleId><ArticleId IdType="pmc">PMC2896496</ArticleId><ArticleId IdType="pubmed">19785622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, McCarson KE, Welch KM, Berman NE. Mechanisms of pain modulation by sex hormones in migraine. Headache. 2011;51(6):905&#x2013;922. doi: 10.1111/j.1526-4610.2011.01908.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2011.01908.x</ArticleId><ArticleId IdType="pubmed">21631476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannahan S, Leffler DA. Diagnosis and updates in celiac disease. Gastrointest Endosc Clin N Am. 2017;27(1):79&#x2013;92. doi: 10.1016/j.giec.2016.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.giec.2016.08.011</ArticleId><ArticleId IdType="pubmed">27908520</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823&#x2013;836. doi: 10.1016/j.cgh.2017.06.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2017.06.037</ArticleId><ArticleId IdType="pubmed">29551598</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani U, Imdad A, Beg M. Rare neurological manifestation of celiac disease. Case Rep Gastroenterol. 2015;9(2):200&#x2013;205. doi: 10.1159/000431170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000431170</ArticleId><ArticleId IdType="pmc">PMC4478317</ArticleId><ArticleId IdType="pubmed">26120302</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaron L, Torsten M, Patricia W. Autoimmunity in celiac disease: Extra-intestinal manifestations. Autoimmun Rev. 2019;18(3):241&#x2013;246. doi: 10.1016/j.autrev.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.09.010</ArticleId><ArticleId IdType="pubmed">30639642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zis P, Julian T, Hadjivassiliou M. Headache associated with coeliac disease: a systematic review and meta-analysis. Nutrients. 2018;10(10):1445. doi: 10.3390/nu10101445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10101445</ArticleId><ArticleId IdType="pmc">PMC6213149</ArticleId><ArticleId IdType="pubmed">30301194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK, Tennyson CA, Green MW, et al. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache. 2013;53(2):344&#x2013;355. doi: 10.1111/j.1526-4610.2012.02260.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2012.02260.x</ArticleId><ArticleId IdType="pubmed">23126519</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, et al. Neurological symptoms in patients with biopsy proven celiac disease. Movement disorders : official journal of the Movement Disorder Society. 2009;24(16):2358&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19845007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetti E, Francavilla R, Maiuri L, Ruggieri M, Spina M, Pavone P, et al. Headache in pediatric patients with celiac disease and its prevalence as a diagnostic clue. J Pediatr Gastroenterol Nutr. 2009;49(2):202&#x2013;207. doi: 10.1097/MPG.0b013e31818f6389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e31818f6389</ArticleId><ArticleId IdType="pubmed">19543115</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaconu G, Burlea M, Grigore I, Anton DT, Trandafir LM. Celiac disease with neurologic manifestations in children. Rev Med Chir Soc Med Nat Iasi. 2013;117(1):88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">24505898</ArticleId></ArticleIdList></Reference><Reference><Citation>Battistella PA, Mattesi P, Casara GL, Carollo C, Condini A, Allegri F, et al. Bilateral cerebral occipital calcifications and migraine-like headache. Cephalalgia. 1987;7(2):125&#x2013;129. doi: 10.1046/j.1468-2982.1987.0702125.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-2982.1987.0702125.x</ArticleId><ArticleId IdType="pubmed">3111714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopishinskaya SV, Gustov AV. Gluten migraine. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(8):13&#x2013;17. doi: 10.17116/jnevro20151158113-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.17116/jnevro20151158113-17</ArticleId><ArticleId IdType="pubmed">26356609</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie S, Hadjivassiliou M, Clark MJ, Sanders DS, Wilkinson ID, Griffiths PD, et al. Should we be &#x2018;nervous&#x2019; about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurological opinion. J Neurol Neurosurg Psychiatry. 2012;83(12):1216&#x2013;1221. doi: 10.1136/jnnp-2012-303281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303281</ArticleId><ArticleId IdType="pubmed">22906616</ArticleId></ArticleIdList></Reference><Reference><Citation>La Mantia L, Pollo B, Savoiardo M, Costa A, Eoli M, Allegranza A, et al. Meningo-cortical calcifying angiomatosis and celiac disease. Clin Neurol Neurosurg. 1998;100(3):209&#x2013;215. doi: 10.1016/S0303-8467(98)00029-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0303-8467(98)00029-8</ArticleId><ArticleId IdType="pubmed">9822844</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico D, Rigamonti A, Spina L, Bianchi-Marzoli S, Vecchi M, Bussone G. Migraine, celiac disease, and cerebral calcifications: a new case. Headache. 2005;45(9):1263&#x2013;1267. doi: 10.1111/j.1526-4610.2005.00253_2.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2005.00253_2.x</ArticleId><ArticleId IdType="pubmed">16178961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormile R. Celiac disease and migraine: is there a common backstage? Int J Color Dis. 2014;29(12):1571. doi: 10.1007/s00384-014-1923-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-014-1923-x</ArticleId><ArticleId IdType="pubmed">24965856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady RK, Farmer K, Dexter JK, Hall J. The bowel and migraine: update on celiac disease and irritable bowel syndrome. Curr Pain Headache Rep. 2012;16(3):278&#x2013;286. doi: 10.1007/s11916-012-0258-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-012-0258-y</ArticleId><ArticleId IdType="pubmed">22447132</ArticleId></ArticleIdList></Reference><Reference><Citation>Nenna R, Petrarca L, Verdecchia P, Florio M, Pietropaoli N, Mastrogiorgio G, et al. Celiac disease in a large cohort of children and adolescents with recurrent headache: a retrospective study. Dig Liver Dis. 2016;48(5):495&#x2013;498. doi: 10.1016/j.dld.2015.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2015.12.015</ArticleId><ArticleId IdType="pubmed">26826905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393&#x2013;406. doi: 10.1517/14728214.2012.709846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728214.2012.709846</ArticleId><ArticleId IdType="pubmed">22862686</ArticleId></ArticleIdList></Reference><Reference><Citation>Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampl C, Togha M. Association of diet and headache. J Headache Pain. 2019;20(1):106. doi: 10.1186/s10194-019-1057-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-019-1057-1</ArticleId><ArticleId IdType="pmc">PMC6854770</ArticleId><ArticleId IdType="pubmed">31726975</ArticleId></ArticleIdList></Reference><Reference><Citation>Serratrice J, Disdier P, de Roux C, Christides C, Weiller PJ. Migraine and coeliac disease. Headache. 1998;38(8):627&#x2013;628. doi: 10.1046/j.1526-4610.1998.3808627.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1526-4610.1998.3808627.x</ArticleId><ArticleId IdType="pubmed">11398309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjivassiliou M, Grunewald RA, Lawden M, Davies-Jones GA, Powell T, Smith CM. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology. 2001;56(3):385&#x2013;388. doi: 10.1212/WNL.56.3.385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.3.385</ArticleId><ArticleId IdType="pubmed">11171906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, Shen B. Classification and Reclassification of Inflammatory Bowel Diseases: From Clinical Perspective. Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications: Elsevier; 2018. p. 17&#x2013;34</Citation></Reference><Reference><Citation>Chehel Cheraghi S, Ebrahimi Daryani N, Ghabaee M. A survey on migraine prevalence in patients with inflammatory bowel disease - a single Centre experience. Middle East journal of digestive diseases. 2016;8(4):282&#x2013;288. doi: 10.15171/mejdd.2016.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/mejdd.2016.37</ArticleId><ArticleId IdType="pmc">PMC5145295</ArticleId><ArticleId IdType="pubmed">27957291</ArticleId></ArticleIdList></Reference><Reference><Citation>Doulberis M, Saleh C, Beyenburg S. Is there an association between migraine and gastrointestinal disorders? Journal of Clinical Neurology. 2017;13(3):215&#x2013;226. doi: 10.3988/jcn.2017.13.3.215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2017.13.3.215</ArticleId><ArticleId IdType="pmc">PMC5532317</ArticleId><ArticleId IdType="pubmed">28748672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14(2):171&#x2013;176. doi: 10.1046/j.1365-2036.2000.00695.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2000.00695.x</ArticleId><ArticleId IdType="pubmed">10651657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential beneficial effects of probiotics on human migraine headache: a literature review. Pain physician. 2017;20(2):E251&#x2013;E2E5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28158162</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-D&#xed;az Julio, Ruiz-Ojeda Francisco, Vilchez-Padial Laura, Gil Angel. Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases. Nutrients. 2017;9(6):555. doi: 10.3390/nu9060555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9060555</ArticleId><ArticleId IdType="pmc">PMC5490534</ArticleId><ArticleId IdType="pubmed">28555037</ArticleId></ArticleIdList></Reference><Reference><Citation>James Sensenig N, Jeffrey Marrongelle D, CCN MJS. T. Treatment of migraine with targeted nutrition focused on improved assimilation and elimination. Altern Med Rev. 2001;6(5):488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703169</ArticleId></ArticleIdList></Reference><Reference><Citation>Martami F, Togha M, Seifishahpar M, Ghorbani Z, Ansari H, Karimi T, et al. The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: a randomized double-blind controlled trial. Cephalalgia. 2019;39(7):841&#x2013;853. doi: 10.1177/0333102418820102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102418820102</ArticleId><ArticleId IdType="pubmed">30621517</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo MG, Romeo DM, Trovato L, Oliveri S, Palermo F, Cota F, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol. 2011;31(1):63&#x2013;69. doi: 10.1038/jp.2010.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jp.2010.57</ArticleId><ArticleId IdType="pmc">PMC3016918</ArticleId><ArticleId IdType="pubmed">20410904</ArticleId></ArticleIdList></Reference><Reference><Citation>Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Investig. 2011;41(4):417&#x2013;422. doi: 10.1111/j.1365-2362.2010.02425.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2010.02425.x</ArticleId><ArticleId IdType="pubmed">21114493</ArticleId></ArticleIdList></Reference><Reference><Citation>de Roos N, van Hemert S, Rovers J, Smits M, Witteman B (2017) The effects of a multispecies probiotic on migraine and markers of intestinal permeability&#x2013;results of a randomized placebo-controlled study. Eur J Clin Nutr</Citation><ArticleIdList><ArticleId IdType="pubmed">28537581</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(8):497&#x2013;505. doi: 10.1038/nrgastro.2014.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.40</ArticleId><ArticleId IdType="pubmed">24751910</ArticleId></ArticleIdList></Reference><Reference><Citation>Evcili G, Utku U, Ogun MN, Ozdemir G. Early and long period follow-up results of low glycemic index diet for migraine prophylaxis. Agri. 2018;30(1):8&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29450870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrandt Marie A., Hoffmann Christian, Sherrill&#x2013;Mix Scott A., Keilbaugh Sue A., Hamady Micah, Chen Ying&#x2013;Yu, Knight Rob, Ahima Rexford S., Bushman Frederic, Wu Gary D. High-Fat Diet Determines the Composition of the Murine Gut Microbiome Independently of Obesity. Gastroenterology. 2009;137(5):1716-1724.e2. doi: 10.1053/j.gastro.2009.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.08.042</ArticleId><ArticleId IdType="pmc">PMC2770164</ArticleId><ArticleId IdType="pubmed">19706296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden CE, Zamora D, Makriyannis A, Wood JT, Mann JD, Faurot KR, et al. Diet-induced changes in n-3-and n-6-derived endocannabinoids and reductions in headache pain and psychological distress. J Pain. 2015;16(8):707&#x2013;716. doi: 10.1016/j.jpain.2015.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2015.04.007</ArticleId><ArticleId IdType="pmc">PMC4522350</ArticleId><ArticleId IdType="pubmed">25958314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bic Z, Blix GG, Hopp HP, Leslie FM, Schell MJ. The influence of a low-fat diet on incidence and severity of migraine headaches. J Womens Health Gend Based Med. 1999;8(5):623&#x2013;630. doi: 10.1089/jwh.1.1999.8.623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.1.1999.8.623</ArticleId><ArticleId IdType="pubmed">10839648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunner AE, Agarwal U, Gonzales JF, Valente F, Barnard ND. Nutrition intervention for migraine: a randomized crossover trial. J Headache Pain. 2014;15(1):69. doi: 10.1186/1129-2377-15-69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1129-2377-15-69</ArticleId><ArticleId IdType="pmc">PMC4227630</ArticleId><ArticleId IdType="pubmed">25339342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashir M, Prietl B, Tauschmann M, Mautner SI, Kump PK, Treiber G, et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr. 2016;55(4):1479&#x2013;1489. doi: 10.1007/s00394-015-0966-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-015-0966-2</ArticleId><ArticleId IdType="pmc">PMC4875045</ArticleId><ArticleId IdType="pubmed">26130323</ArticleId></ArticleIdList></Reference><Reference><Citation>Togha M, Razeghi Jahromi S, Ghorbani Z, Martami F, Seifishahpar M. Serum vitamin D status in a Group of Migraine Patients Compared with Healthy Controls: a case-control study. Headache. 2018;58(10):1530&#x2013;1540. doi: 10.1111/head.13423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13423</ArticleId><ArticleId IdType="pubmed">30341768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani Z, Togha M, Rafiee P, Ahmadi ZS, Rasekh Magham R, Haghighi S, et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurol Sci. 2019;40(12):2459&#x2013;2477. doi: 10.1007/s10072-019-04021-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04021-z</ArticleId><ArticleId IdType="pubmed">31377873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome Dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J Diabetes Res. 2018;2018:3462092. doi: 10.1155/2018/3462092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3462092</ArticleId><ArticleId IdType="pmc">PMC6140100</ArticleId><ArticleId IdType="pubmed">30250849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelaye B, Sacco S, Brown WJ, Nitchie HL, Ornello R, Peterlin BL. Body composition status and the risk of migraine: a meta-analysis. Neurology. 2017;88(19):1795&#x2013;1804. doi: 10.1212/WNL.0000000000003919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003919</ArticleId><ArticleId IdType="pmc">PMC5419981</ArticleId><ArticleId IdType="pubmed">28404807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond DS, Vithiananthan S, Nash JM, Thomas JG, Wing RR. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011;76(13):1135&#x2013;1138. doi: 10.1212/WNL.0b013e318212ab1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318212ab1e</ArticleId><ArticleId IdType="pmc">PMC3068014</ArticleId><ArticleId IdType="pubmed">21444898</ArticleId></ArticleIdList></Reference><Reference><Citation>Novack V, Fuchs L, Lantsberg L, Kama S, Lahoud U, Horev A, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series. Cephalalgia. 2011;31(13):1336&#x2013;1342. doi: 10.1177/0333102411413162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102411413162</ArticleId><ArticleId IdType="pubmed">21700645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahromi SR, Abolhasani M, Ghorbani Z, Sadre-Jahani S, Alizadeh Z, Talebpour M, et al. Bariatric surgery promising in migraine control: a controlled trial on weight loss and its effect on migraine headache. Obes Surg. 2018;28(1):87&#x2013;96. doi: 10.1007/s11695-017-2793-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-017-2793-4</ArticleId><ArticleId IdType="pubmed">28685361</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrotti A, Agostinelli S, D'Egidio C, Di Fonzo A, Carotenuto M, Parisi P, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol. 2013;20(2):394&#x2013;397. doi: 10.1111/j.1468-1331.2012.03771.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03771.x</ArticleId><ArticleId IdType="pubmed">22642299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond DS, Roth J, Nash JM, Wing RR. Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment. Obes Rev. 2011;12(5):e362&#x2013;e371. doi: 10.1111/j.1467-789X.2010.00791.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-789X.2010.00791.x</ArticleId><ArticleId IdType="pmc">PMC2974024</ArticleId><ArticleId IdType="pubmed">20673279</ArticleId></ArticleIdList></Reference><Reference><Citation>Laino D, Vitaliti G, Parisi P, Pavone P, Verrotti A, Lubrano R, et al. Headache, migraine and obesity: an overview on plausible links. J Biol Regul Homeost Agents. 2016;30(2):333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">27358118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36014888</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3382</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu14163382</ELocationID><Abstract><AbstractText>Small intestinal bacterial overgrowth (SIBO) is highly prevalent in irritable bowel syndrome (IBS). The eradication of bacterial overgrowth with antibiotics is the first-line treatment. However, focusing only on the antimicrobial effects without taking care to improve lifestyle factors, especially dietary patterns, may predispose patients to intestinal microbiota dysfunction. The objective of this study is to determine whether the current recommendations regarding nutrition in IBS are suitable for patients with SIBO. A narrative literature review was carried out using databases, including PubMed, ScienceDirect and Google Scholar. Recent studies indicate that dietary manipulation may have a role in alleviating SIBO gastrointestinal symptoms. A low FODMAP diet proposed for IBS may promote a negative shift in the gut microbiota and deepen the existing state of dysbiosis in SIBO patients. Supplementation with soluble fiber can lessen the symptoms in IBS and SIBO. Targeted probiotic therapy may also increase the effectiveness of antibiotic treatment and regulate bowel movements. Therefore, optimal dietary patterns play a key role in the treatment of SIBO. Based on currently available literature, the potential efficacy of the IBS diet in SIBO is largely hypothetical. Future research is needed to characterize a specific diet for the treatment of SIBO.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wielgosz-Grochowska</LastName><ForeName>Justyna Paulina</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-2500-9653</Identifier><AffiliationInfo><Affiliation>Department of Human Nutrition, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domanski</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drywie&#x144;</LastName><ForeName>Ma&#x142;gorzata Ewa</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-8582-8306</Identifier><AffiliationInfo><Affiliation>Department of Human Nutrition, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001944" MajorTopicYN="N">Breath Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007421" MajorTopicYN="N">Intestine, Small</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">SIBO</Keyword><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">fiber</Keyword><Keyword MajorTopicYN="N">microbiota</Keyword><Keyword MajorTopicYN="N">prebiotics</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36014888</ArticleId><ArticleId IdType="pmc">PMC9412469</ArticleId><ArticleId IdType="doi">10.3390/nu14163382</ArticleId><ArticleId IdType="pii">nu14163382</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh R.K., Chang H.W., Yan D., Lee K.M., Ucmak D., Wong K., Abrouk M., Farahnik B., Nakamura M., Zhu T.H., et al. Influence of Diet on the Gut Microbiome and Implications for Human Health. J. Transl. Med. 2017;15:73. doi: 10.1186/s12967-017-1175-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-017-1175-y</ArticleId><ArticleId IdType="pmc">PMC5385025</ArticleId><ArticleId IdType="pubmed">28388917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal U.C., Shukla R., Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196&#x2013;208. doi: 10.5009/gnl16126.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl16126</ArticleId><ArticleId IdType="pmc">PMC5347643</ArticleId><ArticleId IdType="pubmed">28274108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong F., Deng F., Li Y., Zhao J. Identification of Gut Microbiome Signatures Associated with Longevity Provides a Promising Modulation Target for Healthy Aging. Gut Microbes. 2019;10:210&#x2013;215. doi: 10.1080/19490976.2018.1494102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2018.1494102</ArticleId><ArticleId IdType="pmc">PMC6546316</ArticleId><ArticleId IdType="pubmed">30142010</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhoo Kim B.A.B. The Microbiome: An Emerging Key Player in Aging and Longevity. Transl. Med. Aging. 2020;4:103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437988</ArticleId><ArticleId IdType="pubmed">32832742</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Zogg H., Wei L., Bartlett A., Ghoshal U.C., Rajender S., Ro S. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. J. Neurogastroenterol. Motil. 2021;27:19&#x2013;34. doi: 10.5056/jnm20149.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm20149</ArticleId><ArticleId IdType="pmc">PMC7786094</ArticleId><ArticleId IdType="pubmed">33166939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins L.J., Monga M., Miller A.W. Defining Dysbiosis for a Cluster of Chronic Diseases. Sci. Rep. 2019;9:12918. doi: 10.1038/s41598-019-49452-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-49452-y</ArticleId><ArticleId IdType="pmc">PMC6733864</ArticleId><ArticleId IdType="pubmed">31501492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A., Buresi M., Lembo A., Lin H., McCallum R., Rao S., Schmulson M., Valdovinos M., Zakko S., Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am. J. Gastroenterol. 2017;112:775&#x2013;784. doi: 10.1038/ajg.2017.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2017.46</ArticleId><ArticleId IdType="pmc">PMC5418558</ArticleId><ArticleId IdType="pubmed">28323273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M., Saad R.J., Long M.D., Rao S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am. J. Gastroenterol. 2020;115:165&#x2013;178. doi: 10.14309/ajg.0000000000000501.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000501</ArticleId><ArticleId IdType="pubmed">32023228</ArticleId></ArticleIdList></Reference><Reference><Citation>Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome&#x2014;An Update. Front. Psychiatry. 2020;11:664. doi: 10.3389/fpsyt.2020.00664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.00664</ArticleId><ArticleId IdType="pmc">PMC7366247</ArticleId><ArticleId IdType="pubmed">32754068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassard C., Dapoigny M., Scott K.P., Crouzet L., Del&#x2019;Homme C., Marquet P., Martin J.C., Pickering G., Ardid D., Eschalier A., et al. Functional Dysbiosis within the Gut Microbiota of Patients with Constipated-Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 2012;35:828&#x2013;838. doi: 10.1111/j.1365-2036.2012.05007.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2012.05007.x</ArticleId><ArticleId IdType="pubmed">22315951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohm M., Siwiec R.M., Wo J.M. Diagnosis and Management of Small Intestinal Bacterial Overgrowth. Nutr. Clin. Pract. 2013;28:289&#x2013;299. doi: 10.1177/0884533613485882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0884533613485882</ArticleId><ArticleId IdType="pubmed">23614961</ArticleId></ArticleIdList></Reference><Reference><Citation>Avelar Rodriguez D., Ryan P.M.D., Toro Monjaraz E.M., Ramirez Mayans J.A., Quigley E.M. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. Front. Pediatr. 2019;7:363. doi: 10.3389/fped.2019.00363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00363</ArticleId><ArticleId IdType="pmc">PMC6737284</ArticleId><ArticleId IdType="pubmed">31552207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritano E.C., Gabrielli M., Scarpellini E., Lupascu A., Novi M., Sottili S., Vitale G., Cesario V., Serricchio M., Cammarota G., et al. Small Intestinal Bacterial Overgrowth Recurrence after Antibiotic Therapy. Am. J. Gastroenterol. 2008;103:2031&#x2013;2035. doi: 10.1111/j.1572-0241.2008.02030.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2008.02030.x</ArticleId><ArticleId IdType="pubmed">18802998</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Agrawal A., Aziz I., Farmer A.D., Eugenicos M.P., et al. British Society of Gastroenterology Guidelines on the Management of Irritable Bowel Syndrome. Gut. 2021;70:1214&#x2013;1240. doi: 10.1136/gutjnl-2021-324598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto S., Fagoonee S., Battaglia E., Grassini M., Saracco G.M., Pellicano R. Recent Advances in the Treatment of Irritable Bowel Syndrome. Pol. Arch. Intern. Med. 2021;131:709&#x2013;715. doi: 10.20452/pamw.16067.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16067</ArticleId><ArticleId IdType="pubmed">34463082</ArticleId></ArticleIdList></Reference><Reference><Citation>Algera J., Colomier E., Simr&#xe9;n M. The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence. Nutrients. 2019;11:2162. doi: 10.3390/nu11092162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092162</ArticleId><ArticleId IdType="pmc">PMC6770052</ArticleId><ArticleId IdType="pubmed">31505870</ArticleId></ArticleIdList></Reference><Reference><Citation>Patcharatrakul T., Juntrapirat A., Lakananurak N., Gonlachanvit S. Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production. Nutrients. 2019;11:2856. doi: 10.3390/nu11122856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11122856</ArticleId><ArticleId IdType="pmc">PMC6950148</ArticleId><ArticleId IdType="pubmed">31766497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanayakkara W.S., Skidmore P.M., O&#x2019;Brien L., Wilkinson T.J., Gearry R.B. Efficacy of the Low FODMAP Diet for Treating Irritable Bowel Syndrome: The Evidence to Date. Clin. Exp. Gastroenterol. 2016;9:131&#x2013;142. doi: 10.2147/CEG.S86798.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S86798</ArticleId><ArticleId IdType="pmc">PMC4918736</ArticleId><ArticleId IdType="pubmed">27382323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey K.R., Naik S.R., Vakil B.V. Probiotics, Prebiotics and Synbiotics&#x2014;A Review. J. Food Sci. Technol. 2015;52:7577&#x2013;7587. doi: 10.1007/s13197-015-1921-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13197-015-1921-1</ArticleId><ArticleId IdType="pmc">PMC4648921</ArticleId><ArticleId IdType="pubmed">26604335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka J., Major G., Murray K., Singh G., Nowak A., Kurtz C., Silos-Santiago I., Johnston J.M., de Vos W.M., Spiller R. The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls. Int. J. Mol. Sci. 2019;20:433. doi: 10.3390/ijms20020433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020433</ArticleId><ArticleId IdType="pmc">PMC6358997</ArticleId><ArticleId IdType="pubmed">30669509</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Scholz M., Lomer M.C., Ralph F.S., Irving P.M., Lindsay J.O., Fava F., Tuohy K., Whelan K. Gut Microbiota Associations with Diet in Irritable Bowel Syndrome and the Effect of Low FODMAP Diet and Probiotics. Clin. Nutr. 2021;40:1861&#x2013;1870. doi: 10.1016/j.clnu.2020.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.10.013</ArticleId><ArticleId IdType="pubmed">33183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C.E., Anderson J.L., Barrett J.S., Muir J.G., Irving P.M., Whelan K. Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. J. Nutr. 2012;142:1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaman J.W., Mego M., Manichanh C., Ca&#xf1;ellas N., Ca&#xf1;ueto D., Segurola H., Jansana M., Malagelada C., Accarino A., Vulevic J., et al. Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders. Gastroenterology. 2018;155:1004&#x2013;1007. doi: 10.1053/j.gastro.2018.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.06.045</ArticleId><ArticleId IdType="pubmed">29964041</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Feng L., Wang X., Fox M., Luo L., Du L., Chen B., Chen X., He H., Zhu S., et al. Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Compared with Traditional Dietary Advice for Diarrhea-Predominant Irritable Bowel Syndrome: A Parallel-Group, Randomized Controlled Trial with Analysis of Clinical and Micr. Am. J. Clin. Nutr. 2021;113:1531&#x2013;1545. doi: 10.1093/ajcn/nqab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqab005</ArticleId><ArticleId IdType="pubmed">33740048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustoft T.N., Hausken T., Ystad S.O., Valeur J., Brokstad K., Hatlebakk J.G., Lied G.A. Effects of Varying Dietary Content of Fermentable Short-Chain Carbohydrates on Symptoms, Fecal Microenvironment, and Cytokine Profiles in Patients with Irritable Bowel Syndrome. Neurogastroenterol. Motil. 2017;29:e12969. doi: 10.1111/nmo.12969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12969</ArticleId><ArticleId IdType="pubmed">27747984</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G. Diets That Differ in Their FODMAP Content Alter the Colonic Luminal Microenvironment. Gut. 2015;64:93&#x2013;100. doi: 10.1136/gutjnl-2014-307264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307264</ArticleId><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet S.M.P., B&#xf6;hn L., St&#xf6;rsrud S., Liljebo T., Collin L., Lindfors P., T&#xf6;rnblom H., &#xd6;hman L., Simr&#xe9;n M. Multivariate Modelling of Faecal Bacterial Profiles of Patients with IBS Predicts Responsiveness to a Diet Low in FODMAPs. Gut. 2018;67:872&#x2013;881. doi: 10.1136/gutjnl-2016-313128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313128</ArticleId><ArticleId IdType="pubmed">28416515</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K., Reed D.E., Schneider T., Dang F., Keshteli A.H., De Palma G., Madsen K., Bercik P., Vanner S. FODMAPs Alter Symptoms and the Metabolome of Patients with IBS: A Randomised Controlled Trial. Gut. 2017;66:1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Rossi M., Kanno T., Parkes G.C., Anderson S., Mason A.J., Irving P.M., Lomer M.C., Whelan K. &#x3b2;-Galactooligosaccharide in Conjunction with Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. Am. J. Gastroenterol. 2020;115:906&#x2013;915. doi: 10.14309/ajg.0000000000000641.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000641</ArticleId><ArticleId IdType="pubmed">32433273</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M. Long-Term Irritable Bowel Syndrome Symptom Control with Reintroduction of Selected FODMAPs. World J. Gastroenterol. 2017;23:4632&#x2013;4643. doi: 10.3748/wjg.v23.i25.4632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i25.4632</ArticleId><ArticleId IdType="pmc">PMC5504379</ArticleId><ArticleId IdType="pubmed">28740352</ArticleId></ArticleIdList></Reference><Reference><Citation>Naseri K., Dabiri H., Rostami-Nejad M., Yadegar A., Houri H., Olfatifar M., Sadeghi A., Saadati S., Ciacci C., Iovino P., et al. Influence of Low FODMAP-Gluten Free Diet on Gut Microbiota Alterations and Symptom Severity in Iranian Patients with Irritable Bowel Syndrome. BMC Gastroenterol. 2021;21:292. doi: 10.1186/s12876-021-01868-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-021-01868-5</ArticleId><ArticleId IdType="pmc">PMC8278734</ArticleId><ArticleId IdType="pubmed">34261437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M., Tonarelli S., Nagy A.G., Pancetti A., Costa F., Ricchiuti A., de Bortoli N., Mosca M., Marchi S., Rossi A. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients. 2020;12:148. doi: 10.3390/nu12010148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12010148</ArticleId><ArticleId IdType="pmc">PMC7019579</ArticleId><ArticleId IdType="pubmed">31947991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills R.D., Pontefract B.A., Mishcon H.R., Black C.A., Sutton S.C., Theberge C.R. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11:1613. doi: 10.3390/nu11071613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11071613</ArticleId><ArticleId IdType="pmc">PMC6682904</ArticleId><ArticleId IdType="pubmed">31315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann D., Klose P., Lauche R., Dobos G., Langhorst J., Cramer H. Low Fermentable, Oligo-, Di-, Mono-Saccharides and Polyol Diet in the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrition. 2018;45:24&#x2013;31. doi: 10.1016/j.nut.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2017.07.004</ArticleId><ArticleId IdType="pubmed">29129233</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R., Halmos E.P., Muir J.G. Review Article: FODMAPS, Prebiotics and Gut Health-the FODMAP Hypothesis Revisited. Aliment. Pharmacol. Ther. 2020;52:233&#x2013;246. doi: 10.1111/apt.15818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15818</ArticleId><ArticleId IdType="pubmed">32562590</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R.S., Neelamraju J., Ahire J.J., Gupta S.K., Shukla V.K. Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics Antimicrob. Proteins. 2020;12:335&#x2013;342. doi: 10.1007/s12602-019-09542-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-019-09542-9</ArticleId><ArticleId IdType="pubmed">30911991</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A.K., Maity C. Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant] Medicine (Baltimore) 2021;100:e23641. doi: 10.1097/MD.0000000000023641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskesen D., Jespersen L., Michelsen B., Whorwell P.J., M&#xfc;ller-Lissner S., Morberg C.M. Effect of the Probiotic Strain Bifidobacterium Animalis Subsp. Lactis, BB-12&#xae;, on Defecation Frequency in Healthy Subjects with Low Defecation Frequency and Abdominal Discomfort: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial. Br. J. Nutr. 2015;114:1638&#x2013;1646. doi: 10.1017/S0007114515003347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114515003347</ArticleId><ArticleId IdType="pmc">PMC4657032</ArticleId><ArticleId IdType="pubmed">26382580</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Collinot G., Madrigal-Santill&#xe1;n E.O., Mart&#xed;nez-Bencomo M.A., Carranza-Muleiro R.A., Jara L.J., Vera-Lastra O., Montes-Cortes D.H., Medina G., Cruz-Dom&#xed;nguez M.P. Effectiveness of Saccharomyces Boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig. Dis. Sci. 2020;65:1134&#x2013;1143. doi: 10.1007/s10620-019-05830-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05830-0</ArticleId><ArticleId IdType="pubmed">31549334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar K., Saadi M., Ramsey F.V., Schey R., Parkman H.P. Effect of Bifidobacterium Infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth. Dig. Dis. Sci. 2018;63:989&#x2013;995. doi: 10.1007/s10620-018-4945-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-018-4945-3</ArticleId><ArticleId IdType="pubmed">29397491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojetti V., Petruzziello C., Migneco A., Gnarra M., Gasbarrini A., Franceschi F. Effect of Lactobacillus Reuteri (DSM 17938) on Methane Production in Patients Affected by Functional Constipation: A Retrospective Study. Eur. Rev. Med. Pharmacol. Sci. 2017;21:1702&#x2013;1708. doi: 10.1016/s0016-5085(17)33419-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0016-5085(17)33419-4</ArticleId><ArticleId IdType="pubmed">28429333</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., Majeed S., Karri S.K. Bacillus Coagulans MTCC 5856 Supplementation in the Management of Diarrhea Predominant Irritable Bowel Syndrome: A Double Blind Randomized Placebo Controlled Pilot Clinical Study. Nutr. J. 2016;15:21. doi: 10.1186/s12937-016-0140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrott&#xe9; P., Sawant P., Jayanthi V. Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome. World J. Gastroenterol. 2012;18:4012&#x2013;4018. doi: 10.3748/wjg.v18.i30.4012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K.R. Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome. Int. J. Colorectal Dis. 2020;35:139&#x2013;145. doi: 10.1007/s00384-019-03462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhondi-Meybodi M., Rahimian M., Salmanroghani H., Amirbeigy M., Baghbanian M., Ghelmani S. Study of the Effect of Probiotic Saccharomyces Boulardii on the Treatment of Irritable Bowel Syndrome. J. Biol. Today&#x2019;s World. 2014;3:152&#x2013;156. doi: 10.15412/J.JBTW.01030703.</Citation><ArticleIdList><ArticleId IdType="doi">10.15412/J.JBTW.01030703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M. Efficacy of Lactobacillus Paracasei HA-196 and Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients. 2020;12:1159. doi: 10.3390/nu12041159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="pubmed">32326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Attar A., Flourie B., Rambaud J.C., Franchisseur C., Ruszniewski P., Bouhnik Y. Antibiotic Efficacy in Small Intestinal Bacterial Overgrowth-Related Chronic Diarrhea: A Crossover, Randomized Trial. Gastroenterology. 1999;117:794&#x2013;797. doi: 10.1016/S0016-5085(99)70336-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(99)70336-7</ArticleId><ArticleId IdType="pubmed">10500060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubnov R.V., Babenko L.P., Lazarenko L.M., Mokrozub V.V., Spivak M.Y. Specific Properties of Probiotic Strains: Relevance and Benefits for the Host. EPMA J. 2018;9:205&#x2013;223. doi: 10.1007/s13167-018-0132-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13167-018-0132-z</ArticleId><ArticleId IdType="pmc">PMC5972142</ArticleId><ArticleId IdType="pubmed">29896319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong C., Qu C., Wang B., Liang S., Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth. J. Clin. Gastroenterol. 2017;51:300&#x2013;311. doi: 10.1097/MCG.0000000000000814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000814</ArticleId><ArticleId IdType="pubmed">28267052</ArticleId></ArticleIdList></Reference><Reference><Citation>Saffouri G.B., Shields-Cutler R.R., Chen J., Yang Y., Lekatz H.R., Hale V.L., Cho J.M., Battaglioli E.J., Bhattarai Y., Thompson K.J., et al. Small Intestinal Microbial Dysbiosis Underlies Symptoms Associated with Functional Gastrointestinal Disorders. Nat. Commun. 2019;10:2012. doi: 10.1038/s41467-019-09964-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09964-7</ArticleId><ArticleId IdType="pmc">PMC6494866</ArticleId><ArticleId IdType="pubmed">31043597</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Halak A., Tiommny E., Yanai H., Strul H., Naftali T., Vaisman N. Randomized Clinical Study: Partially Hydrolyzed Guar Gum (PHGG) versus Placebo in the Treatment of Patients with Irritable Bowel Syndrome. Nutr. Metab. 2016;13:10. doi: 10.1186/s12986-016-0070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-016-0070-5</ArticleId><ArticleId IdType="pmc">PMC4744437</ArticleId><ArticleId IdType="pubmed">26855665</ArticleId></ArticleIdList></Reference><Reference><Citation>Reider S.J., Moosmang S., Tragust J., Trgovec-Greif L., Tragust S., Perschy L., Przysiecki N., Sturm S., Tilg H., Stuppner H., et al. Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota&#x2014;Results from the PAGODA Trial. Nutrients. 2020;12:1257. doi: 10.3390/nu12051257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12051257</ArticleId><ArticleId IdType="pmc">PMC7281958</ArticleId><ArticleId IdType="pubmed">32354152</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeros D., Beintaris I., Gaglia A., Karamanolis G., Papanikolaou I.S., Dimitriadis G., Triantafyllou K. Partially Hydrolyzed Guar Gum Accelerates Colonic Transit Time and Improves Symptoms in Adults with Chronic Constipation. Dig. Dis. Sci. 2014;59:2207&#x2013;2214. doi: 10.1007/s10620-014-3135-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3135-1</ArticleId><ArticleId IdType="pubmed">24711073</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher H.D., Bauer L.L., Gourineni V., Pelkman C.L., Fahey G.C., Swanson K.S. Agave Inulin Supplementation Affects the Fecal Microbiota of Healthy Adults Participating in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J. Nutr. 2015;145:2025&#x2013;2032. doi: 10.3945/jn.115.217331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.115.217331</ArticleId><ArticleId IdType="pubmed">26203099</ArticleId></ArticleIdList></Reference><Reference><Citation>Linetzky Waitzberg D., Alves Pereira C.C., Logullo L., Manzoni Jacintho T., Almeida D., Teixeira da Silva M.d.L., Matos de Miranda Torrinha R.S. Microbiota Benefits after Inulin and Partially Hydrolized Guar Gum Supplementation: A Randomized Clinical Trial in Constipated Women. Nutr. Hosp. 2012;27:123&#x2013;129. doi: 10.1590/S0212-16112012000100014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0212-16112012000100014</ArticleId><ArticleId IdType="pubmed">22566311</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskouie F.H., Vahedi H., Shahrbaf M.A., Sadeghi A., Rashidkhani B., Hekmatdoost A. Gastroenterology and Hepatology from Bed to Bench. Dietary Fiber and Risk of Irritable Bowel Syndrome: A Case-Control Study. Gastroenterol. Hepatol. Bed Bench. 2018;11:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347982</ArticleId><ArticleId IdType="pubmed">30774803</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P. Inflammation in Irritable Bowel Syndrome (IBS): Role of Psyllium Fiber Supplementation in Decreasing Inflammation and Physiological Management of IBS. Turk. J. Gastroenterol. 2021;32:108&#x2013;110. doi: 10.5152/tjg.2020.20229.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2020.20229</ArticleId><ArticleId IdType="pmc">PMC8975494</ArticleId><ArticleId IdType="pubmed">33893774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginnebaugh B., Chey W.D., Saad R. Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (and Then Treat Again) Gastroenterol. Clin. N. Am. 2020;49:571&#x2013;587. doi: 10.1016/j.gtc.2020.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2020.04.010</ArticleId><ArticleId IdType="pubmed">32718571</ArticleId></ArticleIdList></Reference><Reference><Citation>Khayyatzadeh S.S., Kazemi-Bajestani S.M.R., Mirmousavi S.J., Heshmati M., Khoshmohabbat S., Ferns G.A., Ghayour-Mobarhan M. Dietary Behaviors in Relation to Prevalence of Irritable Bowel Syndrome in Adolescent Girls. J. Gastroenterol. Hepatol. 2018;33:404&#x2013;410. doi: 10.1111/jgh.13908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13908</ArticleId><ArticleId IdType="pubmed">28770579</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L., St&#xf6;rsrud S., Liljebo T., Collin L., Lindfors P., T&#xf6;rnblom H., Simr&#xe9;n M. Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. Gastroenterology. 2015;149:1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaribaf F., Keshteli A.H., Esmaillzadeh A., Saneei P., Feizi A., Daghaghzadeh H., Feinle-Bisset C., Adibi P. Empirically Derived Dietary Habits Are Associated with Irritable Bowel Syndrome. Eur. J. Clin. Nutr. 2018;72:1537&#x2013;1547. doi: 10.1038/s41430-018-0109-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41430-018-0109-y</ArticleId><ArticleId IdType="pubmed">29535405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakhshuury M., Khoshdel A. The Relation between Dietary Patterns and Functional Gastrointestinal Disorders among Iranian Military Men. Adv. Biomed. Res. 2019;8:2. doi: 10.4103/abr.abr_180_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/abr.abr_180_18</ArticleId><ArticleId IdType="pmc">PMC6357671</ArticleId><ArticleId IdType="pubmed">30775344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37686889</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>17</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3856</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu15173856</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a common gastrointestinal disease. The efficacy of different probiotics in treating IBS remains controversial. This network meta-analysis aimed to compare and rank the outcome-specific efficacy of different probiotic strains or combinations in adults with IBS. We searched the literature up to June 2023. Randomized controlled trials (RCTs) that evaluated the efficacy of probiotics in IBS were included. A frequentist framework was used to perform this study. In total, 9253 participants from 81 RCTs were included in the study. Four probiotic strains and five mixtures were significantly superior to placebo in improving IBS Symptom Severity Scale, among which <i>Lactobacillus acidophilus</i> DDS-1 ranked first (surface under the cumulative ranking, SUCRA, 92.9%). A mixture containing five probiotics (SUCRA, 100%) ranked first in improving the IBS-Quality of life. <i>Bacillus coagulans</i> MTCC 5856 (SUCRA, 96.9%) and <i>Bacillus coagulans</i> Unique IS2 (SUCRA, 92.6%) were among the most effective probiotics for improving abdominal pain. Three probiotic strains and two mixtures were effective in alleviating abdominal bloating. Four probiotic strains and a mixture were significantly superior to placebo in reducing the bowel movement frequency in diarrhea-predominant IBS (IBS-D). <i>Bacillus coagulans</i> MTCC 5856 (SUCRA, 99.6%) and <i>Saccharomyces cerevisiae</i> CNCM I-3856 (SUCRA, 89.7%) were among the most effective probiotics for improving the Bristol stool form scale of IBS-D. Only some probiotics are effective for particular outcomes in IBS patients. This study provided the first ranking of outcome-specific efficacy of different probiotic strains and combinations in IBS. Further studies are needed to confirm these results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Peiwei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xuehong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jiahui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Lishou</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81970471</GrantID><Agency>the National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070000" MajorTopicYN="Y">Bacillus coagulans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37686889</ArticleId><ArticleId IdType="pmc">PMC10490209</ArticleId><ArticleId IdType="doi">10.3390/nu15173856</ArticleId><ArticleId IdType="pii">nu15173856</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Functional Gastrointestinal Disorders 2 Irritable bowel syndrome. Lancet. 2020;396:1675&#x2013;1688. doi: 10.1016/S0140-6736(20)31548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Dumitrascu D., Fukudo S., Gerson C., Ghoshal U.C., Gwee K.A., Hungin A.P.S., Kang J.-Y., Minhu C., Schmulson M., et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66:1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory V.C., Ng C.E., Black C.J., Ford A.C. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment. Pharmacol. Ther. 2022;56:110&#x2013;120. doi: 10.1111/apt.16939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16939</ArticleId><ArticleId IdType="pmc">PMC9325446</ArticleId><ArticleId IdType="pubmed">35491477</ArticleId></ArticleIdList></Reference><Reference><Citation>Peery A.F., Crockett S.D., Murphy C.C., Lund J.L., Dellon E.S., Williams J.L., Jensen E.T., Shaheen N.J., Barritt A.S., Lieber S.R., et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019;156:254&#x2013;272. doi: 10.1053/j.gastro.2018.08.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.08.063</ArticleId><ArticleId IdType="pmc">PMC6689327</ArticleId><ArticleId IdType="pubmed">30315778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Xiang W., Li C.Y., Li S.C. Economic burden of irritable bowel syndrome in China. World J. Gastroenterol. 2016;22:10450&#x2013;10460. doi: 10.3748/wjg.v22.i47.10450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i47.10450</ArticleId><ArticleId IdType="pmc">PMC5175258</ArticleId><ArticleId IdType="pubmed">28058026</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. Review article: The economic impact of the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2014;40:1023&#x2013;1034. doi: 10.1111/apt.12938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12938</ArticleId><ArticleId IdType="pubmed">25199904</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;17:473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A., Tornblom H., Jakobsson S., Simren M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am. J. Gastroenterol. 2018;113:1540&#x2013;1549. doi: 10.1038/s41395-018-0262-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0262-x</ArticleId><ArticleId IdType="pubmed">30254230</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Chang L., Schneck S., Blackman C., Norton W.F., Norton N.J. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig. Dis. Sci. 2009;54:1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskov H., Burcharth J., Pommergaard H.-C., Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes. 2016;7:365&#x2013;383. doi: 10.1080/19490976.2016.1218585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2016.1218585</ArticleId><ArticleId IdType="pmc">PMC5046167</ArticleId><ArticleId IdType="pubmed">27472486</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Agrawal A., Aziz I., Farmer A.D., Eugenicos M.P., et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70:1214&#x2013;1240. doi: 10.1136/gutjnl-2021-324598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 1995;125:1401&#x2013;1412. doi: 10.1093/jn/125.6.1401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/125.6.1401</ArticleId><ArticleId IdType="pubmed">7782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T., Xu Z., Xia P., Feng Y., Liu B., Liu H., Chen Y., Yan G., Lv B., Yan Z., et al. The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation. Am. J. Gastroenterol. 2022;118:1256&#x2013;1267. doi: 10.14309/ajg.0000000000002147.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000002147</ArticleId><ArticleId IdType="pubmed">36717369</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantis G., Efstathiou S., Pourzitaki C., Kitsikidou E., Germanidis G., Chourdakis M. Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria. Clin. Nutr. 2023;42:800&#x2013;809. doi: 10.1016/j.clnu.2023.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2023.03.019</ArticleId><ArticleId IdType="pubmed">37031468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Quigley E.M.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M.R., Moayyedi P. Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. Am. J. Gastroenterol. 2014;109:1547&#x2013;1561. doi: 10.1038/ajg.2014.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.202</ArticleId><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Pimentel M., Brenner D.M., Chey W.D., Keefer L.A., Long M.D., Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2021;116:17&#x2013;44. doi: 10.14309/ajg.0000000000001036.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Su G.L., Ko C.W., Bercik P., Falck-Ytter Y., Sultan S., Weizman A.V., Morgan R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159:697&#x2013;705. doi: 10.1053/j.gastro.2020.05.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.059</ArticleId><ArticleId IdType="pubmed">32531291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B., Salanti G., Caldwell D.M., Chaimani A., Schmid C.H., Cameron C., Ioannidis J.P.A., Straus S., Thorlund K., Jansen J.P., et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann. Intern. Med. 2015;162:777&#x2013;784. doi: 10.7326/M14-2385.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.L., Drossman D.A., Frederick I.O., Dicesare J., Puder K.L. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983;67:361&#x2013;370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Savovi&#x107; J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.Y., Corbett M.S., Eldridge S.M., et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G., Del Giovane C., Chaimani A., Caldwell D.M., Higgins J.P.T. Evaluating the Quality of Evidence from a Network Meta-Analysis. PLoS ONE. 2014;9:e99682. doi: 10.1371/journal.pone.0099682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0099682</ArticleId><ArticleId IdType="pmc">PMC4084629</ArticleId><ArticleId IdType="pubmed">24992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res. Synth. Methods. 2010;1:97&#x2013;111. doi: 10.1002/jrsm.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.12</ArticleId><ArticleId IdType="pubmed">26061376</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539&#x2013;1558. doi: 10.1002/sim.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaimani A., Higgins J.P.T., Mavridis D., Spyridonos P., Salanti G. Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE. 2013;8:e76654. doi: 10.1371/journal.pone.0076654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076654</ArticleId><ArticleId IdType="pmc">PMC3789683</ArticleId><ArticleId IdType="pubmed">24098547</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley R.D., Higgins J.P.T., Deeks J.J. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi: 10.1136/bmj.d549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d549</ArticleId><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias S., Welton N.J., Caldwell D.M., Ades A.E. Checking consistency in mixed treatment comparison meta-analysis. Stat. Med. 2010;29:932&#x2013;944. doi: 10.1002/sim.3767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3767</ArticleId><ArticleId IdType="pubmed">20213715</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Jackson D., Barrett J.K., Lu G., Ades A.E., White I.R. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res. Synth. Methods. 2012;3:98&#x2013;110. doi: 10.1002/jrsm.1044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1044</ArticleId><ArticleId IdType="pmc">PMC4433772</ArticleId><ArticleId IdType="pubmed">26062084</ArticleId></ArticleIdList></Reference><Reference><Citation>White I.R. Network meta-analysis. Stata J. 2015;15:951&#x2013;985. doi: 10.1177/1536867X1501500403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X1501500403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaimani A., Salanti G. Visualizing assumptions and results in network meta-analysis: The network graphs package. Stata J. 2015;15:905&#x2013;950. doi: 10.1177/1536867X1501500402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X1501500402</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan R.L., Preidis G.A., Kashyap P.C., Weizman A.V., Sadeghirad B., McMaster Probiotic Prebiotic S. Probiotics Reduce Mortality and Morbidity in Preterm, Low-Birth-Weight Infants: A Systematic Review and Network Meta-analysis of Randomized Trials. Gastroenterology. 2020;159:467&#x2013;480. doi: 10.1053/j.gastro.2020.05.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.096</ArticleId><ArticleId IdType="pmc">PMC8014956</ArticleId><ArticleId IdType="pubmed">32592699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourey F., Decherf A., Jeanne J.-F., Clement-Ziza M., Grisoni M.-L., Machuron F., Legrain-Raspaud S., Bourreille A., Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J. Gastroenterol. 2022;28:2509&#x2013;2522. doi: 10.3748/wjg.v28.i22.2509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i22.2509</ArticleId><ArticleId IdType="pmc">PMC9258277</ArticleId><ArticleId IdType="pubmed">35979259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K., Kim A., Lee J.-H., Cho D., Seo J., Jung E.S., Kang H.-j., Roh J., Kim W. Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1 (TM)) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2022;14:2015. doi: 10.3390/nu14102015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14102015</ArticleId><ArticleId IdType="pmc">PMC9144213</ArticleId><ArticleId IdType="pubmed">35631156</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Ma C., Zhao F., Chen P., Liu Y., Sun Z., Cui L., Kwok L.-Y., Zhang H. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur. J. Nutr. 2021;60:2553&#x2013;2565. doi: 10.1007/s00394-020-02437-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-020-02437-4</ArticleId><ArticleId IdType="pubmed">33225399</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Sowniska A., Cukrowska B. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients. 2021;13:756. doi: 10.3390/nu13030756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030756</ArticleId><ArticleId IdType="pmc">PMC7996889</ArticleId><ArticleId IdType="pubmed">33652763</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yu X., Yu L., Tian F., Zhao J., Zhang H., Qian L., Wang Q., Xue Z., Zhai Q., et al. Lactobacillus plantarum CCFM8610 Alleviates Irritable Bowel Syndrome and Prevents Gut Microbiota Dysbiosis: A Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Trial. Engineering. 2021;7:376&#x2013;385. doi: 10.1016/j.eng.2020.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.06.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A.K., Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome A prospective, interventional, randomized, double-blind, placebo-controlled clinical study CONSORT Compliant. Medicine. 2021;100:e23641. doi: 10.1097/MD.0000000000023641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Barraza-Ortiz D.A., Perez-Lopez N., Medina-Lopez V.M., Minero-Alfaro J.I., Zamarripa-Dorsey F., Fernandez-Martinez N.d.C., Llorente-Ramon A., Ramos-Aguilar G.A. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study. Dig. Dis. 2021;39:294&#x2013;300. doi: 10.1159/000510950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000510950</ArticleId><ArticleId IdType="pubmed">32810850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., Grillasca J.-P., Pons O., Maixent J.-M. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig. Liver Dis. 2020;52:534&#x2013;540. doi: 10.1016/j.dld.2019.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2019.12.009</ArticleId><ArticleId IdType="pubmed">31952938</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C.J., Srivastava S., Leyer G.J. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12:363. doi: 10.3390/nu12020363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients. 2020;12:1159. doi: 10.3390/nu12041159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="pubmed">32326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Cho K., Kim J.S., Jung H.C., Kim B., Park M.S., Ji G.E., Cho J.-Y., Hong K.S. Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial. Food Sci. Biotechnol. 2020;29:837&#x2013;844. doi: 10.1007/s10068-019-00717-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10068-019-00717-2</ArticleId><ArticleId IdType="pmc">PMC7256134</ArticleId><ArticleId IdType="pubmed">32523793</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K.R. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. Int. J. Color. Dis. 2020;35:139&#x2013;145. doi: 10.1007/s00384-019-03462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., Gobbetti M., Portincasa P. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur. J. Clin. Investig. 2020;50:e13201. doi: 10.1111/eci.13201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13201</ArticleId><ArticleId IdType="pubmed">31960952</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol. Hepatol. 2020;5:658&#x2013;666. doi: 10.1016/S2468-1253(20)30056-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Jang Y.S., Kang D., Chang D.K., Min Y.W. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2019;11:2887. doi: 10.3390/nu11122887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11122887</ArticleId><ArticleId IdType="pmc">PMC6950464</ArticleId><ArticleId IdType="pubmed">31783597</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R.S., Ahire J.J., Neelamraju J., Tripathi A., Nanal S. Randomized clinical trial: The effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci. Rep. 2019;9:12210. doi: 10.1038/s41598-019-48554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashtiani S.Y., Amery M. Effect of Multispecies Probiotic Supplementation on Irritable Bowel Syndrome. J. Pharm. Res. Int. 2019;28:1&#x2013;9. doi: 10.9734/jpri/2019/v28i630221.</Citation><ArticleIdList><ArticleId IdType="doi">10.9734/jpri/2019/v28i630221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.-Y., Li M., Li Y.-Y., Li L.-X., Zhai W.-Z., Wang P., Yang X.-X., Gu X., Song L.-J., Li Z., et al. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Sci. Rep. 2018;8:2964. doi: 10.1038/s41598-018-21241-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21241-z</ArticleId><ArticleId IdType="pmc">PMC5813237</ArticleId><ArticleId IdType="pubmed">29445178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B. A double blind, placebo-controlled, randomized clinical trial that breast milk derived Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J. Clin. Biochem. Nutr. 2018;62:179&#x2013;186. doi: 10.3164/jcbn.17-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-73</ArticleId><ArticleId IdType="pmc">PMC5874236</ArticleId><ArticleId IdType="pubmed">29610559</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: A double-blind, randomised, placebo-controlled study. Benef. Microbes. 2018;9:697&#x2013;706. doi: 10.3920/BM2017.0105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0105</ArticleId><ArticleId IdType="pubmed">29888656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.Y., Park Y.J., Lee H.J., Park M.Y., Kwon O. Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: A randomized, double-blind, placebo-controlled, dose-finding trial. Food Sci. Biotechnol. 2018;27:853&#x2013;857. doi: 10.1007/s10068-017-0296-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10068-017-0296-7</ArticleId><ArticleId IdType="pmc">PMC6049675</ArticleId><ArticleId IdType="pubmed">30263811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult (R)) in the management of diarrhea- predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18:71. doi: 10.1186/s12876-018-0788-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0788-9</ArticleId><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United Eur. Gastroenterol. J. 2018;6:604&#x2013;613. doi: 10.1177/2050640617736478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640617736478</ArticleId><ArticleId IdType="pmc">PMC5987284</ArticleId><ArticleId IdType="pubmed">29881616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Martin F.-P., Cominetti O., Welsh C., Rieder A., et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153:448&#x2013;459. doi: 10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobutani K., Sawada D., Fujiwara S., Kuwano Y., Nishida K., Nakayama J., Kutsumi H., Azuma T., Rokutan K. The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. J. Appl. Microbiol. 2017;122:212&#x2013;224. doi: 10.1111/jam.13329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.13329</ArticleId><ArticleId IdType="pubmed">27761980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod K., Sperber A.D., Ron Y., Boaz M., Dickman R., Berliner S., Halpern Z., Maharshak N., Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol. Motil. 2017;29:e13037. doi: 10.1111/nmo.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13037</ArticleId><ArticleId IdType="pubmed">28271623</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A.Y., Clemens C.H.M., Vankerckhoven V., Goossens H., Jonkers D.M.A.E., Masclee A.A.M. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2016;28:8&#x2013;14. doi: 10.1097/MEG.0000000000000484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000484</ArticleId><ArticleId IdType="pubmed">26469356</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Pelerin F., Decherf A.C., Maudet C., Housez B., Cazaubiel M., Justen P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. United Eur. Gastroenterol. J. 2016;4:353&#x2013;362. doi: 10.1177/2050640615602571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzasalma V., Manfrini E., Ferri E., Sandionigi A., La Ferla B., Schiano I., Michelotti A., Nobile V., Labra M., Di Gennaro P. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. BioMed Res. Int. 2016;2016:4740907. doi: 10.1155/2016/4740907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/4740907</ArticleId><ArticleId IdType="pmc">PMC4993960</ArticleId><ArticleId IdType="pubmed">27595104</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., Majeed S., Karri S.K. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: A double blind randomized placebo controlled pilot clinical study. Nutr. J. 2016;21:15&#x2013;25. doi: 10.1186/s12937-016-0140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennila J., Tarpila A., Lahtinen S., Ouwehand A.C., Veijola L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J. Gastroenterol. 2016;22:10631&#x2013;10642. doi: 10.3748/wjg.v22.i48.10631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H., Park Y.S., Lee D.H., Seo J.-G., Shin C.M., Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Clin. Biochem. Nutr. 2015;57:129&#x2013;134. doi: 10.3164/jcbn.15-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.15-14</ArticleId><ArticleId IdType="pmc">PMC4566021</ArticleId><ArticleId IdType="pubmed">26388670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.K., Yang C., Song G.-H., Wong J., Ho K.-Y. Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig. Dis. Sci. 2015;60:186&#x2013;194. doi: 10.1007/s10620-014-3299-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">25092036</ArticleId></ArticleIdList></Reference><Reference><Citation>de Chambrun G.P., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis. 2015;47:119&#x2013;124. doi: 10.1016/j.dld.2014.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.S., Sohn W., Lee O.Y., Lee S.P., Lee K.N., Jun D.W., Lee H.L., Yoon B.C., Choi H.S., Chung W.-S., et al. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol. 2014;29:52&#x2013;59. doi: 10.1111/jgh.12322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.12322</ArticleId><ArticleId IdType="pubmed">23829297</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S. Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition. 2014;30:1151&#x2013;1157. doi: 10.1016/j.nut.2014.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2014.02.010</ArticleId><ArticleId IdType="pubmed">25194614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome&#x2014;A 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:140. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludidi S., Jonkers D.M., Koning C.J., Kruimel J.W., Mulder L., Van der Vaart I.B., Conchillo J.M., Masclee A.A.M. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol. Motil. 2014;26:705&#x2013;714. doi: 10.1111/nmo.12320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12320</ArticleId><ArticleId IdType="pubmed">24588932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Zuniga V., Llop E., Suarez C., Alvarez B., Abreu L., Espadaler J., Serra J.I. 31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J. Gastroenterol. 2014;20:8709&#x2013;8716. doi: 10.3748/wjg.v20.i26.8709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i26.8709</ArticleId><ArticleId IdType="pmc">PMC4093724</ArticleId><ArticleId IdType="pubmed">25024629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic Effects, Tolerability and Safety of a Multi-strain Probiotic in Iranian Adults with Irritable Bowel Syndrome and Bloating. Arch. Iran. Med. 2014;17:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M.W., Shamim S., Islam M. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial. Eur. J. Gastroenterol. Hepatol. 2014;26:630&#x2013;639. doi: 10.1097/MEG.0000000000000094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L.M., McCahon D., Holder R., Wilson S., Hobbs F.D.R. A randomised controlled trial of a probiotic &#x2018;functional food&#x2019; in the management of irritable bowel syndrome. BMC Gastroenterol. 2013;13:45. doi: 10.1186/1471-230X-13-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-45</ArticleId><ArticleId IdType="pmc">PMC3605320</ArticleId><ArticleId IdType="pubmed">23496803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Rheem S., Yun B., Ahn Y., Joung J., Lee S.J., Oh S., Chun T., Rheem I., Yea H.S., et al. Effects of probiotic yoghurt on symptoms and intestinal microbiota in patients with irritable bowel syndrome. Int. J. Dairy Technol. 2013;66:243&#x2013;255. doi: 10.1111/1471-0307.12028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0307.12028</ArticleId></ArticleIdList></Reference><Reference><Citation>Charbonneau D., Gibb R.D., Quigley E.M.M. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4:201&#x2013;211. doi: 10.4161/gmic.24196.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.24196</ArticleId><ArticleId IdType="pmc">PMC3669165</ArticleId><ArticleId IdType="pubmed">23549409</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Color. Dis. 2013;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Begtrup L.M., de Muckadell O.B.S., Kjeldsen J., Christensen R.d., Jarbol D.E. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome&#x2014;A randomised, double-blind, placebo controlled trial. Scand. J. Gastroenterol. 2013;48:1127&#x2013;1135. doi: 10.3109/00365521.2013.825314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2013.825314</ArticleId><ArticleId IdType="pubmed">23957590</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirimani B., Nikfam S., Albaji M., Vahedi S., Nasseri-Moghaddam S., Sharafkhah M., Ansari R., Vahedi H. Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial. Middle East J. Dig. Dis. 2013;5:98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990144</ArticleId><ArticleId IdType="pubmed">24829677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruis W., Chrubasik S., Boehm S., Stange C., Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int. J. Color. Dis. 2012;27:467&#x2013;474. doi: 10.1007/s00384-011-1363-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pmc">PMC3307993</ArticleId><ArticleId IdType="pubmed">22130826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrotte P., Sawant P., Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J. Gastroenterol. 2012;18:4012&#x2013;4018. doi: 10.3748/wjg.v18.i30.4012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J.-M., Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J. Gastroenterol. 2012;18:2067&#x2013;2075. doi: 10.3748/wjg.v18.i17.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int. J. Clin. Exp. Med. 2012;5:238&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403550</ArticleId><ArticleId IdType="pubmed">22837798</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha B.K., Jung S.M., Choi C.H., Song I.-D., Lee H.W., Kim H.J., Do J.H., Chang S.K., Kim K., Chung W.-S., et al. The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome A Randomized, Double-blind, Placebo-controlled Trial. J. Clin. Gastroenterol. 2012;46:220&#x2013;227. doi: 10.1097/MCG.0b013e31823712b1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31823712b1</ArticleId><ArticleId IdType="pubmed">22157240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondergaard B., Olsson J., Ohlson K., Svensson U., Bytzer P., Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: A randomized, placebo-controlled trial. Scand. J. Gastroenterol. 2011;46:663&#x2013;672. doi: 10.3109/00365521.2011.565066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.565066</ArticleId><ArticleId IdType="pubmed">21443416</ArticleId></ArticleIdList></Reference><Reference><Citation>Michail S., Kenche H. Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome. Probiotics Antimicrob. Proteins. 2011;3:1&#x2013;7. doi: 10.1007/s12602-010-9059-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-010-9059-y</ArticleId><ArticleId IdType="pmc">PMC3255476</ArticleId><ArticleId IdType="pubmed">22247743</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life&#x2014;A double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2011;33:1123&#x2013;1132. doi: 10.1111/j.1365-2036.2011.04633.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.-S., Myung S.-J. A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces boulardii in Irritable Bowel Syndrome Effect on Quality of Life. J. Clin. Gastroenterol. 2011;45:679&#x2013;683. doi: 10.1097/MCG.0b013e318204593e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Simren M., Ohman L., Olsson J., Svensson U., Ohlson K., Posserud I., Strid H. Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome&#x2014;A randomized, double-blind, controlled study. Aliment. Pharmacol. Ther. 2010;31:218&#x2013;227. doi: 10.1111/j.1365-2036.2009.04183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04183.x</ArticleId><ArticleId IdType="pubmed">19863495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligaarden S.C., Axelsson L., Naterstad K., Lydersen S., Farup P.G. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: A randomised controlled trial. BMC Gastroenterol. 2010;10:16. doi: 10.1186/1471-230X-10-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-16</ArticleId><ArticleId IdType="pmc">PMC2831047</ArticleId><ArticleId IdType="pubmed">20144246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hun L. Original Research: Bacillus coagulans Significantly Improved Abdominal Pain and Bloating in Patients with IBS. Postgrad. Med. 2009;121:119&#x2013;124. doi: 10.3810/pgm.2009.03.1984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/pgm.2009.03.1984</ArticleId><ArticleId IdType="pubmed">19332970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong K.S., Kang H.W., Im J.P., Ji G.E., Kim S.G., Jung H.C., Song I.S., Kim J.S. Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome. Gut Liver. 2009;3:101&#x2013;107. doi: 10.5009/gnl.2009.3.2.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2009.3.2.101</ArticleId><ArticleId IdType="pmc">PMC2852694</ArticleId><ArticleId IdType="pubmed">20431731</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Klosterhalfen S. Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo. Z. F&#xfc;r Gastroenterol. 2009;47:209&#x2013;214. doi: 10.1055/s-2008-1027702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1027702</ArticleId><ArticleId IdType="pubmed">19197823</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolin B.J. Effects of a proprietary bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find. Exp. Clin. Pharmacol. 2009;31:655&#x2013;659. doi: 10.1358/mf.2009.31.10.1441078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/mf.2009.31.10.1441078</ArticleId><ArticleId IdType="pubmed">20140275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2008;28:994&#x2013;1002. doi: 10.1111/j.1365-2036.2008.03818.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams E.A., Stimpson J., Wang D., Plummer S., Garaiova I., Barker M.E., Corfe B.M. Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 2008;29:97&#x2013;103. doi: 10.1111/j.1365-2036.2008.03848.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03848.x</ArticleId><ArticleId IdType="pubmed">18785988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., Kim Y.-H., Kim J.J., Rhee J.C., Rhee P.-L. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig. Dis. Sci. 2008;53:2714&#x2013;2718. doi: 10.1007/s10620-007-0196-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Kyronpalo S., Rasmussen M., Jarvenpaa S., Zoetendal E.G., De Vos W.M., Vapaatalo H., Korpela R. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 2008;27:48&#x2013;57. doi: 10.1111/j.1365-2036.2007.03542.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03542.x</ArticleId><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Mueller-Lissner S., Martens U., Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome&#x2014;A randomized controlled trial with primary care physicians. Neurogastroenterol. Motil. 2008;20:1103&#x2013;1109. doi: 10.1111/j.1365-2982.2008.01156.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01156.x</ArticleId><ArticleId IdType="pubmed">18565142</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol. Clin. Et Biol. 2008;32:147&#x2013;152. doi: 10.1016/j.gcb.2007.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., Federico A., Chilovi F., Milandri G.L., De Bona M., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome&#x2014;A multicenter, randomized study. J. Clin. Gastroenterol. 2008;42:S218&#x2013;S223. doi: 10.1097/MCG.0b013e31817fadd6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817fadd6</ArticleId><ArticleId IdType="pubmed">18685503</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A., Houghton L.A., Morris J., Reilly B., Guyonnet D., Feuillerat N.G., Schlumberger A., Jakob S., Whorwell P.J. Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2008;29:104&#x2013;114. doi: 10.1111/j.1365-2036.2008.03853.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03853.x</ArticleId><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.H., Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 2007;26:475&#x2013;486. doi: 10.1111/j.1365-2036.2007.03362.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03362.x</ArticleId><ArticleId IdType="pubmed">17635382</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O&#x2019;Mahony L., Kiely B., Shanahan F., Quigley E.M.M. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 2006;101:1581&#x2013;1590. doi: 10.1111/j.1572-0241.2006.00734.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F.Y., Chen K.S., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Naftali T., Hallak R., Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome&#x2014;A double blind, placebo-controlled, randomized study. Clin. Nutr. 2005;24:925&#x2013;931. doi: 10.1016/j.clnu.2005.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2005.06.001</ArticleId><ArticleId IdType="pubmed">16051399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Roque M.I.V., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 2005;17:687&#x2013;696. doi: 10.1111/j.1365-2982.2005.00695.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00695.x</ArticleId><ArticleId IdType="pubmed">16185307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Hatakka K., Poussa T., Markkila M., Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Aliment. Pharmacol. Ther. 2005;22:387&#x2013;394. doi: 10.1111/j.1365-2036.2005.02579.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02579.x</ArticleId><ArticleId IdType="pubmed">16128676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2003;17:895&#x2013;904. doi: 10.1046/j.1365-2036.2003.01543.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2001;13:1143&#x2013;1147. doi: 10.1097/00042737-200110000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-200110000-00004</ArticleId><ArticleId IdType="pubmed">11711768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobaek S., Johansson M.L., Molin G., Ahrne S., Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2000;95:1231&#x2013;1238. doi: 10.1111/j.1572-0241.2000.02015.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2000.02015.x</ArticleId><ArticleId IdType="pubmed">10811333</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics. Nat. Med. 2019;25:716&#x2013;729. doi: 10.1038/s41591-019-0439-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0439-x</ArticleId><ArticleId IdType="pubmed">31061539</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland L.V., Karakan T., Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Eclinicalmedicine. 2021;41:101154. doi: 10.1016/j.eclinm.2021.101154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101154</ArticleId><ArticleId IdType="pmc">PMC8529205</ArticleId><ArticleId IdType="pubmed">34712929</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology. 2016;150:1262&#x2013;1279. doi: 10.1053/j.gastro.2016.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.032</ArticleId><ArticleId IdType="pubmed">27144617</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services Food and Drug Administration Center for Drug Evalution and Research (CDER)  Guidance for industry: Irritable Bowel Syndrome&#x2014;Clinical Evaluation of Drugs for Treatment.  [(accessed on 15 August 2023)];2012  Available online:  https://www.fda.gov/media/78622/download.</Citation></Reference><Reference><Citation>Bijkerk C.J., de Wit N.J., Muris J.W.M., Jones R.H., Knottnerus J.A., Hoes A.W. Outcome measures in irritable bowel syndrome: Comparison of psychometric and methodological characteristics. Am. J. Gastroenterol. 2003;98:122&#x2013;127. doi: 10.1111/j.1572-0241.2003.07158.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2003.07158.x</ArticleId><ArticleId IdType="pubmed">12526947</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrae D.A., Patrick D.L., Drossman D.A., Covington P.S. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual. Life Outcomes. 2013;11:208. doi: 10.1186/1477-7525-11-208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-11-208</ArticleId><ArticleId IdType="pmc">PMC3895767</ArticleId><ArticleId IdType="pubmed">24330412</ArticleId></ArticleIdList></Reference><Reference><Citation>Midenfjord I., Borg A., Tornblom H., Simren M. Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome. Am. J. Gastroenterol. 2021;116:769&#x2013;779. doi: 10.14309/ajg.0000000000001038.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001038</ArticleId><ArticleId IdType="pubmed">33982947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A., Sultan S., Chang L., Heidelbaugh J.J., Smalley W., Verne G.N. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Diarrhea. Gastroenterology. 2022;163:137&#x2013;153. doi: 10.1053/j.gastro.2022.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.017</ArticleId><ArticleId IdType="pubmed">35738725</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., Sultan S., Lembo A., Verne G.N., Smalley W., Heidelbaugh J.J. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Constipation. Gastroenterology. 2022;163:118&#x2013;136. doi: 10.1053/j.gastro.2022.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.016</ArticleId><ArticleId IdType="pubmed">35738724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Zhang C.Z., Zhang J.D., Sun F., Duan L.P. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front. Cell. Infect. Microbiol. 2022;12:349. doi: 10.3389/fcimb.2022.859967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="pubmed">35433498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39060737</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1449</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Probiotics in Functional Gastrointestinal Disorders.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>174</EndPage><MedlinePgn>157-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-031-58572-2_10</ELocationID><Abstract><AbstractText>The most frequent functional gastrointestinal disorders (FGID) in children include infantile colic, constipation, functional abdominal pain (FAP), and irritable bowel syndrome (IBS). Unfortunately, treatment options for FGID in children are limited, therefore many dietary interventions have been evaluated, including probiotics. This chapter summarizes currently available evidence and recommendations for probiotic use in the treatment of frequent FGIDs in children. The strongest evidence exists for the use of Limosilactobacillus (L.) reuteri DSM 17938 and Bifidobacterium animalis subsp. lactis BB-12 for the treatment of infantile colic in breastfed infants. Limited but yet encouraging evidence exists for Lacticaseibacillus rhamnosus GG (LGG) for the treatment of IBS and L. reuteri DSM 17938 for FAP.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hojsak</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Referral Centre for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia. iva.hojsak@kdb.hr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zagreb, School of Medicine, Zagreb, Croatia. iva.hojsak@kdb.hr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University J.J. Strossmayer, School of Medicine Osijek, Osijek, Croatia. iva.hojsak@kdb.hr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052200" MajorTopicYN="N">Limosilactobacillus reuteri</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Functional abdominal pain</Keyword><Keyword MajorTopicYN="N">Infantile colic</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>28</Day><Hour>14</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39060737</ArticleId><ArticleId IdType="doi">10.1007/978-3-031-58572-2_10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbott RA, Martin AE, Newlove-Delgado TV, Bethel A, Whear RS, Coon JT, Logan S (2018) Recurrent abdominal pain in children: summary evidence from 3 systematic reviews of treatment effectiveness. J Pediatr Gastroenterol Nutr 67:23&#x2013;33. https://doi.org/10.1097/MPG.0000000000001922</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001922</ArticleId><ArticleId IdType="pubmed">29470291</ArticleId></ArticleIdList></Reference><Reference><Citation>Anabrees J, Indrio F, Paes B, AlFaleh K (2013) Probiotics for infantile colic: a systematic review. BMC Pediatr 13:186. https://doi.org/10.1186/1471-2431-13-186</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-13-186</ArticleId><ArticleId IdType="pubmed">24238101</ArticleId><ArticleId IdType="pmc">4225660</ArticleId></ArticleIdList></Reference><Reference><Citation>Asburce OB, Sezer OB, Ozcay F (2013) Comparison of probiotic and lactulose treatments in children with functional constipation and determination of the effects of constipation treatment on quality of life [Turkish]. Cocuk Sagligi ve Hastaliklari Dergisi 56(1):1&#x2013;7</Citation></Reference><Reference><Citation>Assa A, Ish-Tov A, Rinawi F, Shamir R (2015) School attendance in children with functional abdominal pain and inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 61(5):553&#x2013;557. https://doi.org/10.1097/MPG.0000000000000850</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000850</ArticleId><ArticleId IdType="pubmed">25950089</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaluri A, Jackson M, Valestin J, Rao SS (2010) Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 105(6):1407&#x2013;1411. https://doi.org/10.1038/ajg.2009.655</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2009.655</ArticleId><ArticleId IdType="pubmed">19953090</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarre ME, Di Mauro A, Tafuri S, Rizzo V, Gallone MS, Mastromarino P, Capobianco D, Laghi L, Zhu C, Capozza M, Laforgia N (2018) Effectiveness and safety of a probiotic-mixture for the treatment of infantile colic: a double-blind, randomized, placebo-controlled clinical trial with fecal real-time PCR and NMR-based metabolomics analysis. Nutrients 10(2):195. https://doi.org/10.3390/nu10020195</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10020195</ArticleId><ArticleId IdType="pubmed">29439395</ArticleId><ArticleId IdType="pmc">5852771</ArticleId></ArticleIdList></Reference><Reference><Citation>Banaszkiewicz A, Szajewska H (2005) Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 146(3):364&#x2013;369. https://doi.org/10.1016/j.jpeds.2004.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2004.10.022</ArticleId><ArticleId IdType="pubmed">15756221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar F, Von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, Bottner M, Wedel T (2009) Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 21(5):559&#x2013;566., e516-557. https://doi.org/10.1111/j.1365-2982.2008.01258.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01258.x</ArticleId><ArticleId IdType="pubmed">19220758</ArticleId></ArticleIdList></Reference><Reference><Citation>Basturk A, Artan R, Yilmaz A (2016) Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol 27(5):439&#x2013;443. https://doi.org/10.5152/tjg.2016.16301</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2016.16301</ArticleId><ArticleId IdType="pubmed">27782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauserman M, Michail S (2005) The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147(2):197&#x2013;201. https://doi.org/10.1016/j.jpeds.2005.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2005.05.015</ArticleId><ArticleId IdType="pubmed">16126049</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninga MA, Voskuijl WP, Taminiau JA (2004) Childhood constipation: is there new light in the tunnel? J Pediatr Gastroenterol Nutr 39(5):448&#x2013;464</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1536-4801.2004.tb00890.x</ArticleId><ArticleId IdType="pubmed">15572881</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S (2016) Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 150(6):1443&#x2013;1455. https://doi.org/10.1053/j.gastro.2016.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Biagioli E, Tarasco V, Lingua C, Moja L, Savino F (2016) Pain-relieving agents for infantile colic. Cochrane Database Syst Rev 9:CD009999. https://doi.org/10.1002/14651858.CD009999.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009999.pub2</ArticleId><ArticleId IdType="pubmed">27631535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla S, Saps M (2013) Early life events predispose the onset of childhood functional gastrointestinal disorders. Rev Gastroenterol Mex 78(2):82&#x2013;91. https://doi.org/10.1016/j.rgmx.2013.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rgmx.2013.02.001</ArticleId><ArticleId IdType="pubmed">23578567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhnik Y, Neut C, Raskine L, Michel C, Riottot M, Andrieux C, Guillemot F, Dyard F, Flourie B (2004) Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 19(8):889&#x2013;899. https://doi.org/10.1111/j.1365-2036.2004.01918.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2004.01918.x</ArticleId><ArticleId IdType="pubmed">15080850</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC (2007) Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 49(4):485&#x2013;490. https://doi.org/10.1111/j.1442-200X.2007.02397.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-200X.2007.02397.x</ArticleId><ArticleId IdType="pubmed">17587273</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, Koren G (2015) Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 166(1):74&#x2013;78. https://doi.org/10.1016/j.jpeds.2014.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2014.09.020</ArticleId><ArticleId IdType="pubmed">25444531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Zhang G, Xie H, You L, Li H, Zhang Y, Du C, Xu S, Melsaether C, Yuan S (2021) Efficacy of Bifidobacterium animalis subsp. lactis, BB-12((R)) on infant colic - a randomised, double-blinded, placebo-controlled study. Benef Microbes 12(6):531&#x2013;540. https://doi.org/10.3920/BM2020.0233</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2020.0233</ArticleId><ArticleId IdType="pubmed">34550055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ (2015) Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42(4):418&#x2013;427. https://doi.org/10.1111/apt.13286</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13286</ArticleId><ArticleId IdType="pubmed">26104013</ArticleId><ArticleId IdType="pmc">4514898</ArticleId></ArticleIdList></Reference><Reference><Citation>Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A (2010) Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr 157(4):598&#x2013;602. https://doi.org/10.1016/j.jpeds.2010.04.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2010.04.066</ArticleId><ArticleId IdType="pubmed">20542295</ArticleId></ArticleIdList></Reference><Reference><Citation>de Meij TG, de Groot EF, Eck A, Budding AE, Kneepkens CM, Benninga MA, van Bodegraven AA, Savelkoul PH (2016) Characterization of microbiota in children with chronic functional constipation. PLoS One 11(10):e0164731. https://doi.org/10.1371/journal.pone.0164731</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164731</ArticleId><ArticleId IdType="pubmed">27760208</ArticleId><ArticleId IdType="pmc">5070844</ArticleId></ArticleIdList></Reference><Reference><Citation>de Weerth C, Fuentes S, Puylaert P, de Vos WM (2013) Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics 131(2):e550&#x2013;e558. https://doi.org/10.1542/peds.2012-1449</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2012-1449</ArticleId><ArticleId IdType="pubmed">23319531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimidi E, Christodoulides S, Scott SM, Whelan K (2017) Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr 8(3):484&#x2013;494. https://doi.org/10.3945/an.116.014407</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.116.014407</ArticleId><ArticleId IdType="pubmed">28507013</ArticleId><ArticleId IdType="pmc">5421123</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryl R, Szajewska H (2018) Probiotics for management of infantile colic: a systematic review of randomized controlled trials. Arch Med Sci 14(5):1137&#x2013;1143. https://doi.org/10.5114/aoms.2017.66055</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2017.66055</ArticleId><ArticleId IdType="pubmed">30154898</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois NE, Gregory KE (2016) Characterizing the intestinal microbiome in infantile colic: findings based on an integrative review of the literature. Biol Res Nurs 18(3):307&#x2013;315. https://doi.org/10.1177/1099800415620840</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1099800415620840</ArticleId><ArticleId IdType="pubmed">26721871</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekhari K, Vahedi Z, Kamali Aghdam M, Noemi Diaz D (2015) A randomized double-blind placebo-controlled trial of lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr 25(6):e2616. https://doi.org/10.5812/ijp.2616</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/ijp.2616</ArticleId><ArticleId IdType="pubmed">26635937</ArticleId><ArticleId IdType="pmc">4662837</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure C, Wieckowska A (2007) Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders. J Pediatr 150(1):66&#x2013;71. https://doi.org/10.1016/j.jpeds.2006.08.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2006.08.072</ArticleId><ArticleId IdType="pubmed">17188617</ArticleId></ArticleIdList></Reference><Reference><Citation>Francavilla R, Miniello V, Magista AM, De Canio A, Bucci N, Gagliardi F, Lionetti E, Castellaneta S, Polimeno L, Peccarisi L, Indrio F, Cavallo L (2010) A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126(6):e1445&#x2013;e1452. https://doi.org/10.1542/peds.2010-0467</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-0467</ArticleId><ArticleId IdType="pubmed">21078735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gawronska A, Dziechciarz P, Horvath A, Szajewska H (2007) A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 25(2):177&#x2013;184. https://doi.org/10.1111/j.1365-2036.2006.03175.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2006.03175.x</ArticleId><ArticleId IdType="pubmed">17229242</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti E, Staiano A (2016) Probiotics for irritable bowel syndrome: clinical data in children. J Pediatr Gastroenterol Nutr 63(Suppl 1):S25&#x2013;S26. https://doi.org/10.1097/MPG.0000000000001220</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001220</ArticleId><ArticleId IdType="pubmed">27380595</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, Miele E, Staiano A (2017) A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome: a multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol 51(1):e5&#x2013;e10. https://doi.org/10.1097/MCG.0000000000000528</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000528</ArticleId><ArticleId IdType="pubmed">27306945</ArticleId></ArticleIdList></Reference><Reference><Citation>Guandalini S, Magazzu G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M (2010) VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 51(1):24&#x2013;30. https://doi.org/10.1097/MPG.0b013e3181ca4d95</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e3181ca4d95</ArticleId><ArticleId IdType="pubmed">20453678</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra PV, Lima LN, Souza TC, Mazochi V, Penna FJ, Silva AM, Nicoli JR, Guimaraes EV (2011) Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol 17(34):3916&#x2013;3921. https://doi.org/10.3748/wjg.v17.i34.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i34.3916</ArticleId><ArticleId IdType="pubmed">22025880</ArticleId><ArticleId IdType="pmc">3198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Castrellon P, Indrio F, Bolio-Galvis A, Jimenez-Gutierrez C, Jimenez-Escobar I, Lopez-Velazquez G (2017) Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: systematic review with network meta-analysis. Medicine 96(51):e9375. https://doi.org/10.1097/MD.0000000000009375</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000009375</ArticleId><ArticleId IdType="pubmed">29390535</ArticleId><ArticleId IdType="pmc">5758237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojsak I (2019) Probiotics in functional gastrointestinal disorders. Adv Exp Med Biol 1125:121&#x2013;137. https://doi.org/10.1007/5584_2018_321</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/5584_2018_321</ArticleId><ArticleId IdType="pubmed">30578460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI (2001) Molecular analysis of commensal host-microbial relationships in the intestine. Science 291(5505):881&#x2013;884. https://doi.org/10.1126/science.291.5505.881</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.291.5505.881</ArticleId><ArticleId IdType="pubmed">11157169</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A, Dziechciarz P, Szajewska H (2011) Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 33(12):1302&#x2013;1310. https://doi.org/10.1111/j.1365-2036.2011.04665.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04665.x</ArticleId><ArticleId IdType="pubmed">21507030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M (2016) Functional disorders: children and adolescents. Gastroenterology 150(6):1456&#x2013;1468. https://doi.org/10.1053/j.gastro.2016.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Indrio F, Dargenio VN, Francavilla R, Szajewska H, Vandenplas Y (2023) Infantile colic and long-term outcomes in childhood: a narrative synthesis of the evidence. Nutrients 15(3):615. https://doi.org/10.3390/nu15030615</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15030615</ArticleId><ArticleId IdType="pubmed">36771322</ArticleId><ArticleId IdType="pmc">9921915</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadresin O, Hojsak I, Misak Z, Kekez AJ, Trbojevic T, Ivkovic L, Kolacek S (2017) Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children: RCT study. J Pediatr Gastroenterol Nutr 64(6):925&#x2013;929. https://doi.org/10.1097/MPG.0000000000001478</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001478</ArticleId><ArticleId IdType="pubmed">27906800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadresin O, Sila S, Trivic I, Misak Z, Hojsak I, Kolacek S (2018) Lack of benefit of Lactobacillus reuteri DSM 17938 as an addition to the treatment of functional constipation. J Pediatr Gastroenterol Nutr 67(6):763&#x2013;766. https://doi.org/10.1097/MPG.0000000000002134</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000002134</ArticleId><ArticleId IdType="pubmed">30134331</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadresin O, Sila S, Trivic I, Misak Z, Kolacek S, Hojsak I (2020) Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: results of the double-blind randomized study. Clin Nutr 39(12):3645&#x2013;3651. https://doi.org/10.1016/j.clnu.2020.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.04.019</ArticleId><ArticleId IdType="pubmed">32362486</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadre&#x161;in O, Sila S, Trivi&#x107; I, Mi&#x161;ak Z, Kola&#x10d;ek S, Hojsak I (2020) Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: results of the double-blind randomized study. Clin Nutr S0261-5614(20):30190&#x2013;30194</Citation></Reference><Reference><Citation>Kianifar H, Jafari SA, Kiani M, Ahanchian H, Ghasemi SV, Grover Z, Mahmoodi LZ, Bagherian R, Khalesi M (2015) Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Electron Physician 7(5):1255&#x2013;1260. https://doi.org/10.14661/1255</Citation><ArticleIdList><ArticleId IdType="doi">10.14661/1255</ArticleId><ArticleId IdType="pubmed">26435825</ArticleId><ArticleId IdType="pmc">4590561</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppen IJN, Vriesman MH, Saps M, Rajindrajith S, Shi X, van Etten-Jamaludin FS, Di Lorenzo C, Benninga MA, Tabbers MM (2018) Prevalence of functional defecation disorders in children: a systematic review and meta-analysis. J Pediatr 198:121&#x2013;130. https://doi.org/10.1016/j.jpeds.2018.02.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2018.02.029</ArticleId><ArticleId IdType="pubmed">29656863</ArticleId></ArticleIdList></Reference><Reference><Citation>Korterink J, Devanarayana NM, Rajindrajith S, Vlieger A, Benninga MA (2015) Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 12(3):159&#x2013;171. https://doi.org/10.1038/nrgastro.2015.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2015.21</ArticleId><ArticleId IdType="pubmed">25666642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota M, Ito K, Tomimoto K, Kanazaki M, Tsukiyama K, Kubota A, Kuroki H, Fujita M, Vandenplas Y (2020) Lactobacillus reuteri DSM 17938 and magnesium oxide in children with functional chronic constipation: a double-blind and randomized clinical trial. Nutrients 12(1):225. https://doi.org/10.3390/nu12010225</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12010225</ArticleId><ArticleId IdType="pubmed">31952280</ArticleId><ArticleId IdType="pmc">7019518</ArticleId></ArticleIdList></Reference><Reference><Citation>Landgren K, Hallstrom I (2011) Parents&#x2019; experience of living with a baby with infantile colic--a phenomenological hermeneutic study. Scand J Caring Sci 25(2):317&#x2013;324. https://doi.org/10.1111/j.1471-6712.2010.00829.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-6712.2010.00829.x</ArticleId><ArticleId IdType="pubmed">20723153</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Hagiwara SI, Bhargava A (2017) Early-life adversity, epigenetics, and visceral hypersensitivity. Neurogastroenterol Motil 29(9):13170. https://doi.org/10.1111/nmo.13170</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13170</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughman A, Quinn T, Nation ML, Reichelt A, Moore RJ, Van TTH, Sung V, Tang MLK (2021) Infant microbiota in colic: predictive associations with problem crying and subsequent child behavior. J Dev Orig Health Dis 12(2):260&#x2013;270. https://doi.org/10.1017/S2040174420000227</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S2040174420000227</ArticleId><ArticleId IdType="pubmed">32279681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucassen P (2015) Colic in infants. BMJ Clin Evid 2015:0309</Citation><ArticleIdList><ArticleId IdType="pubmed">26581647</ArticleId><ArticleId IdType="pmc">4531337</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragkoudaki M, Chouliaras G, Orel R, Horvath A, Szajewska H, Papadopoulou A (2017) Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr 106(11):1857&#x2013;1862. https://doi.org/10.1111/apa.13992</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.13992</ArticleId><ArticleId IdType="pubmed">28712129</ArticleId></ArticleIdList></Reference><Reference><Citation>McHarg AS, Leach S (2022) The role of the gut microbiome in paediatric irritable bowel syndrome. AIMS Microbiol 8(4):454&#x2013;469. https://doi.org/10.3934/microbiol.2022030</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/microbiol.2022030</ArticleId><ArticleId IdType="pubmed">36694592</ArticleId><ArticleId IdType="pmc">9834077</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi GL, Zhao L, Qiao DD, Kang WQ, Tang MQ, Xu JK (2015) Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek 107(6):1547&#x2013;1553. https://doi.org/10.1007/s10482-015-0448-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10482-015-0448-9</ArticleId><ArticleId IdType="pubmed">25876529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocerino R, De Filippis F, Cecere G, Marino A, Micillo M, Di Scala C, de Caro C, Calignano A, Bruno C, Paparo L, Iannicelli AM, Cosenza L, Maddalena Y, Della Gatta G, Coppola S, Carucci L, Ercolini D, Berni Canani R (2020) The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12((R)) in infant colic: a randomised, double blind, placebo-controlled trial. Aliment Pharmacol Ther 51(1):110&#x2013;120. https://doi.org/10.1111/apt.15561</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15561</ArticleId><ArticleId IdType="pubmed">31797399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohman L, Simren M (2013) Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 15(5):323. https://doi.org/10.1007/s11894-013-0323-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-013-0323-7</ArticleId><ArticleId IdType="pubmed">23580243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong TG, Gordon M, Banks SS, Thomas MR, Akobeng AK (2019) Probiotics to prevent infantile colic. Cochrane Database Syst Rev 3(3):Cd012473. https://doi.org/10.1002/14651858.CD012473.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012473.pub2</ArticleId><ArticleId IdType="pubmed">30865287</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Kalliomaki M (2017) Infant colic is still a mysterious disorder of the microbiota-gut-brain axis. Acta Paediatr 106(4):528&#x2013;529. https://doi.org/10.1111/apa.13754</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.13754</ArticleId><ArticleId IdType="pubmed">28318126</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Kalliomaki M, Endo A, Salminen S, Isolauri E (2012) Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS One 7(3):e32495. https://doi.org/10.1371/journal.pone.0032495</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032495</ArticleId><ArticleId IdType="pubmed">22403665</ArticleId><ArticleId IdType="pmc">3293811</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Lehtonen L, Kalliomaki M, Salminen S, Isolauri E (2015) Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res 78(4):470&#x2013;475. https://doi.org/10.1038/pr.2015.127</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/pr.2015.127</ArticleId><ArticleId IdType="pubmed">26151493</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Kalliomaki M, Salminen S, Isolauri E (2017) Infantile colic is associated with low-grade systemic inflammation. J Pediatr Gastroenterol Nutr 64(5):691&#x2013;695. https://doi.org/10.1097/MPG.0000000000001340</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001340</ArticleId><ArticleId IdType="pubmed">27478897</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Burgos A, Wang L, McVey Neufeld KA, Mao YK, Ahmadzai M, Janssen LJ, Stanisz AM, Bienenstock J, Kunze WA (2015) The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. J Physiol 593(17):3943&#x2013;3957. https://doi.org/10.1113/JP270229</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP270229</ArticleId><ArticleId IdType="pubmed">26084409</ArticleId><ArticleId IdType="pmc">4575579</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani P, Ghouran-Orimi A, Motamed F, Moradzadeh A (2020) Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain. Clin Exp Pediatr 63(12):485&#x2013;490. https://doi.org/10.3345/cep.2019.01613</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/cep.2019.01613</ArticleId><ArticleId IdType="pubmed">32718147</ArticleId><ArticleId IdType="pmc">7738771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rej A, Shaw CC, Buckle RL, Trott N, Agrawal A, Mosey K, Sanders K, Allen R, Martin S, Newton A, Robinson K, Elphick D, Chey WD, Aziz I, Sanders DS (2021) The low FODMAP diet for IBS; A multicentre UK study assessing long term follow up. Dig Liver Dis 53(11):1404&#x2013;1411. https://doi.org/10.1016/j.dld.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2021.05.004</ArticleId><ArticleId IdType="pubmed">34083153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexwinkel R, Vlieger AM, Saps M, Tabbers MM, Benninga MA (2022) A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. Eur J Pediatr 181(7):2603&#x2013;2617. https://doi.org/10.1007/s00431-022-04459-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04459-y</ArticleId><ArticleId IdType="pubmed">35460383</ArticleId><ArticleId IdType="pmc">9192445</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano C, Ferrau V, Cavataio F, Iacono G, Spina M, Lionetti E, Comisi F, Famiani A, Comito D (2014) Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 50(10):E68&#x2013;E71. https://doi.org/10.1111/j.1440-1754.2010.01797.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1754.2010.01797.x</ArticleId><ArticleId IdType="pubmed">20626584</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos S, Dicksved J, Tarasco V, Locatelli E, Ricceri F, Grandin U, Savino F (2013) 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938. PLoS One 8(2):e56710. https://doi.org/10.1371/journal.pone.0056710</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056710</ArticleId><ArticleId IdType="pubmed">23468874</ArticleId><ArticleId IdType="pmc">3585302</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo M, Giugliano FP, Quitadamo P, Mancusi V, Miele E, Staiano A (2017) Efficacy of a mixture of probiotic agents as complementary therapy for chronic functional constipation in childhood. Ital J Pediatr 43(1):24. https://doi.org/10.1186/s13052-017-0334-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-017-0334-3</ArticleId><ArticleId IdType="pubmed">28270173</ArticleId><ArticleId IdType="pmc">5341202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbi T (2011) The use of lactobacillus GG in children with functional abdominal pain: a double-blind randomized control trial. Clin Nutr Suppl 6:198</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1744-1161(11)70513-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghzadeh M, Rabieefar A, Khoshnevisasl P, Mousavinasab N, Eftekhari K (2014) The effect of probiotics on childhood constipation: a randomized controlled double blind clinical trial. Int J Pediatr 2014:937212. https://doi.org/10.1155/2014/937212</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/937212</ArticleId><ArticleId IdType="pubmed">24812563</ArticleId><ArticleId IdType="pmc">4000641</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D (2010) Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 126(3):e526&#x2013;e533. https://doi.org/10.1542/peds.2010-0433</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-0433</ArticleId><ArticleId IdType="pubmed">20713478</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Ceratto S, De Marco A, Cordero di Montezemolo L (2014) Looking for new treatments of Infantile Colic. Ital J Pediatr 40:53. https://doi.org/10.1186/1824-7288-40-53</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1824-7288-40-53</ArticleId><ArticleId IdType="pubmed">24898541</ArticleId><ArticleId IdType="pmc">4050441</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Garro M, Montanari P, Galliano I, Bergallo M (2018) Crying time and RORgamma/FOXP3 expression in Lactobacillus reuteri DSM17938-treated infants with colic: a randomized trial. J Pediatr 192:171&#x2013;177 e171. https://doi.org/10.1016/j.jpeds.2017.08.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2017.08.062</ArticleId><ArticleId IdType="pubmed">28969887</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Galliano I, Savino A, Dapra V, Montanari P, Calvi C, Bergallo M (2019) Lactobacillus reuteri DSM 17938 probiotics may increase CC-chemokine receptor 7 expression in infants treated with for colic. Front Pediatr 7:292. https://doi.org/10.3389/fped.2019.00292</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00292</ArticleId><ArticleId IdType="pubmed">31380326</ArticleId><ArticleId IdType="pmc">6646728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreck Bird A, Gregory PJ, Jalloh MA, Risoldi Cochrane Z, Hein DJ (2017) Probiotics for the treatment of infantile colic: a systematic review. J Pharm Pract 30(3):366&#x2013;374. https://doi.org/10.1177/0897190016634516</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0897190016634516</ArticleId><ArticleId IdType="pubmed">26940647</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonson J, Haglund K, Weber E, Fial A, Hanson L (2021) Probiotics for the management of infantile colic: a systematic review. MCN Am J Matern Child Nurs 46(2):88&#x2013;96. https://doi.org/10.1097/nmc.0000000000000691</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nmc.0000000000000691</ArticleId><ArticleId IdType="pubmed">33315632</ArticleId></ArticleIdList></Reference><Reference><Citation>Skonieczna-&#x17b;ydecka K, Janda K, Kaczmarczyk M, Marlicz W, &#x141;oniewski I, &#x141;oniewska B (2020) The effect of probiotics on symptoms, gut microbiota and inflammatory markers in infantile colic: a systematic review, meta-analysis and meta-regression of randomized controlled trials. J Clin Med 9(4):999. https://doi.org/10.3390/jcm9040999</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040999</ArticleId><ArticleId IdType="pubmed">32252419</ArticleId><ArticleId IdType="pmc">7231167</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C, Nordstrom E, Sengupta JN, Miranda A (2007) Neonatal gastric suctioning results in chronic visceral and somatic hyperalgesia: role of corticotropin releasing factor. Neurogastroenterol Motil 19(8):692&#x2013;699. https://doi.org/10.1111/j.1365-2982.2007.00949.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00949.x</ArticleId><ArticleId IdType="pubmed">17640185</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares AC, Lederman HM, Fagundes-Neto U, de Morais MB (2005) Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 39(6):512&#x2013;515</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mcg.0000165665.94777.bd</ArticleId><ArticleId IdType="pubmed">15942438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudha MR, Jayanthi N, Aasin M, Dhanashri RD, Anirudh T (2018) Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes 9(4):563&#x2013;572. https://doi.org/10.3920/BM2017.0129</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0129</ArticleId><ArticleId IdType="pubmed">29695183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, Hiscock H, Tang M, Mensah FK, Heine RG, Stock A, York E, Barr RG, Wake M (2012) Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial. BMC Pediatr 12:135. https://doi.org/10.1186/1471-2431-12-135</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-12-135</ArticleId><ArticleId IdType="pubmed">22928654</ArticleId><ArticleId IdType="pmc">3508922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A, Barr RG, Wake M (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 348:g2107. https://doi.org/10.1136/bmj.g2107</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g2107</ArticleId><ArticleId IdType="pubmed">24690625</ArticleId><ArticleId IdType="pmc">3972414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, D&#x2019;Amico F, Cabana MD, Chau K, Koren G, Savino F, Szajewska H, Deshpande G, Dupont C, Indrio F, Mentula S, Partty A, Tancredi D (2018) Lactobacillus reuteri to Treat Infant Colic: A meta-analysis. Pediatrics 141(1):e20171811. https://doi.org/10.1542/peds.2017-1811</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2017-1811</ArticleId><ArticleId IdType="pubmed">29279326</ArticleId></ArticleIdList></Reference><Reference><Citation>Szajewska H, Gyrczuk E, Horvath A (2013) Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr 162(2):257&#x2013;262. https://doi.org/10.1016/j.jpeds.2012.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2012.08.004</ArticleId><ArticleId IdType="pubmed">22981952</ArticleId></ArticleIdList></Reference><Reference><Citation>Szajewska H, Berni Canani R, Domellof M, Guarino A, Hojsak I, Indrio F, Lo Vecchio A, Mihatsch WA, Mosca A, Orel R, Salvatore S, Shamir R, van den Akker CHP, van Goudoever JB, Vandenplas Y, Weizman Z, Microbiota ESIGoG, Modifications (2023) Probiotics for the management of pediatric gastrointestinal disorders: position paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr 76(2):232&#x2013;247. https://doi.org/10.1097/MPG.0000000000003633</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000003633</ArticleId><ArticleId IdType="pubmed">36219218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabbers MM, Chmielewska A, Roseboom MG, Crastes N, Perrin C, Reitsma JB, Norbruis O, Szajewska H, Benninga MA (2011) Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics 127(6):e1392&#x2013;e1399. https://doi.org/10.1542/peds.2010-2590</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-2590</ArticleId><ArticleId IdType="pubmed">21606153</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, Staiano A, Vandenplas Y, Benninga MA, European Society for Pediatric Gastroenterology H, Nutrition, North American Society for Pediatric G (2014) Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 58(2):258&#x2013;274. https://doi.org/10.1097/MPG.0000000000000266</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000266</ArticleId><ArticleId IdType="pubmed">24345831</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivic I, Hojsak I (2018) Initial diagnosis of functional gastrointestinal disorders in children increases a chance for resolution of symptoms. Pediatr Gastroenterol Hepatol Nutr 21:264</Citation><ArticleIdList><ArticleId IdType="doi">10.5223/pghn.2018.21.4.264</ArticleId><ArticleId IdType="pubmed">30345239</ArticleId><ArticleId IdType="pmc">6182488</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivic I, Niseteo T, Jadresin O, Hojsak I (2021) Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis. Eur J Pediatr 180(2):339&#x2013;351. https://doi.org/10.1007/s00431-020-03809-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03809-y</ArticleId><ArticleId IdType="pubmed">32940743</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schoot A, Helander C, Whelan K, Dimidi E (2022) Probiotics and synbiotics in chronic constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr 41(12):2759&#x2013;2777. https://doi.org/10.1016/j.clnu.2022.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2022.10.015</ArticleId><ArticleId IdType="pubmed">36372047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenplas Y, Gutierrez-Castrellon P, Velasco-Benitez C, Palacios J, Jaen D, Ribeiro H, Shek LP, Lee BW, Alarcon P (2013) Practical algorithms for managing common gastrointestinal symptoms in infants. Nutrition 29(1):184&#x2013;194. https://doi.org/10.1016/j.nut.2012.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2012.08.008</ArticleId><ArticleId IdType="pubmed">23137717</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanuytsel T, Bercik P, Boeckxstaens G (2023) Understanding neuroimmune interactions in disorders of gut-brain interaction: from functional to immune-mediated disorders. Gut 72(4):787&#x2013;798. https://doi.org/10.1136/gutjnl-2020-320633</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320633</ArticleId><ArticleId IdType="pubmed">36657961</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulin K, Hojsak I (2015) Infantile colic - newer approach to an old problem. Lijec Vjesn 137(11&#x2013;12):367&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">26975067</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsham AD, MacKenzie DA, Cook V, Wemyss-Holden S, Hews CL, Juge N, Schuller S (2016) Lactobacillus reuteri inhibition of enteropathogenic Escherichia coli adherence to human intestinal epithelium. Front Microbiol 7:244. https://doi.org/10.3389/fmicb.2016.00244</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.00244</ArticleId><ArticleId IdType="pubmed">26973622</ArticleId><ArticleId IdType="pmc">4771767</ArticleId></ArticleIdList></Reference><Reference><Citation>Warschburger P, Hanig J, Friedt M, Posovszky C, Schier M, Calvano C (2014) Health-related quality of life in children with abdominal pain due to functional or organic gastrointestinal disorders. J Pediatr Psychol 39(1):45&#x2013;54. https://doi.org/10.1093/jpepsy/jst070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpepsy/jst070</ArticleId><ArticleId IdType="pubmed">24055816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegh CAM, Baaleman DF, Tabbers MM, Smidt H, Benninga MA (2022) Nonpharmacologic treatment for children with functional constipation: a systematic review and meta-analysis. J Pediatr 240(136&#x2013;149):e135. https://doi.org/10.1016/j.jpeds.2021.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2021.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegner A, Banaszkiewicz A, Kierkus J, Landowski P, Korlatowicz-Bilar A, Wiecek S, Kwiecien J, Gawronska A, Dembinski L, Czaja-Bulsa G, Socha P (2018) The effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial. Clin Res Hepatol Gastroenterol 42(5):494&#x2013;500. https://doi.org/10.1016/j.clinre.2018.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2018.03.008</ArticleId><ArticleId IdType="pubmed">29650440</ArticleId></ArticleIdList></Reference><Reference><Citation>Weizman Z, Abu-Abed J, Binsztok M (2016) Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr 174:160&#x2013;164 e161. https://doi.org/10.1016/j.jpeds.2016.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2016.04.003</ArticleId><ArticleId IdType="pubmed">27156182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtyniak K, Horvath A, Dziechciarz P, Szajewska H (2017) Lactobacillus casei rhamnosus Lcr35 in the management of functional constipation in children: a randomized trial. J Pediatr 184:101&#x2013;105 e101. https://doi.org/10.1016/j.jpeds.2017.01.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2017.01.068</ArticleId><ArticleId IdType="pubmed">28284477</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HL, Zou LL, Chen MB, Wang H, Shen WM, Zheng QH, Cui WY (2021) Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: a systematic review and meta-analysis. PLoS One 16(8):e0255160. https://doi.org/10.1371/journal.pone.0255160</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255160</ArticleId><ArticleId IdType="pubmed">34358238</ArticleId><ArticleId IdType="pmc">8345868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeevenhooven J, Koppen IJ, Benninga MA (2017) The new Rome IV criteria for functional gastrointestinal disorders in infants and toddlers. Pediatr Gastroenterol Hepatol Nutr 20(1):1&#x2013;13. https://doi.org/10.5223/pghn.2017.20.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.5223/pghn.2017.20.1.1</ArticleId><ArticleId IdType="pubmed">28401050</ArticleId><ArticleId IdType="pmc">5385301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>